メタクリル酸＝2,3 - エポキシプロピルのラットを用いた
吸入によるがん原性試験報告書

試験番号：0794

TABLES

TABLES

TABLES (CONTINUED)

TABLES (CONTINUED)

TABLE A

CONCENTRATIONS OF 2,3-EPOXYPROPYL METHACRYLATE IN THE INHALATION CHAMBER OF THE 2-YEAR INHALATION STUDY

CONCENTRATIONS OF 2,3-EPOXYPROPYL METHACRYLATE IN THE INHALATION CHAMBER OF THE 2-YEAR INHALATION STUDY

Group Name	Concentration(ppm) Mean ± S.D.
Control	0.0 ± 0.0
3.2 ppm	3.2 ± 0.1
8 ppm	8.1 ± 0.1
20 ppm	20.1 ± 0.2

TABLE B1

SURVIVAL ANIMAL NUMBERS : MALE

STUDY NO. : 0794
ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj]
REPORT TYPE : A1 104
SEX : MALE

SURVIVAL ANIMAL NUMBERS

Group Name	Animals At start	Administration (Weeks) 0	1	2	3	4	5	6	7	8	9	10	11	12	13
Control	50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50
		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
3.2ppm	50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50
		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
8ppm	50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50
		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
20ppm	50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50
		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0

Number of survival/ Number of effective animals
Survival rate(%)

STUDY NO. : 0794
ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj]
REPORT TYPE : A1 104
SEX : MALE

SURVIVAL ANIMAL NUMBERS

Group Name	Animals At start	Administration (Weeks) 14	15	16	17	18	19	20	21	22	23	24	25	26	27
Control	50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50
		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
3.2ppm	50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50
		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
8ppm	50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50
		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
20ppm	50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50
		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0

Number of survival/ Number of effective animals
Survival rate(%)

STUDY NO. : 0794 SURVIVAL ANIMAL NUMBERS
ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj]
REPORT TYPE : A1 104
SEX : MALE

Group Name	Animals At start	Administration (Weeks) 28	29	30	31	32	33	34	35	36	37	38	39	40	41
Control	50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50
		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
3.2ppm	50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50
		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
8ppm	50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50
		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
20ppm	50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50
		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0

Number of survival/ Number of effective animals
Survival rate(%)

STUDY NO. : 0794
ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj]
REPORT TYPE : A1 104
SEX : MALE

SURVIVAL ANIMAL NUMBERS

Group Name	Animals At start	Administration (Weeks) 42	43	44	45	46	47	48	49	50	51	52	53	54	55
Control	50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50
		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
3.2ppm	50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50
		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
8ppm	50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50
		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
20ppm	50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50
		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0

Number of survival/ Number of effective animals
Survival rate(%)

STUDY NO. : 0794
ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj]
REPORT TYPE : A1 104
SEX : MALE

SURVIVAL ANIMAL NUMBERS

Group Name	Animals At start	Administration (Weeks) 56	57	58	59	60	61	62	63	64	65	66	67	68	69
Control	50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50
		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
3.2ppm	50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50
		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
8ppm	50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	49/50	49/50	49/50	48/50	48/50	48/50
		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	98.0	98.0	98.0	96.0	96.0	96.0
20ppm	50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	49/50	48/50	46/50	46/50	46/50
		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	98.0	96.0	92.0	92.0	92.0

Number of survival/ Number of effective animals
Survival rate(%)

STUDY NO. : 0794
ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj]
REPORT TYPE : A1 104
SEX : MALE

SURVIVAL ANIMAL NUMBERS

Group Name	Animals At start	Administration (Weeks) 70	71	72	73	74	75	76	77	78	79	80	81	82	83
Control	50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	49/50	48/50
		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	98.0	96.0
3.2ppm	50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50
		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
8ppm	50	48/50	48/50	48/50	48/50	47/50	46/50	46/50	46/50	46/50	46/50	46/50	46/50	46/50	46/50
		96.0	96.0	96.0	96.0	94.0	92.0	92.0	92.0	92.0	92.0	92.0	92.0	92.0	92.0
20ppm	50	46/50	46/50	46/50	45/50	45/50	45/50	44/50	41/50	41/50	37/50	35/50	34/50	31/50	31/50
		92.0	92.0	92.0	90.0	90.0	90.0	88.0	82.0	82.0	74.0	70.0	68.0	62.0	62.0

Number of survival/ Number of effective animals
Survival rate(%)

STUDY NO. : 0794
ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj]
REPORT TYPE : A1 104
SEX : MALE

SURVIVAL ANIMAL NUMBERS

Group Name	Animals At start	Administration (Weeks) 84	85	86	87	88	89	90	91	92	93	94	95	96	97
Control	50	48/50	48/50	48/50	48/50	48/50	47/50	47/50	47/50	46/50	46/50	46/50	45/50	45/50	45/50
		96.0	96.0	96.0	96.0	96.0	94.0	94.0	94.0	92.0	92.0	92.0	90.0	90.0	90.0
3.2ppm	50	50/50	50/50	50/50	50/50	49/50	49/50	49/50	49/50	49/50	48/50	48/50	47/50	47/50	47/50
		100.0	100.0	100.0	100.0	98.0	98.0	98.0	98.0	98.0	96.0	96.0	94.0	94.0	94.0
8ppm	50	46/50	46/50	46/50	46/50	46/50	46/50	45/50	45/50	45/50	45/50	44/50	44/50	44/50	44/50
		92.0	92.0	92.0	92.0	92.0	92.0	90.0	90.0	90.0	90.0	88.0	88.0	88.0	88.0
20ppm	50	30/50	27/50	27/50	26/50	25/50	23/50	20/50	19/50	18/50	17/50	17/50	17/50	15/50	15/50
		60.0	54.0	54.0	52.0	50.0	46.0	40.0	38.0	36.0	34.0	34.0	34.0	30.0	30.0

Number of survival/ Number of effective animals
Survival rate(%)

STUDY NO. : 0794
ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj]
REPORT TYPE : A1 104
SEX : MALE

SURVIVAL ANIMAL NUMBERS

Group Name	Animals At start	Administration (Weeks) 98	99	100	101	102	103	104
Control	50	45/50	45/50	45/50	44/50	43/50	43/50	41/50
		90.0	90.0	90.0	88.0	86.0	86.0	82.0
3.2ppm	50	47/50	47/50	47/50	46/50	45/50	45/50	44/50
		94.0	94.0	94.0	92.0	90.0	90.0	88.0
8ppm	50	43/50	43/50	43/50	42/50	42/50	40/50	39/50
		86.0	86.0	86.0	84.0	84.0	80.0	78.0
20ppm	50	14/50	14/50	14/50	12/50	10/50	9/50	9/50
		28.0	28.0	28.0	24.0	20.0	18.0	18.0

Number of survival/ Number of effective animals
Survival rate(%)

TABLE B2

SURVIVAL ANIMAL NUMBERS : FEMALE

STUDY NO. : 0794
ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj]
REPORT TYPE : A1 104
SEX : FEMALE

SURVIVAL ANIMAL NUMBERS

Group Name	Animals At start	Administration (Weeks) 0	1	2	3	4	5	6	7	8	9	10	11	12	13
Control	50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50
		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
3.2ppm	50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50
		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
8ppm	50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50
		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
20ppm	50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50
		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0

Number of survival/ Number of effective animals
Survival rate(%)

STUDY NO. : 0794
ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj]
REPORT TYPE : A1 104
SEX : FEMALE

SURVIVAL ANIMAL NUMBERS

Group Name	Animals At start	Administration (Weeks) 14	15	16	17	18	19	20	21	22	23	24	25	26	27
Control	50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50
		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
3.2ppm	50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50
		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
8ppm	50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50
		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
20ppm	50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50
		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0

Number of survival/ Number of effective animals
Survival rate(%)

STUDY NO. : 0794
ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj]
REPORT TYPE : A1 104
SEX : FEMALE

SURVIVAL ANIMAL NUMBERS

Group Name	Animals At start	Administration (Weeks) 28	29	30	31	32	33	34	35	36	37	38	39	40	41
Control	50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50
		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
3.2ppm	50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50
		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
8ppm	50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50
		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
20ppm	50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50
		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0

Number of survival/ Number of effective animals
Survival rate(%)

STUDY NO. : 0794
ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj]
REPORT TYPE : A1 104
SEX : FEMALE

SURVIVAL ANIMAL NUMBERS

Group Name	Animals At start	Administration (Weeks) 42	43	44	45	46	47	48	49	50	51	52	53	54	55
Control	50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50
		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
3.2ppm	50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50
		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
8ppm	50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	49/50	49/50	49/50	49/50	49/50
		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	98.0	98.0	98.0	98.0	98.0
20ppm	50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50
		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0

Number of survival/ Number of effective animals
Survival rate(%)

STUDY NO. : 0794
ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj]
REPORT TYPE : A1 104
SEX : FEMALE

SURVIVAL ANIMAL NUMBERS

Group Name	Animals At start	Administration (Weeks) 56	57	58	59	60	61	62	63	64	65	66	67	68	69
Control	50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50
		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
3.2ppm	50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50
		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
8ppm	50	49/50	49/50	48/50	48/50	48/50	48/50	48/50	48/50	48/50	48/50	48/50	48/50	48/50	48/50
		98.0	98.0	96.0	96.0	96.0	96.0	96.0	96.0	96.0	96.0	96.0	96.0	96.0	96.0
20ppm	50	50/50	49/50	48/50	48/50	48/50	48/50	48/50	48/50	48/50	48/50	48/50	48/50	48/50	48/50
		100.0	98.0	96.0	96.0	96.0	96.0	96.0	96.0	96.0	96.0	96.0	96.0	96.0	96.0

Number of survival/ Number of effective animals
Survival rate(%)

STUDY NO. : 0794
ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj]
REPORT TYPE : A1 104
SEX : FEMALE

SURVIVAL ANIMAL NUMBERS

Group Name	Animals At start	Administration (Weeks) 70	71	72	73	74	75	76	77	78	79	80	81	82	83
Control	50	50/50	50/50	50/50	50/50	50/50	50/50	48/50	48/50	48/50	48/50	48/50	47/50	47/50	46/50
		100.0	100.0	100.0	100.0	100.0	100.0	96.0	96.0	96.0	96.0	96.0	94.0	94.0	92.0
3.2ppm	50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	49/50	49/50	49/50	49/50
		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	98.0	98.0	98.0	98.0
8ppm	50	48/50	48/50	48/50	47/50	47/50	47/50	47/50	47/50	47/50	46/50	46/50	46/50	46/50	45/50
		96.0	96.0	96.0	94.0	94.0	94.0	94.0	94.0	94.0	92.0	92.0	92.0	92.0	90.0
20ppm	50	48/50	48/50	47/50	47/50	47/50	47/50	47/50	47/50	46/50	46/50	46/50	45/50	44/50	43/50
		96.0	96.0	94.0	94.0	94.0	94.0	94.0	94.0	92.0	92.0	92.0	90.0	88.0	86.0

Number of survival/ Number of effective animals
Survival rate(%)

STUDY NO. : 0794
ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj]
REPORT TYPE : A1 104
SEX : FEMALE

SURVIVAL ANIMAL NUMBERS

Group Name	Animals At start	Administration (Weeks) 84	85	86	87	88	89	90	91	92	93	94	95	96	97
Control	50	46/50	46/50	46/50	46/50	46/50	46/50	46/50	46/50	46/50	46/50	45/50	44/50	44/50	44/50
		92.0	92.0	92.0	92.0	92.0	92.0	92.0	92.0	92.0	92.0	90.0	88.0	88.0	88.0
3.2ppm	50	49/50	49/50	49/50	49/50	49/50	49/50	48/50	48/50	48/50	47/50	46/50	45/50	43/50	43/50
		98.0	98.0	98.0	98.0	98.0	98.0	96.0	96.0	96.0	94.0	92.0	90.0	86.0	86.0
8ppm	50	45/50	44/50	44/50	43/50	43/50	43/50	42/50	41/50	41/50	40/50	40/50	40/50	39/50	39/50
		90.0	88.0	88.0	86.0	86.0	86.0	84.0	82.0	82.0	80.0	80.0	80.0	78.0	78.0
20ppm	50	43/50	43/50	42/50	41/50	41/50	39/50	38/50	38/50	37/50	37/50	37/50	37/50	37/50	37/50
		86.0	86.0	84.0	82.0	82.0	78.0	76.0	76.0	74.0	74.0	74.0	74.0	74.0	74.0

Number of survival/ Number of effective animals
Survival rate(%)

STUDY NO. : 0794 SURVIVAL ANIMAL NUMBERS
ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj]
REPORT TYPE : A1 104
SEX : FEMALE

Group Name	Animals At start	Administration (Weeks) 98	99	100	101	102	103	104
Control	50	42/50	42/50	42/50	41/50	41/50	41/50	39/50
		84.0	84.0	84.0	82.0	82.0	82.0	78.0
3.2ppm	50	43/50	43/50	42/50	42/50	42/50	42/50	39/50
		86.0	86.0	84.0	84.0	84.0	84.0	78.0
8ppm	50	38/50	36/50	36/50	36/50	36/50	36/50	35/50
		76.0	72.0	72.0	72.0	72.0	72.0	70.0
20ppm	50	37/50	35/50	34/50	31/50	30/50	30/50	29/50
		74.0	70.0	68.0	62.0	60.0	60.0	58.0

Number of survival/ Number of effective animals
Survival rate(%)

TABLE C1

CLINICAL OBSERVATION : MALE

STUDY NO. : 0794
ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj]
REPORT TYPE : A1 104

CLINICAL OBSERVATION (SUMMARY)
ALL ANIMALS

SEX : MALE

Clinical sign	Group Name	Administration Week-day 1-7	2-7	3-7	4-7	5-7	6-7	7-7	8-7	9-7	10-7	11-7	12-7	13-7	14-7
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
LOCOMOTOR MOVEMENT DECR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
WASTING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
FROG BELLY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED PERI-GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXOPHTHALMOS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	1
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0794
ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj]
REPORT TYPE : A1 104

CLINICAL OBSERVATION (SUMMARY)
ALL ANIMALS

SEX : MALE

Clinical sign	Group Name	Administration Week-day 15-7	16-7	17-7	18-7	19-7	20-7	21-7	22-7	23-7	24-7	25-7	26-7	27-7	28-7
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
LOCOMOTOR MOVEMENT DECR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
WASTING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
FROG BELLY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED PERI-GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXOPHTHALMOS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	8ppm	0	0	0	1	1	1	1	1	1	1	1	1	1	1
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0794
ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj]
REPORT TYPE : A1 104

CLINICAL OBSERVATION (SUMMARY)
ALL ANIMALS

SEX : MALE

Clinical sign	Group Name	Administration Week-day 29-7	30-7	31-7	32-7	33-7	34-7	35-7	36-7	37-7	38-7	39-7	40-7	41-7	42-7
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
LOCOMOTOR MOVEMENT DECR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
WASTING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
FROG BELLY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED PERI-GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	1	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXOPHTHALMOS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	8ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0794
ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj]
REPORT TYPE : A1 104

CLINICAL OBSERVATION (SUMMARY)
ALL ANIMALS

SEX : MALE

Clinical sign	Group Name	Administration Week-day 43-7	44-7	45-7	46-7	47-7	48-7	49-7	50-7	51-7	52-7	53-7	54-7	55-7	56-7
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
LOCOMOTOR MOVEMENT DECR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
WASTING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
FROG BELLY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED PERI-GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXOPHTHALMOS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	8ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0794
ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj]
REPORT TYPE : A1 104

CLINICAL OBSERVATION (SUMMARY)
ALL ANIMALS

SEX : MALE

Clinical sign	Group Name	Administration Week-day 57-7	58-7	59-7	60-7	61-7	62-7	63-7	64-7	65-7	66-7	67-7	68-7	69-7	70-7
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	1	1	1	1	1	1	1
	20ppm	0	0	0	0	0	0	0	0	0	1	1	1	1	1
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	1	1	1	1
	20ppm	0	0	0	0	0	0	0	0	1	1	3	3	3	3
LOCOMOTOR MOVEMENT DECR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
WASTING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
FROG BELLY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED PERI-GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	1	0	0	0	0
EXOPHTHALMOS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	8ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0794
ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj]
REPORT TYPE : A1 104

CLINICAL OBSERVATION (SUMMARY)
ALL ANIMALS

SEX : MALE

Clinical sign	Group Name	Administration Week-day 71-7	72-7	73-7	74-7	75-7	76-7	77-7	78-7	79-7	80-7	81-7	82-7	83-7	84-7
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	1	1
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	1	1	1	2	3	3	3	3	3	3	3	3	3	3
	20ppm	1	1	1	1	1	1	3	3	4	5	6	6	6	6
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	1	1	1
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	20ppm	3	3	4	4	4	5	6	6	9	10	10	13	13	14
LOCOMOTOR MOVEMENT DECR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
WASTING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	1	0	0	0
FROG BELLY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	1	0	0	0	0
SOILED PERI-GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXOPHTHALMOS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	8ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0794
ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj]
REPORT TYPE : A1 104

CLINICAL OBSERVATION (SUMMARY)
ALL ANIMALS

SEX : MALE

Clinical sign	Group Name	Administration Week-day 85-7	86-7	87-7	88-7	89-7	90-7	91-7	92-7	93-7	94-7	95-7	96-7	97-7	98-7
DEATH	Control	1	1	1	1	1	1	1	2	2	2	3	3	3	3
	3.2ppm	0	0	0	1	1	1	1	1	1	1	1	1	1	1
	8ppm	3	3	3	3	3	4	4	4	4	5	5	5	5	6
	20ppm	6	6	7	7	7	9	9	9	9	9	9	9	9	9
MORIBUND SACRIFICE	Control	1	1	1	1	2	2	2	2	2	2	2	2	2	2
	3.2ppm	0	0	0	0	0	0	0	0	1	1	2	2	2	2
	8ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	20ppm	17	17	17	18	20	21	22	23	24	24	24	26	26	27
LOCOMOTOR MOVEMENT DECR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
WASTING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
FROG BELLY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	1	1	0	0	0	0	0	0	0	0	0
	20ppm	0	1	0	0	1	0	0	0	0	0	0	1	1	0
SOILED PERI-GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	1	1	1
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXOPHTHALMOS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	8ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 99-7	100-7	101-7	102-7	103-7	104-7
DEATH	Control	3	3	3	4	4	6
	3.2ppm	1	1	2	3	3	3
	8ppm	6	6	6	6	8	8
	20ppm	9	9	10	12	13	13
MORIBUND SACRIFICE	Control	2	2	3	3	3	3
	3.2ppm	2	2	2	2	2	3
	8ppm	1	1	2	2	2	3
	20ppm	27	27	28	28	28	28
LOCOMOTOR MOVEMENT DECR	Control	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0
	8ppm	1	1	0	0	0	0
	20ppm	0	0	0	0	0	0
PARALYTIC GAIT	Control	0	0	1	1	1	0
	3.2ppm	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0
WASTING	Control	0	0	0	0	1	1
	3.2ppm	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0
SOILED	Control	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0
FROG BELLY	Control	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0
	8ppm	0	0	1	2	1	1
	20ppm	0	0	0	0	0	0
SOILED PERI-GENITALIA	Control	0	0	0	0	0	0
	3.2ppm	1	1	1	1	1	1
	8ppm	0	0	0	0	0	0
	20ppm	0	0	0	0	0	1
EXOPHTHALMOS	Control	0	0	0	0	0	0
	3.2ppm	1	1	1	1	0	0
	8ppm	1	1	1	1	1	1
	20ppm	0	0	0	0	0	0

STUDY NO. : 0794
ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj]
REPORT TYPE : A1 104

CLINICAL OBSERVATION (SUMMARY)
ALL ANIMALS

SEX : MALE

Clinical sign	Group Name	Administration Week-day 1-7	2-7	3-7	4-7	5-7	6-7	7-7	8-7	9-7	10-7	11-7	12-7	13-7	14-7
CATARACT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CORNEAL OPACITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ANTERIOR CHAMBER OPACITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
INTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.NOSE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.EYE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.PERI-MOUTH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.ORAL CAVITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0794
ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj]
REPORT TYPE : A1 104

CLINICAL OBSERVATION (SUMMARY)
ALL ANIMALS

SEX : MALE

Clinical sign	Group Name	Administration Week-day 15-7	16-7	17-7	18-7	19-7	20-7	21-7	22-7	23-7	24-7	25-7	26-7	27-7	28-7
CATARACT	Control	0	0	1	1	1	1	1	1	1	1	1	1	1	1
	3.2ppm	0	0	0	0	0	1	1	0	0	0	0	0	0	0
	8ppm	0	0	0	0	1	1	1	1	1	1	1	1	1	1
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CORNEAL OPACITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ANTERIOR CHAMBER OPACITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
INTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.NOSE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.EYE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.PERI-MOUTH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.ORAL CAVITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0794
ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj]
REPORT TYPE : A1 104

CLINICAL OBSERVATION (SUMMARY)
ALL ANIMALS

SEX : MALE

Clinical sign	Group Name	Administration Week-day 29-7	30-7	31-7	32-7	33-7	34-7	35-7	36-7	37-7	38-7	39-7	40-7	41-7	42-7
CATARACT	Control	1	1	1	1	1	1	2	2	2	2	2	2	2	2
	3.2ppm	0	0	0	0	0	0	0	1	1	1	1	2	2	2
	8ppm	1	1	2	2	3	3	3	3	3	3	3	3	3	3
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CORNEAL OPACITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ANTERIOR CHAMBER OPACITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	0	0	0	0	0	0	0	0	1	1	1	1	1	1
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	1	1	1	1	1	1	1
	20ppm	0	0	0	0	0	0	0	0	0	0	0	1	1	1
INTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.NOSE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.EYE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.PERI-MOUTH	Control	0	0	0	0	0	0	0	0	1	1	1	1	1	1
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	1	1	1	1	1	1	1
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.ORAL CAVITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0794
ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj]
REPORT TYPE : A1 104

CLINICAL OBSERVATION (SUMMARY)
ALL ANIMALS

SEX : MALE

Clinical sign	Group Name	Administration Week-day 43-7	44-7	45-7	46-7	47-7	48-7	49-7	50-7	51-7	52-7	53-7	54-7	55-7	56-7
CATARACT	Control	2	2	2	2	2	2	2	2	2	2	2	2	2	2
	3.2ppm	2	2	2	2	3	3	3	4	4	4	4	4	4	4
	8ppm	3	3	3	3	3	3	4	4	4	4	4	4	5	5
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CORNEAL OPACITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ANTERIOR CHAMBER OPACITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	1	1
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	1	1	1	1	1	1	1	1	1	2	2	2	2	2
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	1	1
	8ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	20ppm	1	1	1	1	1	2	2	2	2	2	2	2	2	3
INTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.NOSE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.EYE	Control	0	0	0	0	0	0	0	0	0	1	1	1	1	1
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.PERI-MOUTH	Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	20ppm	0	0	0	0	0	1	1	1	1	1	1	1	1	1
M.ORAL CAVITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0794
ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj]
REPORT TYPE : A1 104

CLINICAL OBSERVATION (SUMMARY)
ALL ANIMALS

SEX : MALE

Clinical sign	Group Name	Administration Week-day 57-7	58-7	59-7	60-7	61-7	62-7	63-7	64-7	65-7	66-7	67-7	68-7	69-7	70-7
CATARACT	Control	2	2	3	3	3	3	3	3	3	3	3	3	3	3
	3.2ppm	4	4	4	4	4	4	4	4	4	4	4	4	4	4
	8ppm	5	5	5	5	5	5	5	4	4	4	4	4	4	4
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CORNEAL OPACITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	1	1	1	1
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ANTERIOR CHAMBER OPACITY	Control	1	1	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	2	2	2	2	2	2	2	2	2	2	2	2	2	2
	3.2ppm	1	1	2	2	2	2	2	2	2	2	2	2	3	3
	8ppm	2	2	2	2	3	3	3	4	4	4	3	3	3	3
	20ppm	3	3	3	3	3	4	5	5	5	5	4	5	7	7
INTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.NOSE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	1	1	1	1	0	0	0	0
M.EYE	Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.PERI-MOUTH	Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	20ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
M.ORAL CAVITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0794
ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj]
REPORT TYPE : A1 104

CLINICAL OBSERVATION (SUMMARY)
ALL ANIMALS

SEX : MALE

Clinical sign	Group Name	Administration Week-day 71-7	72-7	73-7	74-7	75-7	76-7	77-7	78-7	79-7	80-7	81-7	82-7	83-7	84-7
CATARACT	Control	3	3	3	3	5	5	5	5	5	5	5	5	5	5
	3.2ppm	4	4	4	4	4	4	4	4	4	4	4	4	4	4
	8ppm	4	4	4	4	4	4	4	4	4	4	4	5	5	5
	20ppm	0	0	0	0	0	0	0	0	0	0	0	1	1	1
CORNEAL OPACITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	1	1	1	1	1	1	1	0	0	0	0	0	0	0
	20ppm	0	0	0	0	1	1	0	0	0	0	0	0	0	0
ANTERIOR CHAMBER OPACITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	2	2	2	2	2	2	2	2	3	4	4	4	3	3
	3.2ppm	3	3	3	4	5	6	6	6	6	6	6	7	7	7
	8ppm	5	5	5	5	5	5	5	5	5	5	5	5	4	7
	20ppm	7	8	7	7	7	6	6	3	5	5	6	6	7	7
INTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.NOSE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	1	0	0	0	0	0	0	0	0	1	0	0	0
M.EYE	Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.PERI-MOUTH	Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	1	1	1	1	1	1	1	1	1	1	1	1	0	0
	20ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
M.ORAL CAVITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0794
ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj]
REPORT TYPE : A1 104

CLINICAL OBSERVATION (SUMMARY)
ALL ANIMALS

SEX : MALE

Clinical sign	Group Name	Administration Week-day 85-7	86-7	87-7	88-7	89-7	90-7	91-7	92-7	93-7	94-7	95-7	96-7	97-7	98-7
CATARACT	Control	5	5	5	5	5	5	5	5	5	5	5	5	5	5
	3.2ppm	4	4	4	4	4	5	5	5	5	5	5	5	5	5
	8ppm	5	5	5	6	6	6	6	6	6	6	6	6	6	6
	20ppm	1	1	1	1	1	0	0	0	0	0	0	0	0	0
CORNEAL OPACITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ANTERIOR CHAMBER OPACITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	4	4	4	4	4	5	5	4	4	4	4	6	6	6
	3.2ppm	7	7	8	7	8	10	10	10	9	9	8	8	8	9
	8ppm	8	8	10	10	10	10	10	10	10	11	10	10	10	10
	20ppm	6	6	6	7	6	3	5	7	7	7	7	8	8	8
INTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.NOSE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	1	1	1	1	1	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	1	1	0	0	0	1	0	0	0	0	0	0
M.EYE	Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.PERI-MOUTH	Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	2
M.ORAL CAVITY	Control	0	0	0	0	0	1	1	1	1	1	1	1	1	1
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 99-7	100-7	101-7	102-7	103-7	104-7
CATARACT	Control	5	5	5	5	5	6
	3.2ppm	5	5	5	5	5	5
	8ppm	6	6	5	5	5	6
	20ppm	0	0	0	0	0	0
CORNEAL OPACITY	Control	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0
ANTERIOR CHAMBER OPACITY	Control	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0
EXTERNAL MASS	Control	6	6	5	4	4	4
	3.2ppm	10	10	10	10	11	10
	8ppm	10	10	11	14	14	14
	20ppm	8	8	7	6	5	5
INTERNAL MASS	Control	0	0	0	0	1	0
	3.2ppm	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0
M.NOSE	Control	0	0	0	0	0	1
	3.2ppm	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0
M.EYE	Control	1	1	1	1	1	1
	3.2ppm	0	0	0	0	0	0
	8ppm	1	1	1	1	1	1
	20ppm	0	0	0	0	0	0
M.PERI-MOUTH	Control	1	1	0	0	0	0
	3.2ppm	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0
	20ppm	2	2	1	1	1	1
M.ORAL CAVITY	Control	1	1	1	1	1	1
	3.2ppm	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 1-7	2-7	3-7	4-7	5-7	6-7	7-7	8-7	9-7	10-7	11-7	12-7	13-7	14-7
M.EAR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.PERI EAR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.BREAST	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.ABDOMEN	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.ANTERIOR.DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.POSTERIOR DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.HINDLIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 15-7	16-7	17-7	18-7	19-7	20-7	21-7	22-7	23-7	24-7	25-7	26-7	27-7	28-7
M.EAR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.PERI EAR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.BREAST	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.ABDOMEN	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.ANTERIOR.DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.POSTERIOR DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.HINDLIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 29-7	30-7	31-7	32-7	33-7	34-7	35-7	36-7	37-7	38-7	39-7	40-7	41-7	42-7
M.EAR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.PERI EAR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.BREAST	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.ABDOMEN	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.ANTERIOR.DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	1	1	1
M.POSTERIOR DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.HINDLIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0794
ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj]
REPORT TYPE : A1 104

CLINICAL OBSERVATION (SUMMARY)
ALL ANIMALS

SEX : MALE

Clinical sign	Group Name	Administration Week-day 43-7	44-7	45-7	46-7	47-7	48-7	49-7	50-7	51-7	52-7	53-7	54-7	55-7	56-7
M.EAR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.PERI EAR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.BREAST	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	1	1
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.ABDOMEN	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.ANTERIOR.DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
M.POSTERIOR DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	1
M.HINDLIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0794
ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj]
REPORT TYPE : A1 104

CLINICAL OBSERVATION (SUMMARY)
ALL ANIMALS

SEX : MALE

Clinical sign	Group Name	Administration Week-day 57-7	58-7	59-7	60-7	61-7	62-7	63-7	64-7	65-7	66-7	67-7	68-7	69-7	70-7
M.EAR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	1	1	1	1	1	1	1	1	1	1
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.PERI EAR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.BREAST	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.ABDOMEN	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	1	1	1	1	1	1	1	1	1	1	1	1
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	1	1	1
M.ANTERIOR.DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	1	1
	8ppm	0	0	0	0	0	0	0	1	1	1	0	0	0	0
	20ppm	1	1	1	1	1	1	1	1	1	1	1	1	2	2
M.POSTERIOR DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	1	1	1	1	1	2	2	2	2	2	2	2	3	3
M.HINDLIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	1	0	0	0	0	0	0	0	0	0

STUDY NO. : 0794
ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj]
REPORT TYPE : A1 104

CLINICAL OBSERVATION (SUMMARY)
ALL ANIMALS

SEX : MALE

Clinical sign	Group Name	Administration Week-day 71-7	72-7	73-7	74-7	75-7	76-7	77-7	78-7	79-7	80-7	81-7	82-7	83-7	84-7
M.EAR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.PERI EAR	Control	0	0	0	0	0	0	0	0	0	1	1	1	1	1
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.BREAST	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	1	1	1	2	2	2	2	3	3	3	3	3	3	3
	8ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.ABDOMEN	Control	0	0	0	0	0	0	0	0	1	1	1	1	1	1
	3.2ppm	1	1	1	1	2	2	2	2	2	2	2	2	2	2
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	1
	20ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
M.ANTERIOR.DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	1	1	1	1	1	2	2	2	2	2	2	3	3	3
	8ppm	1	1	1	1	1	1	1	1	1	1	1	2	2	3
	20ppm	2	2	2	2	2	2	2	0	2	2	2	2	3	3
M.POSTERIOR DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	3	3	3	3	3	2	2	1	1	1	1	2	2	2
M.HINDLIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	1	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	1	0	0	0	0	0	1

STUDY NO. : 0794
ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj]
REPORT TYPE : A1 104

CLINICAL OBSERVATION (SUMMARY)
ALL ANIMALS

SEX : MALE

Clinical sign	Group Name	Administration Week-day 85-7	86-7	87-7	88-7	89-7	90-7	91-7	92-7	93-7	94-7	95-7	96-7	97-7	98-7
M.EAR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	20ppm	0	0	0	0	0	0	0	0	1	1	1	1	1	1
M.PERI EAR	Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.BREAST	Control	1	1	1	1	1	1	1	0	0	0	0	1	1	1
	3.2ppm	3	3	3	2	2	2	2	2	2	2	2	2	2	3
	8ppm	1	1	2	2	2	2	2	2	2	2	2	2	2	2
	20ppm	0	0	0	0	0	0	0	1	1	1	1	1	1	1
M.ABDOMEN	Control	1	1	1	1	1	1	1	1	1	1	1	2	2	2
	3.2ppm	2	2	2	2	2	2	2	2	2	2	2	2	2	2
	8ppm	1	1	2	2	2	2	2	2	2	2	2	2	2	2
	20ppm	1	1	1	1	1	0	0	2	2	2	2	2	2	1
M.ANTERIOR.DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	3	3	4	3	4	4	4	4	3	3	3	3	3	3
	8ppm	3	3	3	3	3	3	3	3	3	4	4	4	4	4
	20ppm	2	2	1	1	1	0	1	2	2	2	2	2	2	3
M.POSTERIOR DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	1	1	1	1	1	1	1	1	1
	8ppm	1	1	1	1	1	1	1	1	1	1	0	0	0	0
	20ppm	2	2	2	3	3	2	2	1	1	1	1	1	1	1
M.HINDLIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	1	1	1	1	1	1	1	1
M.GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	1	1	1
ANEMIA	Control	0	0	0	0	1	1	1	1	1	1	1	1	1	1
	3.2ppm	0	0	0	0	0	0	0	1	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	1	0	0	0	0	0	0	0	0	0	1	0	0	0

STUDY NO. : 0794
ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj]
REPORT TYPE : A1 104

CLINICAL OBSERVATION (SUMMARY)
ALL ANIMALS

SEX : MALE

Clinical sign	Group Name	Administration Week-day 99-7	100-7	101-7	102-7	103-7	104-7
M.EAR	Control	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0
	8ppm	1	1	1	1	1	1
	20ppm	1	1	1	1	1	1
M.PERI EAR	Control	1	1	1	0	0	0
	3.2ppm	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0
M.BREAST	Control	1	2	1	1	2	2
	3.2ppm	4	5	5	5	6	6
	8ppm	2	2	2	2	2	2
	20ppm	1	1	1	1	0	0
M.ABDOMEN	Control	2	2	2	2	1	1
	3.2ppm	2	2	2	2	2	2
	8ppm	2	2	2	3	3	3
	20ppm	1	1	2	1	1	1
M.ANTERIOR.DORSUM	Control	0	0	0	0	0	0
	3.2ppm	3	2	2	2	2	1
	8ppm	4	4	4	6	6	6
	20ppm	3	3	3	2	2	3
M.POSTERIOR DORSUM	Control	0	0	0	0	0	0
	3.2ppm	1	1	2	2	2	2
	8ppm	0	0	2	2	2	2
	20ppm	2	2	1	1	1	1
M.HINDLIMB	Control	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0
	20ppm	1	1	1	1	0	0
M.GENITALIA	Control	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0
	20ppm	1	1	1	1	1	1
ANEMIA	Control	1	2	2	0	0	1
	3.2ppm	0	0	0	0	0	0
	8ppm	0	0	3	2	1	2
	20ppm	0	0	2	1	0	0

Clinical sign	Group Name	Administration Week-day 1-7	2-7	3-7	4-7	5-7	6-7	7-7	8-7	9-7	10-7	11-7	12-7	13-7	14-7
ULCER	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EROSION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PROLAPSE OF PENIS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
IRREGULAR BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
RESPIRATORY SOUND ABNOR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NOISY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 15-7	16-7	17-7	18-7	19-7	20-7	21-7	22-7	23-7	24-7	25-7	26-7	27-7	28-7
ULCER	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EROSION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PROLAPSE OF PENIS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
IRREGULAR BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
RESPIRATORY SOUND ABNOR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NOISY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 29-7	30-7	31-7	32-7	33-7	34-7	35-7	36-7	37-7	38-7	39-7	40-7	41-7	42-7
ULCER	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EROSION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PROLAPSE OF PENIS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
IRREGULAR BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
RESPIRATORY SOUND ABNOR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NOISY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 43-7	44-7	45-7	46-7	47-7	48-7	49-7	50-7	51-7	52-7	53-7	54-7	55-7	56-7
ULCER	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EROSION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PROLAPSE OF PENIS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
IRREGULAR BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
RESPIRATORY SOUND ABNOR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NOISY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 57-7	58-7	59-7	60-7	61-7	62-7	63-7	64-7	65-7	66-7	67-7	68-7	69-7	70-7
ULCER	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EROSION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PROLAPSE OF PENIS	Control	0	0	0	0	0	1	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
IRREGULAR BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	1	2	2	2	1	0	0	0	0
RESPIRATORY SOUND ABNOR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NOISY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 71-7	72-7	73-7	74-7	75-7	76-7	77-7	78-7	79-7	80-7	81-7	82-7	83-7	84-7
ULCER	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EROSION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PROLAPSE OF PENIS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	1
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
IRREGULAR BREATHING	Control	0	0	0	0	0	0	0	0	0	0	1	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	1	1	1	1	2	0	3	2	2	4	1	2	3
RESPIRATORY SOUND ABNOR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	2	2	0	1	0	0	0
NOISY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	1	1	1	0	0	0	2	2	1	1	2

Clinical sign	Group Name	Administration Week-day 85-7	86-7	87-7	88-7	89-7	90-7	91-7	92-7	93-7	94-7	95-7	96-7	97-7	98-7
ULCER	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	1	1	1	1	1	1	1	1	1	1	1	1	1
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EROSION	Control	0	0	0	0	0	0	0	0	0	0	0	0	1	1
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HEMORRHAGE	Control	0	0	0	0	0	1	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PROLAPSE OF PENIS	Control	1	1	1	1	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
IRREGULAR BREATHING	Control	0	0	1	1	1	1	1	1	1	2	2	2	2	2
	3.2ppm	0	0	0	0	0	0	0	1	1	2	1	1	1	1
	8ppm	0	0	0	0	0	0	0	0	0	0	0	1	1	1
	20ppm	0	1	2	3	2	1	0	2	1	2	2	1	1	3
RESPIRATORY SOUND ABNOR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NOISY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	1	1
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	1	2	2	1	1	0	1	1	1	1	0	0	0

Clinical sign	Group Name	Administration Week-day 99-7	100-7	101-7	102-7	103-7	104-7
ULCER	Control	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0
	8ppm	1	1	0	0	0	0
	20ppm	0	0	0	0	0	0
EROSION	Control	1	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0
HEMORRHAGE	Control	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0
PROLAPSE OF PENIS	Control	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0
	20ppm	0	0	0	0	0	1
IRREGULAR BREATHING	Control	2	2	2	1	1	1
	3.2ppm	1	0	1	1	1	1
	8ppm	1	1	0	0	1	0
	20ppm	3	4	3	1	1	1
RESPIRATORY SOUND ABNOR	Control	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0
NOISY	Control	0	0	0	0	0	0
	3.2ppm	1	1	1	1	1	0
	8ppm	0	0	0	0	0	0
	20ppm	2	2	0	0	0	0

TABLE C2

CLINICAL OBSERVATION : FEMALE

STUDY NO. : 0794
ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj]
REPORT TYPE : A1 104

CLINICAL OBSERVATION (SUMMARY)
ALL ANIMALS

SEX : FEMALE

Clinical sign	Group Name	Administration Week-day 1-7	2-7	3-7	4-7	5-7	6-7	7-7	8-7	9-7	10-7	11-7	12-7	13-7	14-7
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
LOCOMOTOR MOVEMENT DECR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ATAXIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
WASTING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
FROG BELLY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED PERI-GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0794
ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj]
REPORT TYPE : A1 104

CLINICAL OBSERVATION (SUMMARY)
ALL ANIMALS

SEX : FEMALE

Clinical sign	Group Name	Administration Week-day 15-7	16-7	17-7	18-7	19-7	20-7	21-7	22-7	23-7	24-7	25-7	26-7	27-7	28-7
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
LOCOMOTOR MOVEMENT DECR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ATAXIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
WASTING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
FROG BELLY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED PERI-GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0794
ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj]
REPORT TYPE : A1 104

CLINICAL OBSERVATION (SUMMARY)
ALL ANIMALS

SEX : FEMALE

Clinical sign	Group Name	Administration Week-day 29-7	30-7	31-7	32-7	33-7	34-7	35-7	36-7	37-7	38-7	39-7	40-7	41-7	42-7
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
LOCOMOTOR MOVEMENT DECR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ATAXIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
WASTING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
FROG BELLY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED PERI-GENITALIA	Control	0	0	0	0	0	0	0	0	0	1	1	0	0	1
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0794
ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj]
REPORT TYPE : A1 104

CLINICAL OBSERVATION (SUMMARY)
ALL ANIMALS

SEX : FEMALE

Clinical sign	Group Name	Administration Week-day 43-7	44-7	45-7	46-7	47-7	48-7	49-7	50-7	51-7	52-7	53-7	54-7	55-7	56-7
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	1	1	1	1	1	1
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
LOCOMOTOR MOVEMENT DECR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ATAXIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	1	1	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
WASTING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	1
FROG BELLY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED PERI-GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	1	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	1	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	1

STUDY NO. : 0794
ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj]
REPORT TYPE : A1 104

CLINICAL OBSERVATION (SUMMARY)
ALL ANIMALS

SEX : FEMALE

Clinical sign	Group Name	Administration Week-day 57-7	58-7	59-7	60-7	61-7	62-7	63-7	64-7	65-7	66-7	67-7	68-7	69-7	70-7
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	1	2	2	2	2	2	2	2	2	2	2	2	2	2
	20ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	1	1	1	1	1	1	1	1	1	1	1	1	1
LOCOMOTOR MOVEMENT DECR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ATAXIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
WASTING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
FROG BELLY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED PERI-GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 71-7	72-7	73-7	74-7	75-7	76-7	77-7	78-7	79-7	80-7	81-7	82-7	83-7	84-7
DEATH	Control	0	0	0	0	0	2	2	2	2	2	2	2	3	3
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	2	2	2	2	2	2	2	2	3	3	3	3	4	4
	20ppm	1	2	2	2	2	2	2	2	2	2	2	2	2	2
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	1	1	1	1
	3.2ppm	0	0	0	0	0	0	0	0	0	1	1	1	1	1
	8ppm	0	0	1	1	1	1	1	1	1	1	1	1	1	1
	20ppm	1	1	1	1	1	1	1	2	2	2	3	4	5	5
LOCOMOTOR MOVEMENT DECR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ATAXIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	1	0	0	0	0	0	0	0	0	0	0	0	0	0
PARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
WASTING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
FROG BELLY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED PERI-GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	1	0	0	0	1	1	0	0

Clinical sign	Group Name	Administration Week-day 85-7	86-7	87-7	88-7	89-7	90-7	91-7	92-7	93-7	94-7	95-7	96-7	97-7	98-7
DEATH	Control	3	3	3	3	3	3	3	3	3	3	4	4	4	5
	3.2ppm	0	0	0	0	0	0	0	0	1	1	1	1	1	1
	8ppm	4	4	4	4	4	5	6	6	6	6	6	6	6	6
	20ppm	2	3	3	3	4	5	5	6	6	6	6	6	6	6
MORIBUND SACRIFICE	Control	1	1	1	1	1	1	1	1	1	2	2	2	2	3
	3.2ppm	1	1	1	1	1	2	2	2	2	3	4	6	6	6
	8ppm	2	2	3	3	3	3	3	3	4	4	4	5	5	6
	20ppm	5	5	6	6	7	7	7	7	7	7	7	7	7	7
LOCOMOTOR MOVEMENT DECR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	1	0	0	0	0	0	0	0	0	0	0
ATAXIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
WASTING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	1	0	0	0	0	0	0	0	0	0	0	0	1
SOILED	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
FROG BELLY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED PERI-GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	1	1	1	0	0	0	1	0	0	0
	20ppm	0	0	0	1	0	0	0	0	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 99-7	100-7	101-7	102-7	103-7	104-7
DEATH	Control	5	5	5	5	5	6
	3.2ppm	1	2	2	2	2	3
	8ppm	6	6	6	6	6	7
	20ppm	6	7	7	7	7	8
MORIBUND SACRIFICE	Control	3	3	4	4	4	5
	3.2ppm	6	6	6	6	6	8
	8ppm	8	8	8	8	8	8
	20ppm	9	9	12	13	13	13
LOCOMOTOR MOVEMENT DECR	Control	0	0	0	0	0	0
	3.2ppm	0	0	0	0	1	0
	8ppm	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0
ATAXIC GAIT	Control	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0
PARALYTIC GAIT	Control	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0
WASTING	Control	0	0	0	0	0	0
	3.2ppm	0	0	0	0	1	0
	8ppm	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0
SOILED	Control	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0
FROG BELLY	Control	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0
	20ppm	0	0	0	0	0	1
SOILED PERI-GENITALIA	Control	0	0	0	0	0	0
	3.2ppm	0	1	1	1	1	1
	8ppm	0	0	1	0	0	0
	20ppm	0	0	0	0	1	2

Clinical sign	Group Name	Administration Week-day 1-7	2-7	3-7	4-7	5-7	6-7	7-7	8-7	9-7	10-7	11-7	12-7	13-7	14-7
EXOPHTHALMOS	Control	0	0	0	0	1	1	1	1	1	1	1	1	2	2
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CATARACT	Control	0	0	0	0	0	0	0	0	0	1	1	1	1	1
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	1
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CORNEAL OPACITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ANTERIOR CHAMBER OPACITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
INTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.PERI-MOUTH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.ORAL CAVITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.PERI EAR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 15-7	16-7	17-7	18-7	19-7	20-7	21-7	22-7	23-7	24-7	25-7	26-7	27-7	28-7
EXOPHTHALMOS	Control	2	2	2	2	2	2	2	2	2	2	2	2	2	2
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CATARACT	Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	3.2ppm	1	1	1	1	1	1	1	1	1	1	2	2	2	2
	8ppm	0	0	0	0	0	0	1	1	1	1	1	1	1	1
	20ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
CORNEAL OPACITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ANTERIOR CHAMBER OPACITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
INTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.PERI-MOUTH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.ORAL CAVITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.PERI EAR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0794
ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj]
REPORT TYPE : A1 104

CLINICAL OBSERVATION (SUMMARY)
ALL ANIMALS

SEX : FEMALE

Clinical sign	Group Name	Administration Week-day 29-7	30-7	31-7	32-7	33-7	34-7	35-7	36-7	37-7	38-7	39-7	40-7	41-7	42-7
EXOPHTHALMOS	Control	2	2	2	2	2	1	1	1	1	1	1	1	1	1
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CATARACT	Control	1	2	2	2	2	2	3	3	3	3	3	3	3	4
	3.2ppm	2	2	2	2	2	2	2	2	2	2	2	2	2	2
	8ppm	1	1	1	1	1	1	1	2	2	2	2	2	2	2
	20ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
CORNEAL OPACITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ANTERIOR CHAMBER OPACITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
INTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.PERI-MOUTH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.ORAL CAVITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.PERI EAR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 43-7	44-7	45-7	46-7	47-7	48-7	49-7	50-7	51-7	52-7	53-7	54-7	55-7	56-7
EXOPHTHALMOS	Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CATARACT	Control	4	4	4	4	4	4	4	4	4	4	4	4	4	4
	3.2ppm	2	2	2	2	2	2	2	2	2	2	2	2	2	2
	8ppm	2	2	2	2	2	2	2	2	2	2	2	2	2	2
	20ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
CORNEAL OPACITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ANTERIOR CHAMBER OPACITY	Control	0	0	0	0	0	0	0	0	0	0	0	1	1	1
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	1	1
	3.2ppm	0	0	0	0	0	0	1	1	1	1	1	1	1	1
	8ppm	0	0	0	0	0	0	1	1	0	0	1	1	1	1
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
INTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	1
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	1
M.PERI-MOUTH	Control	0	0	0	0	0	0	0	0	0	0	0	0	1	1
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	1	1	1	1
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.ORAL CAVITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.PERI EAR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 57-7	58-7	59-7	60-7	61-7	62-7	63-7	64-7	65-7	66-7	67-7	68-7	69-7	70-7
EXOPHTHALMOS	Control	1	1	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CATARACT	Control	4	4	4	5	5	5	5	5	5	5	5	5	5	5
	3.2ppm	2	2	2	2	2	2	2	2	2	2	2	2	2	2
	8ppm	2	2	2	2	2	2	2	2	2	2	2	2	2	2
	20ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
CORNEAL OPACITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ANTERIOR CHAMBER OPACITY	Control	1	1	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	3.2ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	2
	8ppm	1	1	1	1	1	1	1	1	1	1	2	2	2	2
	20ppm	1	1	1	1	1	2	2	2	3	3	3	3	4	5
INTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	1	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.PERI-MOUTH	Control	1	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.ORAL CAVITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.PERI EAR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 71-7	72-7	73-7	74-7	75-7	76-7	77-7	78-7	79-7	80-7	81-7	82-7	83-7	84-7
EXOPHTHALMOS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CATARACT	Control	5	5	5	5	5	5	5	5	5	5	5	5	5	5
	3.2ppm	2	2	2	2	2	2	2	2	2	2	2	2	2	2
	8ppm	2	2	2	2	2	2	2	2	2	2	2	2	2	2
	20ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
CORNEAL OPACITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ANTERIOR CHAMBER OPACITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	1	1	1	2	2	2	2	2	2	2	2	2	2	2
	3.2ppm	2	2	2	2	3	3	3	3	3	2	3	3	3	3
	8ppm	2	4	4	4	4	4	4	4	4	4	4	4	4	4
	20ppm	6	5	6	6	6	6	6	7	7	8	8	8	7	7
INTERNAL MASS	Control	0	1	1	1	1	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.PERI-MOUTH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	1	1	1	1	1	1	1	1	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.ORAL CAVITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.PERI EAR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 85-7	86-7	87-7	88-7	89-7	90-7	91-7	92-7	93-7	94-7	95-7	96-7	97-7	98-7
EXOPHTHALMOS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CATARACT	Control	5	5	5	5	5	5	6	6	6	6	6	6	6	6
	3.2ppm	2	2	2	2	2	2	2	2	2	2	2	2	2	2
	8ppm	2	2	2	2	2	2	2	2	2	2	2	2	2	2
	20ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
CORNEAL OPACITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	1	1	1	1
ANTERIOR CHAMBER OPACITY	Control	0	0	0	0	0	0	1	1	1	1	1	1	1	1
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	2	2	2	2	2	2	2	2	2	2	3	4	4	3
	3.2ppm	5	7	7	7	8	7	7	8	7	9	9	9	9	11
	8ppm	4	4	5	6	7	6	7	7	7	8	9	10	14	14
	20ppm	7	7	7	7	7	6	6	5	6	6	6	7	7	7
INTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	1	0	0	0	0
	8ppm	0	0	0	0	0	0	0	1	0	0	1	0	0	0
	20ppm	0	1	1	1	0	0	0	0	0	0	0	0	0	0
M.PERI-MOUTH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	1	1	1	1	1	1	1	1	1	1
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.ORAL CAVITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.PERI EAR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	1	1	1
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 99-7	100-7	101-7	102-7	103-7	104-7
EXOPHTHALMOS	Control	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0
CATARACT	Control	6	6	6	6	6	5
	3.2ppm	2	2	2	2	2	2
	8ppm	2	2	2	2	2	2
	20ppm	1	1	1	1	1	1
CORNEAL OPACITY	Control	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0
ANTERIOR CHAMBER OPACITY	Control	1	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0
EXTERNAL MASS	Control	4	4	6	6	6	6
	3.2ppm	11	10	12	13	13	15
	8ppm	13	13	15	14	16	15
	20ppm	7	6	6	8	13	15
INTERNAL MASS	Control	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0
	8ppm	0	0	0	1	1	1
	20ppm	0	0	1	0	0	0
M.PERI-MOUTH	Control	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0
	8ppm	1	1	1	1	1	1
	20ppm	0	0	0	0	0	0
M.ORAL CAVITY	Control	0	0	0	0	0	0
	3.2ppm	0	0	1	1	1	1
	8ppm	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0
M.PERI EAR	Control	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0
	8ppm	1	1	1	1	1	1
	20ppm	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 1-7	2-7	3-7	4-7	5-7	6-7	7-7	8-7	9-7	10-7	11-7	12-7	13-7	14-7
M.NECK	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.BREAST	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.ABDOMEN	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.ANTERIOR.DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.POSTERIOR DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.HINDLIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CRUSTA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 15-7	16-7	17-7	18-7	19-7	20-7	21-7	22-7	23-7	24-7	25-7	26-7	27-7	28-7
M. NECK	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. BREAST	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. ABDOMEN	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. ANTERIOR. DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. POSTERIOR DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. HINDLIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CRUSTA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 29-7	30-7	31-7	32-7	33-7	34-7	35-7	36-7	37-7	38-7	39-7	40-7	41-7	42-7
M.NECK	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.BREAST	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.ABDOMEN	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.ANTERIOR.DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.POSTERIOR DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.HINDLIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CRUSTA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	1	1	1
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 43-7	44-7	45-7	46-7	47-7	48-7	49-7	50-7	51-7	52-7	53-7	54-7	55-7	56-7
M.NECK	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.BREAST	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	1	1	1	1	1	1	1	1
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.ABDOMEN	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.ANTERIOR.DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	1	1	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.POSTERIOR DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.HINDLIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	1	1	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CRUSTA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	1	1	1	1	1	1	1	1	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0794
ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj]
REPORT TYPE : A1 104

CLINICAL OBSERVATION (SUMMARY)
ALL ANIMALS

SEX : FEMALE

Clinical sign	Group Name	Administration Week-day 57-7	58-7	59-7	60-7	61-7	62-7	63-7	64-7	65-7	66-7	67-7	68-7	69-7	70-7
M.NECK	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.BREAST	Control	0	1	1	1	1	1	1	1	1	1	1	1	1	1
	3.2ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	2
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	1
M.ABDOMEN	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	1	1	1	1
	20ppm	0	0	0	0	0	1	1	1	1	1	1	1	1	1
M.ANTERIOR.DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.POSTERIOR DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.HINDLIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	1	1	1	1	1	1	1	1	2	2	2	2	3	3
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	1	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	1	0	0	0	0	0	0	0	0	0
CRUSTA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0794
ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj]
REPORT TYPE : A1 104

CLINICAL OBSERVATION (SUMMARY)
ALL ANIMALS

SEX : FEMALE

Clinical sign	Group Name	Administration Week-day 71-7	72-7	73-7	74-7	75-7	76-7	77-7	78-7	79-7	80-7	81-7	82-7	83-7	84-7
M.NECK	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.BREAST	Control	1	1	1	2	2	2	2	2	2	2	2	2	2	2
	3.2ppm	2	2	2	2	2	2	2	2	2	1	1	1	1	1
	8ppm	0	1	1	1	1	1	1	1	1	1	1	1	1	1
	20ppm	1	1	1	1	1	1	1	2	2	3	3	3	3	3
M.ABDOMEN	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	1
	8ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	20ppm	2	2	2	2	2	2	2	2	2	2	1	1	1	1
M.ANTERIOR.DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.POSTERIOR DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	1	1	1	1	1	1	1	1	1	1
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.HINDLIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	1	1	1	0
	8ppm	0	1	1	1	1	1	1	1	2	2	2	2	2	2
	20ppm	3	2	3	3	3	3	3	3	3	3	4	4	3	3
ANEMIA	Control	0	1	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	1	1	1	1	1	1	1	1
	20ppm	0	0	0	0	0	0	0	0	0	0	0	1	1	1
CRUSTA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 85-7	86-7	87-7	88-7	89-7	90-7	91-7	92-7	93-7	94-7	95-7	96-7	97-7	98-7
M.NECK	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	1	1	1	1	1	1	1	1	1	1
M.BREAST	Control	2	2	2	2	2	2	2	2	2	2	3	4	4	3
	3.2ppm	3	4	4	4	4	4	4	5	5	7	7	7	7	8
	8ppm	1	1	2	2	2	2	3	3	3	3	4	4	8	8
	20ppm	3	3	3	3	3	3	3	3	4	4	4	4	4	4
M.ABDOMEN	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	1	1	1	1	2	1	1	1	1	1	1	1	1	2
	8ppm	1	1	1	2	2	2	2	2	2	3	3	3	4	4
	20ppm	1	1	1	1	1	1	1	0	0	0	0	1	1	1
M.ANTERIOR.DORSUM	Control	0	0	0	0	0	0	0	0	0	0	1	1	1	1
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.POSTERIOR DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	1	1	1	1	1	1	1	1	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.HINDLIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	1	1	1	1	1	1	1	1	1	1	1	1	1
	8ppm	2	2	2	2	2	1	1	1	1	1	1	1	1	1
	20ppm	3	3	3	3	2	1	1	1	1	1	1	1	1	1
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	1	1	0
	3.2ppm	0	0	0	0	0	0	0	0	1	1	0	0	0	0
	8ppm	3	2	1	1	2	1	1	2	1	1	1	1	0	0
	20ppm	1	1	1	1	0	0	0	0	0	0	0	0	0	0
CRUSTA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 99-7	100-7	101-7	102-7	103-7	104-7
M. NECK	Control	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0
	20ppm	2	2	2	2	2	1
M. BREAST	Control	3	3	3	3	3	3
	3.2ppm	8	7	8	9	9	10
	8ppm	8	8	8	9	10	9
	20ppm	3	2	2	4	9	12
M. ABDOMEN	Control	1	1	2	2	2	2
	3.2ppm	2	2	2	2	2	3
	8ppm	3	3	5	4	5	4
	20ppm	1	1	1	1	1	1
M. ANTERIOR. DORSUM	Control	1	1	1	1	1	1
	3.2ppm	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0
M. POSTERIOR DORSUM	Control	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0
M. HINDLIMB	Control	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0
M. GENITALIA	Control	0	0	1	1	1	1
	3.2ppm	1	1	1	2	2	2
	8ppm	1	1	1	1	1	1
	20ppm	1	1	1	1	1	2
ANEMIA	Control	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0
	8ppm	0	0	2	2	1	1
	20ppm	0	1	1	0	0	0
CRUSTA	Control	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 1-7	2-7	3-7	4-7	5-7	6-7	7-7	8-7	9-7	10-7	11-7	12-7	13-7	14-7
HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
IRREGULAR BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
RESPIRATORY SOUND ABNOR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NOISY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 15-7	16-7	17-7	18-7	19-7	20-7	21-7	22-7	23-7	24-7	25-7	26-7	27-7	28-7
HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
IRREGULAR BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
RESPIRATORY SOUND ABNOR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NOISY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 29-7	30-7	31-7	32-7	33-7	34-7	35-7	36-7	37-7	38-7	39-7	40-7	41-7	42-7
HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
IRREGULAR BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
RESPIRATORY SOUND ABNOR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NOISY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 43-7	44-7	45-7	46-7	47-7	48-7	49-7	50-7	51-7	52-7	53-7	54-7	55-7	56-7
HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
IRREGULAR BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	1	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
RESPIRATORY SOUND ABNOR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NOISY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 57-7	58-7	59-7	60-7	61-7	62-7	63-7	64-7	65-7	66-7	67-7	68-7	69-7	70-7
HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
IRREGULAR BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
RESPIRATORY SOUND ABNOR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NOISY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 71-7	72-7	73-7	74-7	75-7	76-7	77-7	78-7	79-7	80-7	81-7	82-7	83-7	84-7
HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	1	0	0	0	0	0
IRREGULAR BREATHING	Control	0	1	0	0	0	0	0	0	0	1	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	1	0	0	0	0	0	1	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
RESPIRATORY SOUND ABNOR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NOISY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 85-7	86-7	87-7	88-7	89-7	90-7	91-7	92-7	93-7	94-7	95-7	96-7	97-7	98-7
HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
IRREGULAR BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	1	1	0	0	1
	8ppm	0	1	1	1	2	1	0	1	0	0	1	0	1	1
	20ppm	1	0	0	1	0	0	0	0	0	0	0	0	1	2
RESPIRATORY SOUND ABNOR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NOISY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	1	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 99-7	100-7	101-7	102-7	103-7	104-7
HEMORRHAGE	Control	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0
IRREGULAR BREATHING	Control	0	1	0	0	0	0
	3.2ppm	1	1	1	1	1	0
	8ppm	0	0	0	0	0	0
	20ppm	3	3	1	0	0	1
RESPIRATORY SOUND ABNOR	Control	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0
	20ppm	1	1	0	0	0	0
NOISY	Control	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0

TABLE D1

BODY WEIGHT CHANGES AND SURVIVAL ANIMAL NUMBERS : MALE

STUDY NO. : 0794
ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj]
UNIT : g
REPORT TYPE : A1 104
SEX : MALE

MEAN BODY WEIGHTS AND SURVIVAL

Week on Study	Control Av.Wt.	Control No.of Surviv. <50>	3.2ppm Av.Wt.	3.2ppm % of cont. <50>	3.2ppm No.of Surviv.	8ppm Av.Wt.	8ppm % of cont. <50>	8ppm No.of Surviv.	20ppm Av.Wt.	20ppm % of cont. <50>	20ppm No.of Surviv.
0	120 (50)	50/50	120 (50)	100	50/50	120 (50)	100	50/50	120 (50)	100	50/50
1	151 (50)	50/50	150 (50)	99	50/50	151 (50)	100	50/50	141 (50)	93	50/50
2	182 (50)	50/50	182 (50)	100	50/50	181 (50)	99	50/50	167 (50)	92	50/50
3	206 (50)	50/50	206 (50)	100	50/50	205 (50)	100	50/50	187 (50)	91	50/50
4	227 (50)	50/50	227 (50)	100	50/50	226 (50)	100	50/50	205 (50)	90	50/50
5	242 (50)	50/50	243 (50)	100	50/50	242 (50)	100	50/50	222 (50)	92	50/50
6	255 (50)	50/50	257 (50)	101	50/50	255 (50)	100	50/50	235 (50)	92	50/50
7	269 (50)	50/50	270 (50)	100	50/50	268 (50)	100	50/50	250 (50)	93	50/50
8	282 (50)	50/50	283 (50)	100	50/50	281 (50)	100	50/50	259 (50)	92	50/50
9	292 (50)	50/50	292 (50)	100	50/50	292 (50)	100	50/50	267 (50)	91	50/50
10	299 (50)	50/50	300 (50)	100	50/50	300 (50)	100	50/50	275 (50)	92	50/50
11	304 (50)	50/50	305 (50)	100	50/50	306 (50)	101	50/50	279 (50)	92	50/50
12	312 (50)	50/50	314 (50)	101	50/50	314 (50)	101	50/50	285 (50)	91	50/50
13	318 (50)	50/50	320 (50)	101	50/50	320 (50)	101	50/50	292 (50)	92	50/50
14	323 (50)	50/50	325 (50)	101	50/50	326 (50)	101	50/50	297 (50)	92	50/50
18	338 (50)	50/50	341 (50)	101	50/50	343 (50)	101	50/50	312 (50)	92	50/50
22	352 (50)	50/50	352 (50)	100	50/50	357 (50)	101	50/50	326 (50)	93	50/50
26	364 (50)	50/50	362 (50)	99	50/50	367 (50)	101	50/50	333 (50)	91	50/50
30	375 (50)	50/50	373 (50)	99	50/50	377 (50)	101	50/50	344 (50)	92	50/50
34	386 (50)	50/50	382 (50)	99	50/50	386 (50)	100	50/50	353 (50)	91	50/50
38	393 (50)	50/50	386 (50)	98	50/50	392 (50)	100	50/50	356 (50)	91	50/50
42	399 (50)	50/50	390 (50)	98	50/50	396 (50)	99	50/50	358 (50)	90	50/50
46	405 (50)	50/50	398 (50)	98	50/50	402 (50)	99	50/50	363 (50)	90	50/50
50	410 (50)	50/50	404 (50)	99	50/50	408 (50)	100	50/50	371 (50)	90	50/50
54	413 (50)	50/50	407 (50)	99	50/50	410 (50)	99	50/50	370 (50)	90	50/50
58	417 (50)	50/50	410 (50)	98	50/50	413 (50)	99	50/50	368 (50)	88	50/50
62	419 (50)	50/50	412 (50)	98	50/50	415 (50)	99	50/50	366 (50)	87	50/50
66	422 (50)	50/50	415 (50)	98	50/50	419 (49)	99	49/50	368 (48)	87	48/50
70	426 (50)	50/50	418 (50)	98	50/50	419 (48)	98	48/50	365 (46)	86	46/50
74	428 (50)	50/50	418 (50)	98	50/50	421 (47)	98	47/50	364 (45)	85	45/50
78	428 (50)	50/50	419 (50)	98	50/50	419 (46)	98	46/50	354 (41)	83	41/50
82	429 (49)	49/50	419 (50)	98	50/50	416 (46)	97	46/50	357 (31)	83	31/50
86	422 (48)	48/50	417 (50)	99	50/50	416 (46)	99	46/50	357 (27)	85	27/50
90	421 (47)	47/50	416 (49)	99	49/50	412 (45)	98	45/50	347 (20)	82	20/50
94	410 (46)	46/50	408 (48)	100	48/50	405 (44)	99	44/50	344 (17)	84	17/50
98	404 (45)	45/50	403 (47)	100	47/50	399 (43)	99	43/50	334 (14)	83	14/50
102	396 (43)	43/50	399 (45)	101	45/50	398 (42)	101	42/50	335 (10)	85	10/50
104	394 (41)	41/50	394 (44)	100	44/50	388 (39)	98	39/50	315 (9)	80	9/50

< >:No.of effective animals, ( ):No.of measured animals Av.Wt. : g

TABLE D2

BODY WEIGHT CHANGES AND SURVIVAL ANIMAL NUMBERS : FEMALE

STUDY NO. : 0794
ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj]
UNIT : g
REPORT TYPE : A1 104
SEX : FEMALE

MEAN BODY WEIGHTS AND SURVIVAL

Week on Study	Control Av. Wt.	Control No. of Surviv. <50>	3.2ppm Av. Wt.	3.2ppm % of cont. <50>	3.2ppm No. of Surviv.	8ppm Av. Wt.	8ppm % of cont. <50>	8ppm No. of Surviv.	20ppm Av. Wt.	20ppm % of cont. <50>	20ppm No. of Surviv.
0	97 (50)	50/50	97 (50)	100	50/50	97 (50)	100	50/50	97 (50)	100	50/50
1	112 (50)	50/50	110 (50)	98	50/50	111 (50)	99	50/50	106 (50)	95	50/50
2	126 (50)	50/50	125 (50)	99	50/50	125 (50)	99	50/50	119 (50)	94	50/50
3	136 (50)	50/50	134 (50)	99	50/50	134 (50)	99	50/50	129 (50)	95	50/50
4	144 (50)	50/50	144 (50)	100	50/50	143 (50)	99	50/50	137 (50)	95	50/50
5	151 (50)	50/50	151 (50)	100	50/50	150 (50)	99	50/50	145 (50)	96	50/50
6	157 (50)	50/50	158 (50)	101	50/50	155 (50)	99	50/50	150 (50)	96	50/50
7	161 (50)	50/50	162 (50)	101	50/50	160 (50)	99	50/50	157 (50)	98	50/50
8	165 (50)	50/50	167 (50)	101	50/50	164 (50)	99	50/50	161 (50)	98	50/50
9	168 (50)	50/50	170 (50)	101	50/50	167 (50)	99	50/50	167 (50)	99	50/50
10	172 (50)	50/50	174 (50)	101	50/50	172 (50)	100	50/50	170 (50)	99	50/50
11	174 (50)	50/50	178 (50)	102	50/50	174 (50)	100	50/50	172 (50)	99	50/50
12	178 (50)	50/50	183 (50)	103	50/50	178 (50)	100	50/50	176 (50)	99	50/50
13	180 (50)	50/50	184 (50)	102	50/50	180 (50)	100	50/50	177 (50)	98	50/50
14	182 (50)	50/50	186 (50)	102	50/50	181 (50)	99	50/50	180 (50)	99	50/50
18	188 (50)	50/50	194 (50)	103	50/50	190 (50)	101	50/50	186 (50)	99	50/50
22	193 (50)	50/50	199 (50)	103	50/50	195 (50)	101	50/50	192 (50)	99	50/50
26	197 (50)	50/50	202 (50)	103	50/50	199 (50)	101	50/50	197 (50)	100	50/50
30	203 (50)	50/50	209 (50)	103	50/50	205 (50)	101	50/50	201 (50)	99	50/50
34	209 (50)	50/50	213 (50)	102	50/50	207 (50)	99	50/50	206 (50)	99	50/50
38	213 (50)	50/50	216 (50)	101	50/50	211 (50)	99	50/50	208 (50)	98	50/50
42	216 (50)	50/50	218 (50)	101	50/50	214 (50)	99	50/50	209 (50)	97	50/50
46	219 (50)	50/50	223 (50)	102	50/50	219 (50)	100	50/50	213 (50)	97	50/50
50	225 (50)	50/50	229 (50)	102	50/50	224 (50)	100	50/50	219 (50)	97	50/50
54	229 (50)	50/50	233 (50)	102	50/50	227 (49)	99	49/50	219 (50)	96	50/50
58	234 (50)	50/50	237 (50)	101	50/50	230 (48)	98	48/50	221 (48)	94	48/50
62	240 (50)	50/50	245 (50)	102	50/50	235 (48)	98	48/50	225 (48)	94	48/50
66	246 (50)	50/50	251 (50)	102	50/50	244 (48)	99	48/50	230 (48)	93	48/50
70	253 (50)	50/50	257 (50)	102	50/50	249 (48)	98	48/50	230 (48)	91	48/50
74	259 (50)	50/50	263 (50)	102	50/50	253 (47)	98	47/50	232 (47)	90	47/50
78	263 (48)	48/50	267 (50)	102	50/50	256 (47)	97	47/50	234 (46)	89	46/50
82	270 (47)	47/50	272 (49)	101	49/50	258 (46)	96	46/50	237 (44)	88	44/50
86	274 (46)	46/50	277 (49)	101	49/50	258 (44)	94	44/50	242 (42)	88	42/50
90	279 (46)	46/50	281 (48)	101	48/50	262 (42)	94	42/50	246 (38)	88	38/50
94	280 (45)	45/50	280 (46)	100	46/50	265 (40)	95	40/50	246 (37)	88	37/50
98	283 (42)	42/50	285 (43)	101	43/50	266 (38)	94	38/50	242 (37)	86	37/50
102	287 (41)	41/50	281 (42)	98	42/50	270 (36)	94	36/50	251 (30)	87	30/50
104	287 (39)	39/50	286 (39)	100	39/50	265 (35)	92	35/50	249 (29)	87	29/50

< >:No. of effective animals, ( ):No. of measured animals Av. Wt. : g

TABLE D3

BODY WEIGHT CHANGES : MALE

STUDY NO. : 0794
ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj]
UNIT : g
REPORT TYPE : A1 104
SEX : MALE

BODY WEIGHT CHANGES (SUMMARY)
ALL ANIMALS

Group Name	Administration week 0	1	2	3	4	5	6
Control	120± 6	151± 9	182± 11	206± 11	227± 13	242± 13	255± 14
3.2ppm	120± 6	150± 8	182± 10	206± 11	227± 12	243± 12	257± 13
8ppm	120± 6	151± 8	181± 10	205± 11	226± 12	242± 13	255± 14
20ppm	120± 6	141± 7**	167± 8**	187± 9**	205± 10**	222± 10**	235± 10**

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0794
ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj]
UNIT : g
REPORT TYPE : A1 104
SEX : MALE

BODY WEIGHT CHANGES (SUMMARY)
ALL ANIMALS

Group Name	Administration week 7	8	9	10	11	12	13
Control	269± 15	282± 17	292± 17	299± 18	304± 18	312± 18	318± 18
3.2ppm	270± 13	283± 15	292± 15	300± 16	305± 16	314± 16	320± 17
8ppm	268± 14	281± 15	292± 16	300± 15	306± 15	314± 16	320± 17
20ppm	250± 10**	259± 11**	267± 11**	275± 11**	279± 11**	285± 11**	292± 11**

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0794
ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj]
UNIT : g
REPORT TYPE : A1 104
SEX : MALE

BODY WEIGHT CHANGES (SUMMARY)
ALL ANIMALS

Group Name	Administration week 14	18	22	26	30	34	38
Control	323± 18	338± 19	352± 21	364± 21	375± 23	386± 24	393± 26
3.2ppm	325± 18	341± 18	352± 19	362± 20	373± 21	382± 22	386± 22
8ppm	326± 17	343± 17	357± 18	367± 18	377± 18	386± 19	392± 19
20ppm	297± 12**	312± 12**	326± 13**	333± 14**	344± 14**	353± 14**	356± 14**

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0794
ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj]
UNIT : g
REPORT TYPE : A1 104
SEX : MALE

BODY WEIGHT CHANGES (SUMMARY)
ALL ANIMALS

Group Name	Administration week 42	46	50	54	58	62	66
Control	399± 27	405± 27	410± 29	413± 30	417± 31	419± 32	422± 33
3.2ppm	390± 23	398± 23	404± 23	407± 23	410± 24	412± 23	415± 24
8ppm	396± 19	402± 18	408± 19	410± 20	413± 19	415± 19	419± 19
20ppm	358± 15**	363± 15**	371± 15**	370± 16**	368± 16**	366± 22**	368± 25**

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0794
ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj]
UNIT : g
REPORT TYPE : A1 104
SEX : MALE

BODY WEIGHT CHANGES (SUMMARY)
ALL ANIMALS

Group Name	Administration week 70	74	78	82	86	90	94
Control	426± 33	428± 35	428± 35	429± 35	422± 37	421± 35	410± 34
3.2ppm	418± 25	418± 24	419± 25	419± 26	417± 27	416± 28	408± 29
8ppm	419± 19	421± 18	419± 17	416± 18*	416± 18	412± 18	405± 20
20ppm	365± 19**	364± 21**	354± 28**	357± 22**	357± 25**	347± 26**	344± 21**

Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0794
ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj]
UNIT : g
REPORT TYPE : A1 104
SEX : MALE

BODY WEIGHT CHANGES (SUMMARY)
ALL ANIMALS

Group Name	Administration week 98		102		104	
Control	404±	36	396±	41	394±	37
3.2ppm	403±	32	399±	36	394±	37
8ppm	399±	26	398±	40	388±	52
20ppm	334±	24**	335±	28**	315±	42**

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

TABLE D4

BODY WEIGHT CHANGES : FEMALE

STUDY NO. : 0794
ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj]
UNIT : g
REPORT TYPE : A1 104
SEX : FEMALE

BODY WEIGHT CHANGES (SUMMARY)
ALL ANIMALS

Group Name	Administration week 0	1	2	3	4	5	6
Control	97± 3	112± 4	126± 5	136± 6	144± 7	151± 7	157± 8
3.2ppm	97± 3	110± 4	125± 5	134± 6	144± 7	151± 7	158± 8
8ppm	97± 3	111± 4	125± 5	134± 6	143± 7	150± 8	155± 8
20ppm	97± 3	106± 4**	119± 5**	129± 5**	137± 7**	145± 7**	150± 8**

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0794
ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj]
UNIT : g
REPORT TYPE : A1 104
SEX : FEMALE

BODY WEIGHT CHANGES (SUMMARY)
ALL ANIMALS

Group Name	Administration week 7	8	9	10	11	12	13
Control	161± 9	165± 10	168± 11	172± 11	174± 11	178± 11	180± 11
3.2ppm	162± 9	167± 10	170± 10	174± 10	178± 11	183± 11	184± 11
8ppm	160± 9	164± 9	167± 10	172± 11	174± 10	178± 11	180± 10
20ppm	157± 9*	161± 9	167± 11	170± 11	172± 11	176± 11	177± 11

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0794
ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj]
UNIT : g
REPORT TYPE : A1 104
SEX : FEMALE

BODY WEIGHT CHANGES (SUMMARY)
ALL ANIMALS

Group Name	Administration week 14	18	22	26	30	34	38
Control	182± 12	188± 12	193± 13	197± 14	203± 14	209± 16	213± 16
3.2ppm	186± 11	194± 11	199± 12	202± 12	209± 12	213± 13	216± 13
8ppm	181± 10	190± 12	195± 12	199± 12	205± 13	207± 12	211± 13
20ppm	180± 11	186± 13	192± 13	197± 14	201± 13	206± 14	208± 15

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0794
ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj]
UNIT : g
REPORT TYPE : A1 104
SEX : FEMALE

BODY WEIGHT CHANGES (SUMMARY)
ALL ANIMALS

Group Name	Administration week 42	46	50	54	58	62	66
Control	216± 17	219± 18	225± 19	229± 19	234± 20	240± 22	246± 22
3.2ppm	218± 14	223± 13	229± 15	233± 16	237± 18	245± 19	251± 21
8ppm	214± 14	219± 14	224± 15	227± 15	230± 17	235± 18	244± 24
20ppm	209± 14*	213± 16	219± 17	219± 18**	221± 16**	225± 16**	230± 17**

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0794
ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj]
UNIT : g
REPORT TYPE : A1 104
SEX : FEMALE

BODY WEIGHT CHANGES (SUMMARY)
ALL ANIMALS

Group Name	Administration week 70	74	78	82	86	90	94
Control	253± 23	259± 23	263± 24	270± 25	274± 23	279± 24	280± 26
3.2ppm	257± 21	263± 22	267± 24	272± 24	277± 26	281± 31	280± 36
8ppm	249± 26	253± 19	256± 20	258± 21*	258± 22**	262± 23*	265± 24*
20ppm	230± 18**	232± 18**	234± 18**	237± 19**	242± 22**	246± 21**	246± 26**

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0794
ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj]
UNIT : g
REPORT TYPE : A1 104
SEX : FEMALE

BODY WEIGHT CHANGES (SUMMARY)
ALL ANIMALS

Group Name	Administration week 98	102	104
Control	283± 31	287± 33	287± 35
3.2ppm	285± 41	281± 43	286± 43
8ppm	266± 32	270± 34*	265± 33**
20ppm	242± 30**	251± 26**	249± 25**

Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

TABLE E1

FOOD CONSUMPTION CHANGES AND SURVIVAL ANIMAL NUMBERS : MALE

STUDY NO. : 0794
ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj]
UNIT : g
REPORT TYPE : A1 104
SEX : MALE

MEAN FOOD CONSUMPTION(FC) AND SURVIVAL

Week-Day on Study	Control Av.FC.	Control No.of Surviv. <50>	3.2ppm Av.FC.	3.2ppm % of cont. <50>	3.2ppm No.of Surviv.	8ppm Av.FC.	8ppm % of cont. <50>	8ppm No.of Surviv.	20ppm Av.FC.	20ppm % of cont. <50>	20ppm No.of Surviv.
1-7	14.8 (50)	50/50	14.5 (50)	98	50/50	14.3 (50)	97	50/50	12.7 (50)	86	50/50
2-7	16.7 (50)	50/50	16.5 (50)	99	50/50	16.3 (50)	98	50/50	14.1 (50)	84	50/50
3-7	17.2 (50)	50/50	17.4 (50)	101	50/50	16.9 (50)	98	50/50	14.7 (50)	85	50/50
4-7	17.1 (50)	50/50	17.0 (50)	99	50/50	16.6 (50)	97	50/50	14.5 (50)	85	50/50
5-7	16.7 (50)	50/50	16.9 (50)	101	50/50	16.8 (50)	101	50/50	15.7 (50)	94	50/50
6-7	17.0 (50)	50/50	16.8 (50)	99	50/50	16.7 (50)	98	50/50	15.9 (50)	94	50/50
7-7	16.6 (50)	50/50	16.5 (50)	99	50/50	16.4 (50)	99	50/50	16.0 (50)	96	50/50
8-7	17.0 (50)	50/50	16.8 (50)	99	50/50	16.8 (50)	99	50/50	16.0 (50)	94	50/50
9-7	16.7 (50)	50/50	16.3 (50)	98	50/50	16.4 (50)	98	50/50	15.2 (50)	91	50/50
10-7	16.5 (50)	50/50	16.4 (50)	99	50/50	16.3 (50)	99	50/50	15.3 (50)	93	50/50
11-7	15.8 (50)	50/50	16.1 (50)	102	50/50	16.1 (50)	102	50/50	15.1 (50)	96	50/50
12-7	16.2 (50)	50/50	16.2 (50)	100	50/50	16.2 (50)	100	50/50	14.9 (50)	92	50/50
13-7	15.9 (50)	50/50	16.0 (50)	101	50/50	16.0 (50)	101	50/50	15.2 (50)	96	50/50
14-7	15.5 (50)	50/50	15.7 (50)	101	50/50	15.8 (50)	102	50/50	15.1 (50)	97	50/50
18-7	15.9 (50)	50/50	15.7 (50)	99	50/50	16.1 (50)	101	50/50	15.1 (50)	95	50/50
22-7	15.8 (50)	50/50	15.7 (50)	99	50/50	16.1 (50)	102	50/50	15.4 (50)	97	50/50
26-7	15.5 (50)	50/50	15.5 (50)	100	50/50	15.7 (50)	101	50/50	14.9 (50)	96	50/50
30-7	16.1 (50)	50/50	15.9 (50)	99	50/50	16.1 (50)	100	50/50	15.5 (50)	96	50/50
34-7	16.4 (50)	50/50	16.2 (50)	99	50/50	16.4 (50)	100	50/50	15.9 (50)	97	50/50
38-7	16.2 (50)	50/50	16.0 (50)	99	50/50	16.3 (50)	101	50/50	15.6 (50)	96	50/50
42-7	16.3 (50)	50/50	15.8 (50)	97	50/50	16.0 (50)	98	50/50	15.5 (50)	95	50/50
46-7	16.2 (50)	50/50	16.1 (50)	99	50/50	16.4 (50)	101	50/50	15.7 (50)	97	50/50
50-7	16.6 (50)	50/50	16.5 (50)	99	50/50	16.8 (50)	101	50/50	16.6 (50)	100	50/50
54-7	16.4 (50)	50/50	16.4 (50)	100	50/50	16.5 (50)	101	50/50	15.9 (50)	97	50/50
58-7	16.6 (50)	50/50	16.2 (50)	98	50/50	16.5 (50)	99	50/50	15.7 (50)	95	50/50
62-7	16.3 (50)	50/50	16.2 (50)	99	50/50	16.4 (50)	101	50/50	15.5 (50)	95	50/50
66-7	16.5 (50)	50/50	16.3 (50)	99	50/50	16.3 (49)	99	49/50	15.3 (48)	93	48/50
70-7	16.6 (50)	50/50	16.3 (50)	98	50/50	16.3 (48)	98	48/50	15.1 (46)	91	46/50
74-7	16.6 (50)	50/50	16.2 (50)	98	50/50	16.3 (47)	98	47/50	15.3 (45)	92	45/50
78-7	16.2 (50)	50/50	16.0 (50)	99	50/50	16.3 (46)	101	46/50	14.0 (41)	86	41/50
82-7	16.4 (49)	49/50	16.1 (50)	98	50/50	16.2 (46)	99	46/50	15.1 (31)	92	31/50
86-7	16.0 (48)	48/50	15.8 (50)	99	50/50	16.0 (46)	100	46/50	14.7 (27)	92	27/50
90-7	16.3 (47)	47/50	16.3 (49)	100	49/50	16.0 (45)	98	45/50	14.8 (20)	91	20/50
94-7	16.0 (46)	46/50	15.9 (48)	99	48/50	16.0 (44)	100	44/50	14.7 (17)	92	17/50
98-7	16.3 (45)	45/50	16.4 (47)	101	47/50	16.2 (43)	99	43/50	15.4 (14)	94	14/50
102-7	16.3 (43)	43/50	16.8 (45)	103	45/50	16.1 (42)	99	42/50	16.2 (10)	99	10/50
104-7	16.3 (41)	41/50	16.4 (44)	101	44/50	15.5 (39)	95	39/50	15.4 (9)	94	9/50

< >:No.of effective animals, ( ):No.of measured animals Av.FC.: g

TABLE E2

FOOD CONSUMPTION CHANGES AND SURVIVAL ANIMAL NUMBERS : FEMALE

STUDY NO. : 0794
ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj]
UNIT : g
REPORT TYPE : A1 104
SEX : FEMALE

MEAN FOOD CONSUMPTION(FC) AND SURVIVAL

Week-Day on Study	Control Av.FC.	Control No.of Surviv. <50>	3.2ppm Av.FC.	3.2ppm % of cont. <50>	3.2ppm No.of Surviv.	8ppm Av.FC.	8ppm % of cont. <50>	8ppm No.of Surviv.	20ppm Av.FC.	20ppm % of cont. <50>	20ppm No.of Surviv.
1-7	11.3 (50)	50/50	11.2 (50)	99	50/50	11.0 (50)	97	50/50	10.1 (50)	89	50/50
2-7	12.0 (50)	50/50	12.0 (50)	100	50/50	11.7 (50)	98	50/50	10.8 (50)	90	50/50
3-7	11.8 (50)	50/50	11.7 (50)	99	50/50	11.7 (50)	99	50/50	10.9 (50)	92	50/50
4-7	11.7 (50)	50/50	11.7 (50)	100	50/50	11.4 (50)	97	50/50	10.4 (50)	89	50/50
5-7	11.5 (50)	50/50	11.7 (50)	102	50/50	11.5 (50)	100	50/50	11.5 (50)	100	50/50
6-7	11.7 (50)	50/50	11.9 (50)	102	50/50	11.7 (50)	100	50/50	11.6 (50)	99	50/50
7-7	11.0 (50)	50/50	11.3 (50)	103	50/50	11.0 (50)	100	50/50	11.3 (50)	103	50/50
8-7	11.1 (50)	50/50	11.5 (50)	104	50/50	10.7 (50)	96	50/50	11.5 (50)	104	50/50
9-7	10.6 (50)	50/50	10.8 (50)	102	50/50	10.6 (50)	100	50/50	11.0 (50)	104	50/50
10-7	10.9 (50)	50/50	11.1 (50)	102	50/50	10.8 (50)	99	50/50	11.0 (50)	101	50/50
11-7	10.5 (50)	50/50	10.7 (50)	102	50/50	10.5 (50)	100	50/50	10.7 (50)	102	50/50
12-7	10.8 (50)	50/50	11.4 (50)	106	50/50	10.9 (50)	101	50/50	11.0 (50)	102	50/50
13-7	10.7 (50)	50/50	11.6 (50)	108	50/50	10.6 (50)	99	50/50	11.1 (50)	104	50/50
14-7	10.5 (50)	50/50	10.9 (50)	104	50/50	10.5 (50)	100	50/50	11.1 (50)	106	50/50
18-7	10.8 (50)	50/50	11.2 (50)	104	50/50	11.1 (50)	103	50/50	10.7 (50)	99	50/50
22-7	10.8 (50)	50/50	11.2 (50)	104	50/50	10.9 (50)	101	50/50	11.1 (50)	103	50/50
26-7	10.5 (50)	50/50	10.4 (50)	99	50/50	10.3 (50)	98	50/50	10.4 (50)	99	50/50
30-7	11.1 (50)	50/50	11.4 (50)	103	50/50	11.0 (50)	99	50/50	11.0 (50)	99	50/50
34-7	11.3 (50)	50/50	11.1 (50)	98	50/50	10.6 (50)	94	50/50	11.3 (50)	100	50/50
38-7	11.1 (50)	50/50	11.1 (50)	100	50/50	11.1 (50)	100	50/50	11.3 (50)	102	50/50
42-7	11.4 (50)	50/50	11.2 (50)	98	50/50	11.0 (50)	96	50/50	10.9 (50)	96	50/50
46-7	11.1 (50)	50/50	11.1 (50)	100	50/50	11.2 (50)	101	50/50	11.7 (50)	105	50/50
50-7	11.6 (50)	50/50	11.8 (50)	102	50/50	11.7 (50)	101	50/50	12.1 (50)	104	50/50
54-7	11.6 (50)	50/50	11.9 (50)	103	50/50	11.4 (49)	98	49/50	11.5 (50)	99	50/50
58-7	11.9 (50)	50/50	11.9 (50)	100	50/50	11.4 (48)	96	48/50	11.3 (48)	95	48/50
62-7	11.7 (50)	50/50	12.0 (50)	103	50/50	11.7 (48)	100	48/50	11.6 (48)	99	48/50
66-7	12.1 (50)	50/50	12.1 (50)	100	50/50	11.7 (47)	97	48/50	11.6 (48)	96	48/50
70-7	12.0 (50)	50/50	12.2 (50)	102	50/50	12.1 (48)	101	48/50	11.4 (48)	95	48/50
74-7	12.0 (50)	50/50	12.2 (50)	102	50/50	11.7 (47)	98	47/50	11.3 (47)	94	47/50
78-7	12.0 (48)	48/50	12.1 (50)	101	50/50	11.7 (47)	98	47/50	11.2 (46)	93	46/50
82-7	12.6 (47)	47/50	12.5 (49)	99	49/50	11.9 (46)	94	46/50	11.8 (44)	94	44/50
86-7	12.1 (46)	46/50	12.3 (49)	102	49/50	11.2 (44)	93	44/50	11.3 (42)	93	42/50
90-7	12.7 (46)	46/50	12.5 (48)	98	48/50	11.7 (42)	92	42/50	11.8 (38)	93	38/50
94-7	12.7 (45)	45/50	12.4 (45)	98	46/50	12.3 (40)	97	40/50	12.0 (37)	94	37/50
98-7	12.8 (42)	42/50	13.2 (43)	103	43/50	11.7 (38)	91	38/50	11.9 (37)	93	37/50
102-7	13.2 (41)	41/50	12.8 (42)	97	42/50	12.6 (36)	95	36/50	12.7 (30)	96	30/50
104-7	12.8 (39)	39/50	12.9 (39)	101	39/50	12.4 (35)	97	35/50	12.2 (29)	95	29/50

< >:No.of effective animals, ( ):No.of measured animals Av.FC. : g

TABLE E3

FOOD CONSUMPTION CHANGES : MALE

STUDY NO. : 0794
ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj]
UNIT : g
REPORT TYPE : A1 104
SEX : MALE

FOOD CONSUMPTION CHANGES (SUMMARY)
ALL ANIMALS

Group Name	Administration week-day(effective) 1-7(7)	2-7(7)	3-7(7)	4-7(7)	5-7(7)	6-7(7)	7-7(7)
Control	14.8± 1.2	16.7± 1.6	17.2± 1.5	17.1± 1.4	16.7± 1.2	17.0± 1.5	16.6± 1.5
3.2ppm	14.5± 1.1	16.5± 1.3	17.4± 1.5	17.0± 1.3	16.9± 1.2	16.8± 1.1	16.5± 1.1
8ppm	14.3± 1.0	16.3± 1.3	16.9± 1.4	16.6± 1.2	16.8± 1.2	16.7± 1.3	16.4± 1.2
20ppm	12.7± 0.8**	14.1± 0.8**	14.7± 0.8**	14.5± 0.8**	15.7± 1.1**	15.9± 1.0**	16.0± 1.0

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0794
ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj]
UNIT : g
REPORT TYPE : A1 104
SEX : MALE

FOOD CONSUMPTION CHANGES (SUMMARY)
ALL ANIMALS

Group Name	Administration week-day(effective) 8-7(7)	9-7(7)	10-7(7)	11-7(7)	12-7(7)	13-7(7)	14-7(7)
Control	17.0± 1.4	16.7± 1.4	16.5± 1.4	15.8± 1.2	16.2± 1.1	15.9± 1.1	15.5± 0.9
3.2ppm	16.8± 1.4	16.3± 1.2	16.4± 1.3	16.1± 1.1	16.2± 1.1	16.0± 1.0	15.7± 1.2
8ppm	16.8± 1.2	16.4± 1.1	16.3± 1.0	16.1± 1.0	16.2± 1.0	16.0± 1.0	15.8± 0.9
20ppm	16.0± 1.1**	15.2± 0.9**	15.3± 1.0**	15.1± 0.8**	14.9± 0.8**	15.2± 0.8**	15.1± 0.7*

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0794
ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj]
UNIT : g
REPORT TYPE : A1 104
SEX : MALE

FOOD CONSUMPTION CHANGES (SUMMARY)
ALL ANIMALS

Group Name	Administration week-day(effective) 18-7(7)	22-7(7)	26-7(7)	30-7(7)	34-7(7)	38-7(7)	42-7(7)
Control	15.9± 0.9	15.8± 1.0	15.5± 0.9	16.1± 1.0	16.4± 1.0	16.2± 1.0	16.3± 1.0
3.2ppm	15.7± 1.1	15.7± 1.0	15.5± 0.9	15.9± 1.0	16.2± 1.0	16.0± 0.9	15.8± 1.0
8ppm	16.1± 0.9	16.1± 1.1	15.7± 0.9	16.1± 0.8	16.4± 0.9	16.3± 0.8	16.0± 0.8
20ppm	15.1± 0.7**	15.4± 0.7*	14.9± 0.8**	15.5± 0.7**	15.9± 0.8*	15.6± 0.7**	15.5± 0.7**

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0794
ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj]
UNIT : g
REPORT TYPE : A1 104
SEX : MALE

FOOD CONSUMPTION CHANGES (SUMMARY)
ALL ANIMALS

Group Name	Administration week-day(effective) 46-7(7)	50-7(7)	54-7(7)	58-7(7)	62-7(7)	66-7(7)	70-7(7)
Control	16.2± 1.0	16.6± 1.1	16.4± 0.9	16.6± 1.1	16.3± 1.3	16.5± 1.2	16.6± 1.1
3.2ppm	16.1± 0.9	16.5± 0.9	16.4± 0.9	16.2± 0.9	16.2± 0.9	16.3± 1.0	16.3± 1.0
8ppm	16.4± 0.8	16.8± 0.8	16.5± 1.1	16.5± 0.9	16.4± 0.7	16.3± 1.2	16.3± 0.9
20ppm	15.7± 0.8*	16.6± 0.8	15.9± 0.8*	15.7± 0.8**	15.5± 1.7**	15.3± 0.9**	15.1± 0.9**

Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0794
ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj]
UNIT : g
REPORT TYPE : A1 104
SEX : MALE

FOOD CONSUMPTION CHANGES (SUMMARY)
ALL ANIMALS

Group Name	Administration week-day(effective) 74-7(7)	78-7(7)	82-7(7)	86-7(7)	90-7(7)	94-7(7)	98-7(7)
Control	16.6± 1.2	16.2± 1.3	16.4± 1.6	16.0± 1.7	16.3± 1.3	16.0± 1.2	16.3± 1.5
3.2ppm	16.2± 1.0	16.0± 0.9	16.1± 1.0	15.8± 0.9	16.3± 1.1	15.9± 1.6	16.4± 1.3
8ppm	16.3± 1.2	16.3± 0.7	16.2± 1.0	16.0± 1.0	16.0± 1.0	16.0± 1.1	16.2± 1.4
20ppm	15.3± 1.0**	14.0± 2.3**	15.1± 1.0**	14.7± 1.7**	14.8± 1.2**	14.7± 1.5**	15.4± 1.2

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0794
ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj]
UNIT : g
REPORT TYPE : A1 104
SEX : MALE

FOOD CONSUMPTION CHANGES (SUMMARY)
ALL ANIMALS

Group Name	Administration week-day(effective) 102-7(7)	104-7(7)
Control	16.3± 1.7	16.3± 1.3
3.2ppm	16.8± 1.5	16.4± 1.5
8ppm	16.1± 2.3	15.5± 2.3*
20ppm	16.2± 0.6	15.4± 1.2

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

TABLE E4

FOOD CONSUMPTION CHANGES : FEMALE

STUDY NO. : 0794
ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj]
UNIT : g
REPORT TYPE : A1 104
SEX : FEMALE

FOOD CONSUMPTION CHANGES (SUMMARY)
ALL ANIMALS

Group Name	Administration week-day(effective) 1-7(7)	2-7(7)	3-7(7)	4-7(7)	5-7(7)	6-7(7)	7-7(7)
Control	11.3± 0.7	12.0± 0.9	11.8± 0.8	11.7± 0.8	11.5± 0.8	11.7± 1.0	11.0± 0.9
3.2ppm	11.2± 0.7	12.0± 0.8	11.7± 0.8	11.7± 1.0	11.7± 1.0	11.9± 1.1	11.3± 0.9
8ppm	11.0± 0.6	11.7± 0.9	11.7± 0.9	11.4± 1.0	11.5± 0.9	11.7± 1.1	11.0± 1.1
20ppm	10.1± 0.6**	10.8± 0.8**	10.9± 0.7**	10.4± 0.8**	11.5± 0.9	11.6± 1.2	11.3± 1.4

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0794
ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj]
UNIT : g
REPORT TYPE : A1 104
SEX : FEMALE

FOOD CONSUMPTION CHANGES (SUMMARY)
ALL ANIMALS

Group Name	Administration week-day(effective) 8-7(7)	9-7(7)	10-7(7)	11-7(7)	12-7(7)	13-7(7)	14-7(7)
Control	11.1± 1.0	10.6± 0.9	10.9± 0.8	10.5± 0.9	10.8± 0.8	10.7± 0.9	10.5± 1.1
3.2ppm	11.5± 1.0	10.8± 0.9	11.1± 1.1	10.7± 0.9	11.4± 0.8**	11.6± 1.2**	10.9± 0.9
8ppm	10.7± 0.9	10.6± 1.0	10.8± 1.1	10.5± 1.0	10.9± 0.9	10.6± 0.8	10.5± 0.8
20ppm	11.5± 1.4	11.0± 1.3	11.0± 1.1	10.7± 0.9	11.0± 1.1	11.1± 1.3	11.1± 1.3

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0794
ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj]
UNIT : g
REPORT TYPE : A1 104
SEX : FEMALE

FOOD CONSUMPTION CHANGES (SUMMARY)
ALL ANIMALS

Group Name	Administration week-day(effective) 18-7(7)	22-7(7)	26-7(7)	30-7(7)	34-7(7)	38-7(7)	42-7(7)
Control	10.8± 0.9	10.8± 0.9	10.5± 0.8	11.1± 0.9	11.3± 1.1	11.1± 0.9	11.4± 1.0
3.2ppm	11.2± 0.8	11.2± 1.0	10.4± 0.6	11.4± 0.9	11.1± 1.0	11.1± 0.7	11.2± 1.0
8ppm	11.1± 1.3	10.9± 1.1	10.3± 0.8	11.0± 1.1	10.6± 0.8**	11.1± 0.9	11.0± 1.2
20ppm	10.7± 1.1	11.1± 1.1	10.4± 1.1	11.0± 1.3	11.3± 1.2	11.3± 1.2	10.9± 1.0

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0794
ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj]
UNIT : g
REPORT TYPE : A1 104
SEX : FEMALE

FOOD CONSUMPTION CHANGES (SUMMARY)
ALL ANIMALS

Group Name	Administration week-day(effective) 46-7(7)	50-7(7)	54-7(7)	58-7(7)	62-7(7)	66-7(7)	70-7(7)
Control	11.1± 0.8	11.6± 0.9	11.6± 1.0	11.9± 0.9	11.7± 1.0	12.1± 0.9	12.0± 0.9
3.2ppm	11.1± 0.8	11.8± 0.7	11.9± 1.1	11.9± 1.0	12.0± 1.0	12.1± 1.2	12.2± 1.0
8ppm	11.2± 0.9	11.7± 1.1	11.4± 1.2	11.4± 0.9*	11.7± 1.1	11.7± 0.9	12.1± 1.9
20ppm	11.7± 1.2	12.1± 1.4	11.5± 1.4	11.3± 0.9**	11.6± 0.9	11.6± 0.9*	11.4± 1.0**

Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0794
ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj]
UNIT : g
REPORT TYPE : A1 104
SEX : FEMALE

FOOD CONSUMPTION CHANGES (SUMMARY)
ALL ANIMALS

Group Name	Administration week-day(effective) 74-7(7)	78-7(7)	82-7(7)	86-7(7)	90-7(7)	94-7(7)	98-7(7)
Control	12.0± 0.8	12.0± 1.3	12.6± 0.9	12.1± 1.0	12.7± 1.1	12.7± 1.6	12.8± 1.7
3.2ppm	12.2± 1.0	12.1± 1.1	12.5± 1.2	12.3± 1.5	12.5± 1.6	12.4± 1.8	13.2± 2.0
8ppm	11.7± 0.9	11.7± 0.8	11.9± 0.8**	11.2± 1.9**	11.7± 1.1**	12.3± 1.2	11.7± 2.4*
20ppm	11.3± 0.9**	11.2± 0.7**	11.8± 1.0**	11.3± 1.5**	11.8± 1.3**	12.0± 1.7	11.9± 2.2

Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0794
ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj]
UNIT : g
REPORT TYPE : A1 104
SEX : FEMALE

FOOD CONSUMPTION CHANGES (SUMMARY)
ALL ANIMALS

Group Name	Administration week-day(effective) 102-7(7)	104-7(7)
Control	13.2± 2.1	12.8± 2.2
3.2ppm	12.8± 2.9	12.9± 2.7
8ppm	12.6± 1.9	12.4± 2.7
20ppm	12.7± 1.9	12.2± 1.7

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

TABLE F1

HEMATOLOGY : MALE

STUDY NO. : 0794
ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj]
MEASURE. TIME : 1
SEX : MALE REPORT TYPE : A1

HEMATOLOGY (SUMMARY)
ALL ANIMALS (105W)

Group Name	NO. of Animals	RED BLOOD CELL $10^6/\mu\ell$	HEMOGLOBIN g/dℓ	HEMATOCRIT %	MCV fℓ	MCH pg	MCHC g/dℓ	PLATELET $10^3/\mu\ell$
Control	40	8.01± 1.46	12.8± 2.3	39.0± 6.1	49.2± 5.3	16.1± 2.0	32.7± 1.5	920± 293
3.2ppm	44	7.59± 1.73	11.9± 3.1	36.8± 8.0	48.7± 2.8	15.6± 1.4	32.0± 2.2	1014± 339
8ppm	39	6.49± 2.15**	10.3± 3.5**	32.5± 9.0**	51.6± 7.9	16.0± 2.2	31.1± 2.4**	1085± 416
20ppm	9	7.79± 1.38	11.2± 2.1	35.8± 5.6	46.1± 3.1	14.5± 1.7	31.3± 1.9*	1077± 270

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0794
ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj]
MEASURE. TIME : 1
SEX : MALE REPORT TYPE : A1

HEMATOLOGY (SUMMARY)
ALL ANIMALS (105W)

Group Name	NO. of Animals	RETICULOCYTE %	
Control	40	4.6±	4.1
3.2ppm	44	6.0±	5.3
8ppm	39	9.8±	7.6**
20ppm	9	5.4±	3.4

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0794
ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj]
MEASURE. TIME : 1
SEX : MALE REPORT TYPE : A1

HEMATOLOGY (SUMMARY)
ALL ANIMALS (105W)

Group Name	NO. of Animals	WBC $10^3/\mu\ell$		Differential WBC (%) NEUTRO		LYMPHO		MONO		EOSINO		BASO		OTHER	
Control	40	3.75±	1.29	54±	8	40±	8	4±	1	1±	1	0±	0	1±	0
3.2ppm	44	4.49±	1.63	51±	9	43±	9	4±	1	1±	1	0±	0	1±	0
8ppm	39	9.80±	34.78	52±	14	40±	13	4±	1	1±	1*	0±	0	4±	15
20ppm	9	4.87±	2.22	62±	10	32±	9	4±	1	1±	1	0±	0	2±	1*

Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

TABLE F2

HEMATOLOGY : FEMALE

STUDY NO. : 0794
ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj]
MEASURE. TIME : 1
SEX : FEMALE REPORT TYPE : A1

HEMATOLOGY (SUMMARY)
ALL ANIMALS (105W)

Group Name	NO. of Animals	RED BLOOD CELL $10^6/\mu\ell$		HEMOGLOBIN g/dℓ		HEMATOCRIT %		MCV fℓ		MCH pg		MCHC g/dℓ		PLATELET $10^3/\mu\ell$	
Control	38	8.23±	0.75	14.7±	1.2	42.5±	2.9	51.8±	2.6	17.9±	0.8	34.5±	0.6	652±	68
3.2ppm	37	7.81±	1.00**	14.0±	1.7*	40.6±	4.2*	52.4±	3.1	18.0±	1.0	34.3±	1.3	668±	149
8ppm	32	7.61±	1.18**	13.7±	2.1*	39.9±	5.2*	52.7±	3.3	18.0±	1.4	34.1±	1.7	679±	186
20ppm	28	7.80±	1.20*	13.9±	2.0*	40.7±	4.7*	52.8±	4.5	17.9±	1.1	34.0±	1.6	668±	135

Significant difference : * : $P \leqq 0.05$ ** : $P \leqq 0.01$ Test of Dunnett

STUDY NO. : 0794
ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj]
MEASURE. TIME : 1
SEX : FEMALE REPORT TYPE : A1

HEMATOLOGY (SUMMARY)
ALL ANIMALS (105W)

Group Name	NO. of Animals	RETICULOCYTE %	
Control	38	2.4±	1.1
3.2ppm	37	3.5±	4.0
8ppm	32	3.6±	3.1
20ppm	28	4.1±	6.5

Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0794
ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj]
MEASURE. TIME : 1
SEX : FEMALE REPORT TYPE : A1

HEMATOLOGY (SUMMARY)
ALL ANIMALS (105W)

Group Name	NO. of Animals	WBC $10^3/\mu\ell$		Differential WBC (%) NEUTRO		LYMPHO		MONO		EOSINO		BASO		OTHER	
Control	38	2.54±	2.02	42±	12	52±	12	3±	1	2±	1	0±	0	1±	0
3.2ppm	37	3.85±	3.44*	44±	16	47±	16	3±	1	1±	1	0±	1	4±	13
8ppm	32	3.31±	4.06	46±	13	47±	12	3±	1	2±	1	0±	1	1±	1
20ppm	28	3.26±	2.39	47±	11	48±	12	3±	1	2±	1	0±	0	1±	1

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

TABLE G1

BIOCHEMISTRY : MALE

STUDY NO. : 0794
ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj]
MEASURE. TIME : 1
SEX : MALE REPORT TYPE : A1

BIOCHEMISTRY (SUMMARY)
ALL ANIMALS (105W)

Group Name	NO. of Animals	TOTAL PROTEIN g/dℓ		ALBUMIN g/dℓ		A/G RATIO		T-BILIRUBIN mg/dℓ		GLUCOSE mg/dℓ		T-CHOLESTEROL mg/dℓ		TRIGLYCERIDE mg/dℓ	
Control	40	6.5±	0.3	2.8±	0.2	0.8±	0.1	0.12±	0.23	169±	31	163±	66	82±	69
3.2ppm	44	6.3±	0.3	2.8±	0.3	0.8±	0.1	0.08±	0.05	170±	27	151±	34	75±	54
8ppm	39	6.2±	0.5	2.6±	0.3*	0.7±	0.1	0.15±	0.44	160±	26	145±	41	84±	86
20ppm	9	5.8±	0.8*	2.4±	0.5**	0.7±	0.2	1.43±	4.08	130±	50*	162±	61	49±	19

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0794
ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj]
MEASURE. TIME : 1
SEX : MALE REPORT TYPE : A1

BIOCHEMISTRY (SUMMARY)
ALL ANIMALS (105W)

Group Name	NO. of Animals	PHOSPHOLIPID mg/dℓ	AST U/L	ALT U/L	LDH U/L	ALP U/L	G-GTP U/L	CK U/L
Control	40	241± 94	89± 49	37± 11	128± 53	353± 167	6.9± 4.5	103± 35
3.2ppm	44	223± 41	102± 77	45± 54	140± 87	362± 101	7.0± 3.7	108± 34
8ppm	39	223± 56	110± 134	36± 22	144± 140	367± 159	6.2± 4.3	114± 39
20ppm	9	275± 192	410± 992	71± 118	246± 370	566± 524	8.0± 10.3	199± 271

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0794
ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj]
MEASURE. TIME : 1
SEX : MALE REPORT TYPE : A1

BIOCHEMISTRY (SUMMARY)
ALL ANIMALS (105W)

Group Name	NO. of Animals	UREA NITROGEN mg/dℓ	CREATININE mg/dℓ	SODIUM mEq/ℓ	POTASSIUM mEq/ℓ	CHLORIDE mEq/ℓ	CALCIUM mg/dℓ	INORGANIC PHOSPHORUS mg/dℓ
Control	40	18.5± 3.5	0.37± 0.08	143± 2	3.9± 0.4	107± 2	10.3± 0.4	3.9± 0.6
3.2ppm	44	19.8± 4.7	0.35± 0.04	144± 2	4.0± 0.3	107± 2	10.2± 0.3	4.0± 0.5
8ppm	39	20.1± 6.2	0.35± 0.06	143± 1	4.0± 0.4	107± 1	10.2± 0.3	4.3± 0.6**
20ppm	9	26.0± 25.7	0.29± 0.04**	145± 3	4.2± 0.4	108± 2	10.0± 0.3*	4.6± 1.8

Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

TABLE G2

BIOCHEMISTRY : FEMALE

STUDY NO. : 0794
ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj]
MEASURE. TIME : 1
SEX : FEMALE REPORT TYPE : A1

BIOCHEMISTRY (SUMMARY)
ALL ANIMALS (105W)

Group Name	NO. of Animals	TOTAL PROTEIN g/dl	ALBUMIN g/dl	A/G RATIO	T-BILIRUBIN mg/dl	GLUCOSE mg/dl	T-CHOLESTEROL mg/dl	TRIGLYCERIDE mg/dl
Control	39	6.8± 0.6	3.5± 0.3	1.0± 0.1	0.06± 0.02	161± 22	140± 39	72± 56
3.2ppm	38	6.8± 0.5	3.5± 0.4	1.1± 0.2	0.07± 0.04	156± 21	141± 47	74± 57
8ppm	35	6.7± 0.5	3.5± 0.4	1.1± 0.1	0.07± 0.04	158± 21	126± 22	61± 39
20ppm	28	6.4± 0.8	3.3± 0.5	1.1± 0.1	0.09± 0.20	152± 33	123± 27	59± 35

Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0794
ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj]
MEASURE. TIME : 1
SEX : FEMALE REPORT TYPE : A1

BIOCHEMISTRY (SUMMARY)
ALL ANIMALS (105W)

Group Name	NO. of Animals	PHOSPHOLIPID mg/dℓ	AST U/L	ALT U/L	LDH U/L	ALP U/L	G-GTP U/L	CK U/L
Control	39	247± 64	124± 74	59± 35	151± 57	205± 92	2.4± 1.3	92± 23
3.2ppm	38	250± 75	134± 85	59± 33	163± 86	228± 139	3.0± 3.3	97± 32
8ppm	35	227± 39	129± 86	54± 17	125± 47	220± 82	2.3± 1.7	94± 25
20ppm	28	227± 48	136± 79	56± 27	154± 101	248± 180	2.8± 2.6	113± 116

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0794
ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj]
MEASURE. TIME : 1
SEX : FEMALE REPORT TYPE : A1

BIOCHEMISTRY (SUMMARY)
ALL ANIMALS (105W)

Group Name	NO. of Animals	UREA NITROGEN mg／dℓ		CREATININE mg／dℓ		SODIUM mEq／ℓ		POTASSIUM mEq／ℓ		CHLORIDE mEq／ℓ		CALCIUM mg／dℓ		INORGANIC PHOSPHORUS mg／dℓ	
Control	39	17.5±	2.5	0.30±	0.05	143±	2	3.7±	0.4	105±	1	10.3±	0.4	3.6±	0.7
3.2ppm	38	17.0±	2.3	0.29±	0.04	142±	1	3.7±	0.4	104±	2	10.5±	0.3	3.8±	0.6
8ppm	35	17.7±	4.1	0.28±	0.04	143±	2	3.6±	0.3	105±	2	10.2±	0.4	3.6±	0.9
20ppm	28	20.1±	9.6	0.26±	0.04**	142±	2	3.9±	0.8	105±	2	10.2±	0.3	4.2±	1.6

Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

TABLE H1

URINALYSIS : MALE

STUDY NO. : 0794 URINALYSIS
ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj]
MEASURE. TIME : 1
SEX : MALE REPORT TYPE : A1

Group Name	NO. of Animals	pH 5.0	6.0	6.5	7.0	7.5	8.0	8.5	CHI	Protein −	±	+	2+	3+	4+	CHI	Glucose −	±	+	2+	3+	4+	CHI	Ketone body −	±	+	2+	3+	4+	CHI	Bilirubin −	+	2+	3+	CHI
Control	42	0	1	4	3	15	10	9		0	0	1	21	20	0		42	0	0	0	0	0		32	8	1	1	0	0		42	0	0	0	
3.2ppm	45	0	0	2	4	22	12	5		0	0	1	16	28	0		45	0	0	0	0	0		40	5	0	0	0	0		45	0	0	0	
8ppm	39	0	0	1	7	12	8	11		0	0	0	7	31	1	*	39	0	0	0	0	0		22	14	3	0	0	0		37	1	0	1	
20ppm	9	0	0	0	3	4	2	0		0	0	1	4	4	0		9	0	0	0	0	0		9	0	0	0	0	0		8	0	0	1	*

Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of CHI SQUARE

STUDY NO. : 0794 URINALYSIS
ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj]
MEASURE. TIME : 1
SEX : MALE REPORT TYPE : A1

Group Name	NO. of Animals	Occult blood −	±	+	2+	3+	CHI	Urobilinogen ±	+	2+	3+	4+	CHI
Control	42	36	4	0	1	1		42	0	0	0	0	
3.2ppm	45	40	1	2	1	1		45	0	0	0	0	
8ppm	39	34	0	2	1	2		39	0	0	0	0	
20ppm	9	6	1	1	0	1		9	0	0	0	0	

Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of CHI SQUARE

TABLE H2

URINALYSIS : FEMALE

STUDY NO. : 0794 URINALYSIS
ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj]
MEASURE. TIME : 1
SEX : FEMALE REPORT TYPE : A1

Group Name	NO. of Animals	pH 5.0	6.0	6.5	7.0	7.5	8.0	8.5	CHI	Protein −	±	+	2+	3+	4+	CHI	Glucose −	±	+	2+	3+	4+	CHI	Ketone body −	±	+	2+	3+	4+	CHI	Bilirubin −	+	2+	3+	CHI
Control	39	0	0	0	0	5	12	22		0	5	7	11	16	0		39	0	0	0	0	0		9	27	2	1	0	0		39	0	0	0	
3.2ppm	41	0	2	1	3	3	11	21		1	5	11	7	17	0		41	0	0	0	0	0		15	23	3	0	0	0		40	1	0	0	
8ppm	36	0	1	2	1	3	3	26		1	4	15	7	9	0		36	0	0	0	0	0		13	22	1	0	0	0		36	0	0	0	
20ppm	30	0	2	1	2	0	9	16		1	8	11	7	3	0	*	30	0	0	0	0	0		9	20	0	1	0	0		30	0	0	0	

Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of CHI SQUARE

STUDY NO. : 0794 URINALYSIS
ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj]
MEASURE. TIME : 1
SEX : FEMALE REPORT TYPE : A1

Group Name	NO. of Animals	Occult blood −	±	+	2+	3+	CHI	Urobilinogen ±	+	2+	3+	4+	CHI
Control	39	36	0	0	1	2		39	0	0	0	0	
3.2ppm	41	38	1	0	2	0		41	0	0	0	0	
8ppm	36	35	0	0	0	1		36	0	0	0	0	
20ppm	30	25	0	2	0	3		30	0	0	0	0	

Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of CHI SQUARE

TABLE I 1

GROSS FINDINGS : MALE

STUDY NO. : 0794
ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj]
REPORT TYPE : A1
SEX : MALE

GROSS FINDINGS (SUMMARY)
ALL ANIMALS (0-105W)

Organ	Findings	Group Name / NO. of Animals	Control 50	(%)	3.2ppm 50	(%)	8ppm 50	(%)	20ppm 50	(%)
skin/app	nodule		1	(2)	8	(16)	5	(10)	8	(16)
subcutis	jaundice		0	(0)	0	(0)	0	(0)	1	(2)
	mass		11	(22)	9	(18)	10	(20)	14	(28)
nasal cavit	white zone		0	(0)	0	(0)	0	(0)	1	(2)
	nodule		0	(0)	1	(2)	2	(4)	14	(28)
lung	white zone		2	(4)	3	(6)	4	(8)	2	(4)
	red zone		2	(4)	1	(2)	1	(2)	2	(4)
	nodule		1	(2)	1	(2)	3	(6)	2	(4)
	voluminous		0	(0)	0	(0)	0	(0)	4	(8)
lymph node	enlarged		1	(2)	0	(0)	1	(2)	3	(6)
thymus	enlarged		0	(0)	0	(0)	1	(2)	0	(0)
spleen	enlarged		6	(12)	8	(16)	8	(16)	5	(10)
	white zone		0	(0)	0	(0)	1	(2)	1	(2)
	nodule		0	(0)	0	(0)	2	(4)	0	(0)
	adhesion		0	(0)	0	(0)	0	(0)	1	(2)
heart	white zone		1	(2)	0	(0)	1	(2)	0	(0)
oral cavity	nodule		0	(0)	1	(2)	0	(0)	0	(0)
tongue	white zone		0	(0)	1	(2)	0	(0)	0	(0)
stomach	gas		0	(0)	0	(0)	0	(0)	4	(8)
	forestomach:nodule		0	(0)	0	(0)	1	(2)	2	(4)
	glandular stomach:erosion		0	(0)	1	(2)	0	(0)	0	(0)
	glandular stomach:nodule		1	(2)	0	(0)	1	(2)	0	(0)

Organ	Findings	Group Name / NO. of Animals	Control 50	(%)	3.2ppm 50	(%)	8ppm 50	(%)	20ppm 50	(%)
stomach	glandular stomach:black zone		0	(0)	1	(2)	0	(0)	1	(2)
	glandular stomach:thick		1	(2)	0	(0)	0	(0)	0	(0)
small intes	gas		0	(0)	0	(0)	0	(0)	5	(10)
large intes	gas		0	(0)	0	(0)	0	(0)	5	(10)
liver	enlarged		2	(4)	1	(2)	3	(6)	2	(4)
	white zone		1	(2)	0	(0)	0	(0)	1	(2)
	nodule		0	(0)	2	(4)	2	(4)	1	(2)
	cyst		0	(0)	0	(0)	1	(2)	0	(0)
	rough		1	(2)	0	(0)	4	(8)	0	(0)
	herniation		7	(14)	9	(18)	5	(10)	11	(22)
pancreas	nodule		0	(0)	0	(0)	1	(2)	0	(0)
kidney	white zone		0	(0)	0	(0)	0	(0)	1	(2)
	cyst		0	(0)	0	(0)	1	(2)	0	(0)
	granular		4	(8)	1	(2)	2	(4)	0	(0)
urin bladd	urine:marked retention		1	(2)	1	(2)	1	(2)	1	(2)
pituitary	enlarged		6	(12)	3	(6)	4	(8)	0	(0)
	red zone		6	(12)	7	(14)	3	(6)	1	(2)
	nodule		3	(6)	3	(6)	3	(6)	0	(0)
	cyst		0	(0)	0	(0)	1	(2)	0	(0)
thyroid	enlarged		3	(6)	3	(6)	3	(6)	1	(2)
	red zone		0	(0)	0	(0)	1	(2)	0	(0)
adrenal	enlarged		0	(0)	0	(0)	1	(2)	1	(2)

Organ	Findings	Group Name / NO. of Animals	Control 50 (%)	3.2ppm 50 (%)	8ppm 50 (%)	20ppm 50 (%)
testis	nodule		39 (78)	46 (92)	44 (88)	24 (48)
brain	enlarged		1 (2)	0 (0)	0 (0)	0 (0)
	red zone		1 (2)	0 (0)	0 (0)	3 (6)
	nodule		0 (0)	0 (0)	1 (2)	2 (4)
spinal cord	red zone		0 (0)	0 (0)	0 (0)	1 (2)
	black zone		0 (0)	0 (0)	0 (0)	1 (2)
eye	turbid		0 (0)	0 (0)	0 (0)	4 (8)
	white		6 (12)	5 (10)	8 (16)	2 (4)
	red		0 (0)	0 (0)	0 (0)	1 (2)
Zymbal gl	nodule		1 (2)	0 (0)	1 (2)	0 (0)
muscle	nodule		1 (2)	0 (0)	1 (2)	1 (2)
pleura	nodule		0 (0)	0 (0)	0 (0)	2 (4)
peritoneum	nodule		2 (4)	7 (14)	14 (28)	11 (22)
abdominal c	hemorrhage		1 (2)	0 (0)	0 (0)	0 (0)
	ascites		0 (0)	1 (2)	11 (22)	8 (16)
thoracic ca	pleural fluid		1 (2)	2 (4)	1 (2)	0 (0)
other	lip:nodule		1 (2)	1 (2)	0 (0)	1 (2)
	eye lid:nodule		1 (2)	0 (0)	1 (2)	0 (0)
	ear:nodule		0 (0)	0 (0)	0 (0)	1 (2)
	hindlimb:swollen		0 (0)	0 (0)	1 (2)	0 (0)
	nose:elevated		0 (0)	0 (0)	0 (0)	3 (6)
	nose:nodule		1 (2)	0 (0)	0 (0)	13 (26)

Organ	Findings	Group Name / NO. of Animals	Control 50	(%)	3.2ppm 50	(%)	8ppm 50	(%)	20ppm 50	(%)
whole body	anemic		0	(0)	0	(0)	0	(0)	3	(6)

TABLE I 2

GROSS FINDINGS : FEMALE

Organ	Findings	Group Name / NO. of Animals	Control 50	(%)	3.2ppm 50	(%)	8ppm 50	(%)	20ppm 50	(%)
skin/app	nodule		0	(0)	1	(2)	3	(6)	0	(0)
	erosion		0	(0)	1	(2)	0	(0)	0	(0)
	scab		0	(0)	0	(0)	1	(2)	0	(0)
subcutis	jaundice		0	(0)	1	(2)	3	(6)	1	(2)
	mass		8	(16)	19	(38)	19	(38)	29	(58)
nasal cavit	nodule		0	(0)	0	(0)	1	(2)	6	(12)
lung	white zone		0	(0)	1	(2)	0	(0)	2	(4)
	red zone		1	(2)	0	(0)	1	(2)	0	(0)
	nodule		0	(0)	2	(4)	0	(0)	0	(0)
lymph node	enlarged		1	(2)	0	(0)	1	(2)	1	(2)
thymus	enlarged		0	(0)	0	(0)	0	(0)	1	(2)
spleen	enlarged		5	(10)	7	(14)	9	(18)	7	(14)
	nodule		0	(0)	0	(0)	1	(2)	0	(0)
heart	white zone		0	(0)	0	(0)	0	(0)	1	(2)
tongue	nodule		0	(0)	2	(4)	0	(0)	2	(4)
stomach	forestomach:ulcer		1	(2)	2	(4)	0	(0)	1	(2)
	forestomach:erosion		0	(0)	0	(0)	1	(2)	0	(0)
	forestomach:nodule		0	(0)	0	(0)	1	(2)	1	(2)
	glandular stomach:ulcer		0	(0)	0	(0)	1	(2)	0	(0)
	glandular stomach:erosion		1	(2)	0	(0)	1	(2)	1	(2)
	glandular stomach:nodule		0	(0)	0	(0)	1	(2)	0	(0)
	glandular stomach:black zone		0	(0)	0	(0)	1	(2)	0	(0)

Organ	Findings	Group Name / NO. of Animals	Control 50	(%)	3.2ppm 50	(%)	8ppm 50	(%)	20ppm 50	(%)
small intes	adhesion		0	(0)	0	(0)	0	(0)	1	(2)
liver	white zone		0	(0)	0	(0)	1	(2)	1	(2)
	red zone		0	(0)	1	(2)	1	(2)	1	(2)
	nodule		0	(0)	0	(0)	1	(2)	1	(2)
	cyst		0	(0)	1	(2)	0	(0)	0	(0)
	rough		0	(0)	3	(6)	3	(6)	0	(0)
	nodular		0	(0)	1	(2)	0	(0)	0	(0)
	herniation		13	(26)	10	(20)	10	(20)	12	(24)
pancreas	nodule		0	(0)	1	(2)	0	(0)	0	(0)
kidney	small		1	(2)	0	(0)	0	(0)	0	(0)
	cyst		1	(2)	1	(2)	0	(0)	0	(0)
	deformed		0	(0)	0	(0)	1	(2)	0	(0)
	granular		0	(0)	0	(0)	1	(2)	0	(0)
	hydronephrosis		0	(0)	0	(0)	0	(0)	1	(2)
urin bladd	urine:marked retention		0	(0)	0	(0)	2	(4)	2	(4)
	urine:red		0	(0)	0	(0)	0	(0)	1	(2)
pituitary	enlarged		12	(24)	15	(30)	9	(18)	5	(10)
	red zone		12	(24)	14	(28)	6	(12)	5	(10)
	nodule		1	(2)	2	(4)	3	(6)	3	(6)
thyroid	enlarged		0	(0)	0	(0)	4	(8)	1	(2)
adrenal	enlarged		1	(2)	0	(0)	1	(2)	0	(0)
ovary	enlarged		0	(0)	0	(0)	1	(2)	2	(4)

Organ	Findings	Group Name / NO. of Animals	Control 50	(%)	3.2ppm 50	(%)	8ppm 50	(%)	20ppm 50	(%)
ovary	cyst		2	(4)	1	(2)	3	(6)	0	(0)
uterus	black zone		0	(0)	1	(2)	1	(2)	1	(2)
	nodule		5	(10)	4	(8)	4	(8)	11	(22)
	dilated lumen		0	(0)	0	(0)	1	(2)	2	(4)
vagina	nodule		0	(0)	0	(0)	1	(2)	1	(2)
	prolapse		0	(0)	1	(2)	0	(0)	0	(0)
brain	hemorrhage		1	(2)	0	(0)	0	(0)	0	(0)
	nodule		0	(0)	0	(0)	0	(0)	1	(2)
eye	turbid		0	(0)	0	(0)	0	(0)	1	(2)
	white		5	(10)	2	(4)	2	(4)	1	(2)
	red		1	(2)	0	(0)	0	(0)	0	(0)
muscle	nodule		0	(0)	1	(2)	1	(2)	0	(0)
pleura	nodule		0	(0)	0	(0)	0	(0)	1	(2)
peritoneum	nodule		1	(2)	0	(0)	0	(0)	0	(0)
retroperit	mass		0	(0)	0	(0)	1	(2)	0	(0)
abdominal c	hemorrhage		1	(2)	0	(0)	0	(0)	0	(0)
	ascites		0	(0)	0	(0)	1	(2)	2	(4)
thoracic ca	pleural fluid		0	(0)	0	(0)	1	(2)	1	(2)
other	lip:nodule		0	(0)	1	(2)	0	(0)	0	(0)
	ear:nodule		0	(0)	0	(0)	1	(2)	0	(0)
	upper jaw:nodule		1	(2)	0	(0)	0	(0)	0	(0)
	nose:elevated		0	(0)	0	(0)	0	(0)	1	(2)

Organ	Findings	Group Name / NO. of Animals	Control 50	(%)	3.2ppm 50	(%)	8ppm 50	(%)	20ppm 50	(%)
other	nose:nodule		0	(0)	0	(0)	0	(0)	1	(2)
whole body	anemic		0	(0)	1	(2)	0	(0)	2	(4)

TABLE J1

ORGAN WEIGHT, ABSOLUTE : MALE

STUDY NO. : 0794
ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj]
REPORT TYPE : A1
SEX : MALE
UNIT: g

ORGAN WEIGHT:ABSOLUTE (SUMMARY)
SURVIVAL ANIMALS (105W)

Group Name	NO. of Animals	Body Weight	ADRENALS	TESTES	HEART	LUNGS	KIDNEYS
Control	40	373± 28	0.077± 0.016	3.216± 1.300	1.165± 0.103	1.355± 0.103	2.649± 0.224
3.2ppm	44	369± 35	0.075± 0.013	3.723± 1.270	1.198± 0.109	1.455± 0.351	2.682± 0.182
8ppm	39	363± 53*	0.080± 0.015	3.790± 1.523	1.239± 0.125*	1.439± 0.233	2.733± 0.229
20ppm	9	295± 39**	0.105± 0.112	3.278± 1.261	1.150± 0.162	1.302± 0.166	2.583± 0.213

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0794
ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj]
REPORT TYPE : A1
SEX : MALE
UNIT: g

ORGAN WEIGHT:ABSOLUTE (SUMMARY)
SURVIVAL ANIMALS (105W)

Group Name	NO. of Animals	SPLEEN		LIVER		BRAIN	
Control	40	1.141±	1.287	10.400±	1.679	2.065±	0.068
3.2ppm	44	1.093±	0.856	10.427±	1.539	2.057±	0.070
8ppm	39	1.519±	2.386**	10.643±	1.938	2.059±	0.058
20ppm	9	0.729±	0.230	8.934±	0.871	2.005±	0.060

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

TABLE J2

ORGAN WEIGHT, ABSOLUTE : FEMALE

STUDY NO. : 0794
ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj]
REPORT TYPE : A1
SEX : FEMALE
UNIT: g

ORGAN WEIGHT:ABSOLUTE (SUMMARY)
SURVIVAL ANIMALS (105W)

Group Name	NO. of Animals	Body Weight	ADRENALS	OVARIES	HEART	LUNGS	KIDNEYS
Control	39	269± 36	0.081± 0.027	0.125± 0.031	0.844± 0.066	0.961± 0.052	1.802± 0.143
3.2ppm	38	265± 35	0.077± 0.014	0.141± 0.085	0.875± 0.073	1.010± 0.160	1.819± 0.180
8ppm	35	247± 33*	0.111± 0.216	0.700± 3.283	0.827± 0.074	0.984± 0.147	1.753± 0.122
20ppm	28	232± 25**	0.076± 0.017	0.134± 0.068	0.836± 0.063	0.995± 0.132	1.807± 0.129

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0794
ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj]
REPORT TYPE : A1
SEX : FEMALE
UNIT: g

ORGAN WEIGHT:ABSOLUTE (SUMMARY)
SURVIVAL ANIMALS (105W)

Group Name	NO. of Animals	SPLEEN	LIVER	BRAIN
Control	39	0.589± 0.217	6.759± 1.376	1.888± 0.082
3.2ppm	38	0.824± 0.911	6.932± 1.412	1.880± 0.067
8ppm	35	0.862± 1.302	6.311± 0.970	1.852± 0.081*
20ppm	28	0.595± 0.459	6.544± 2.461	1.862± 0.051*

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

TABLE K1

ORGAN WEIGHT, RELATIVE : MALE

STUDY NO. : 0794
ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj]
REPORT TYPE : A1
SEX : MALE
UNIT: %

ORGAN WEIGHT:RELATIVE (SUMMARY)
SURVIVAL ANIMALS (105W)

Group Name	NO. of Animals	Body Weight (g)	ADRENALS	TESTES	HEART	LUNGS	KIDNEYS
Control	40	373± 28	0.021± 0.004	0.869± 0.370	0.314± 0.030	0.365± 0.029	0.712± 0.051
3.2ppm	44	369± 35	0.021± 0.003	1.023± 0.369	0.327± 0.039	0.396± 0.092	0.732± 0.068
8ppm	39	363± 53*	0.022± 0.006	1.048± 0.406	0.346± 0.050**	0.404± 0.098**	0.764± 0.110**
20ppm	9	295± 39**	0.037± 0.040*	1.089± 0.335	0.393± 0.047**	0.448± 0.075**	0.887± 0.103**

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0794
ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj]
REPORT TYPE : A1
SEX : MALE
UNIT: %

ORGAN WEIGHT:RELATIVE (SUMMARY)
SURVIVAL ANIMALS (105W)

Group Name	NO. of Animals	SPLEEN	LIVER	BRAIN
Control	40	0.304± 0.331	2.790± 0.405	0.557± 0.036
3.2ppm	44	0.294± 0.221	2.833± 0.339	0.562± 0.052
8ppm	39	0.435± 0.805**	2.958± 0.598	0.576± 0.068
20ppm	9	0.247± 0.075	3.078± 0.487*	0.693± 0.114**

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

TABLE K2

ORGAN WEIGHT, RELATIVE : FEMALE

STUDY NO. : 0794
ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj]
REPORT TYPE : A1
SEX : FEMALE
UNIT: %

ORGAN WEIGHT:RELATIVE (SUMMARY)
SURVIVAL ANIMALS (105W)

Group Name	NO. of Animals	Body Weight (g)	ADRENALS	OVARIES	HEART	LUNGS	KIDNEYS
Control	39	269± 36	0.030± 0.012	0.047± 0.012	0.316± 0.028	0.361± 0.041	0.675± 0.062
3.2ppm	38	265± 35	0.029± 0.004	0.054± 0.034	0.334± 0.038	0.385± 0.065	0.693± 0.072
8ppm	35	247± 33*	0.044± 0.082	0.267± 1.224	0.338± 0.044*	0.405± 0.089*	0.719± 0.101
20ppm	28	232± 25**	0.033± 0.006*	0.059± 0.035*	0.363± 0.035**	0.434± 0.080**	0.783± 0.050**

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0794
ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj]
REPORT TYPE : A1
SEX : FEMALE
UNIT: %

ORGAN WEIGHT:RELATIVE (SUMMARY)
SURVIVAL ANIMALS (105W)

Group Name	NO. of Animals	SPLEEN	LIVER	BRAIN
Control	39	0.221± 0.086	2.510± 0.364	0.711± 0.083
3.2ppm	38	0.309± 0.334	2.615± 0.368	0.720± 0.084
8ppm	35	0.371± 0.613	2.570± 0.397	0.758± 0.081*
20ppm	28	0.263± 0.233	2.861± 1.277**	0.811± 0.082**

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

TABLE L1

HISTOPATHOLOGICAL FINDINGS :

NON-NEOPLASTIC LESIONS : MALE

Organ	Findings	Group Name / No. of Animals on Study / Grade	Control 50 1+ (%)	Control 50 2+ (%)	Control 50 3+ (%)	Control 50 4+ (%)	3.2ppm 50 1+ (%)	3.2ppm 50 2+ (%)	3.2ppm 50 3+ (%)	3.2ppm 50 4+ (%)	8ppm 50 1+ (%)	8ppm 50 2+ (%)	8ppm 50 3+ (%)	8ppm 50 4+ (%)	20ppm 50 1+ (%)	20ppm 50 2+ (%)	20ppm 50 3+ (%)	20ppm 50 4+ (%)
{Integumentary system/appandage}																		
subcutis		<50>																
	inflammation		0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	inflammatory infiltration		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
{Respiratory system}																		
nasal cavit		<50>																
	thrombus		1 (2)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	mineralization		41 (82)	0 (0)	0 (0)	0 (0)	46 (92)	0 (0)	0 (0)	0 (0)	42 (84)	0 (0)	0 (0)	0 (0)	22 (44)	0 (0)	0 (0)	0 ** (0)
	squamous cell hyperplasia with atypia		0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	0 (0)	4 (8)	16 (32)	7 (14)	0 ** (0)
	eosinophilic change:olfactory epithelium		42 (84)	5 (10)	0 (0)	0 (0)	43 (86)	5 (10)	0 (0)	0 (0)	40 (80)	2 (4)	0 (0)	0 (0)	17 (34)	0 (0)	0 (0)	0 ** (0)
	eosinophilic change:respiratory epithelium		6 (12)	0 (0)	0 (0)	0 (0)	12 (24)	0 (0)	0 (0)	0 (0)	11 (22)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name / No. of Animals on Study / Grade	Control 50 1+ (%)	Control 50 2+ (%)	Control 50 3+ (%)	Control 50 4+ (%)	3.2ppm 50 1+ (%)	3.2ppm 50 2+ (%)	3.2ppm 50 3+ (%)	3.2ppm 50 4+ (%)	8ppm 50 1+ (%)	8ppm 50 2+ (%)	8ppm 50 3+ (%)	8ppm 50 4+ (%)	20ppm 50 1+ (%)	20ppm 50 2+ (%)	20ppm 50 3+ (%)	20ppm 50 4+ (%)
{Respiratory system}																		
nasal cavit		<50>					<50>				<50>				<50>			
	inflammation:foreign body		11	5	0	0	19	7	0	0	14	4	0	0	0	0	0	0 **
			(22)	(10)	(0)	(0)	(38)	(14)	(0)	(0)	(28)	(8)	(0)	(0)	(0)	(0)	(0)	(0)
	inflammation:respiratory epithelium		9	0	0	0	17	0	0	0	9	0	0	0	6	0	0	0
			(18)	(0)	(0)	(0)	(34)	(0)	(0)	(0)	(18)	(0)	(0)	(0)	(12)	(0)	(0)	(0)
	respiratory metaplasia:olfactory epithelium		0	0	0	0	0	0	0	0	7	0	0	0 *	14	0	0	0 **
			(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(14)	(0)	(0)	(0)	(28)	(0)	(0)	(0)
	respiratory metaplasia:gland		46	2	0	0	40	6	0	0	36	9	0	0 *	23	3	0	0 **
			(92)	(4)	(0)	(0)	(80)	(12)	(0)	(0)	(72)	(18)	(0)	(0)	(46)	(6)	(0)	(0)
	squamous cell metaplasia:respiratory epithelium		0	0	0	0	4	0	0	0	8	0	0	0 **	4	3	0	0 *
			(0)	(0)	(0)	(0)	(8)	(0)	(0)	(0)	(16)	(0)	(0)	(0)	(8)	(6)	(0)	(0)
	squamous cell metaplasia:olfactory epithelium		0	0	0	0	0	0	0	0	0	0	0	0	2	1	0	0
			(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(4)	(2)	(0)	(0)
	ulcer:respiratory epithelium		0	1	0	0	0	0	0	0	1	0	0	0	5	2	1	0
			(0)	(2)	(0)	(0)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(10)	(4)	(2)	(0)
	ulcer:olfactory epithelium		0	0	0	0	0	0	0	0	0	0	0	0	2	1	0	0
			(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(4)	(2)	(0)	(0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name / No. of Animals on Study / Grade	Control 50 1+ (%)	Control 50 2+ (%)	Control 50 3+ (%)	Control 50 4+ (%)	3.2ppm 50 1+ (%)	3.2ppm 50 2+ (%)	3.2ppm 50 3+ (%)	3.2ppm 50 4+ (%)	8ppm 50 1+ (%)	8ppm 50 2+ (%)	8ppm 50 3+ (%)	8ppm 50 4+ (%)	20ppm 50 1+ (%)	20ppm 50 2+ (%)	20ppm 50 3+ (%)	20ppm 50 4+ (%)
[Respiratory system]																		
nasal cavit		<50>					<50>				<50>				<50>			
	squamous cell metaplasia with atypia:respiratory epithelium	0	0	0	0	5	0	0	0	10	15	0	0 **	2	4	0	0 *
		(0)	(0)	(0)	(0)	(10)	(0)	(0)	(0)	(20)	(30)	(0)	(0)	(4)	(8)	(0)	(0)
	hyperplasia:nasal gland	0	0	0	0	0	0	0	0	0	0	0	0	3	1	0	0
		(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(6)	(2)	(0)	(0)
	hyperplasia:transitional epithelium	0	0	0	0	15	1	0	0 **	26	7	2	0 **	2	0	0	0
		(0)	(0)	(0)	(0)	(30)	(2)	(0)	(0)	(52)	(14)	(4)	(0)	(4)	(0)	(0)	(0)
	regeneration:respiratory epithelium	0	0	0	0	0	0	0	0	3	0	0	0	0	0	0	0
		(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(6)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
	regeneration:olfactory epithelium	0	0	0	0	0	0	0	0	2	0	0	0	1	0	0	0
		(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(4)	(0)	(0)	(0)	(2)	(0)	(0)	(0)
	atrophy:olfactory epithelium	2	0	0	0	5	0	0	0	10	4	0	0 **	16	3	0	0 **
		(4)	(0)	(0)	(0)	(10)	(0)	(0)	(0)	(20)	(8)	(0)	(0)	(32)	(6)	(0)	(0)
	necrosis:olfactory epithelium	0	0	0	0	0	1	0	0	7	0	0	0 *	0	0	0	0
		(0)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(14)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
	necrosis:respiratory epithelium	0	0	0	0	1	0	0	0	2	0	0	0	0	0	0	0
		(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(4)	(0)	(0)	(0)	(0)	(0)	(0)	(0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name / No. of Animals on Study / Grade	Control 50 1+ (%)	Control 50 2+ (%)	Control 50 3+ (%)	Control 50 4+ (%)	3.2ppm 50 1+ (%)	3.2ppm 50 2+ (%)	3.2ppm 50 3+ (%)	3.2ppm 50 4+ (%)	8ppm 50 1+ (%)	8ppm 50 2+ (%)	8ppm 50 3+ (%)	8ppm 50 4+ (%)	20ppm 50 1+ (%)	20ppm 50 2+ (%)	20ppm 50 3+ (%)	20ppm 50 4+ (%)
[Respiratory system]																		
nasal cavit		<50>	0	0	0	0	3	1	1	0	1	0	0	0	2	2	0	0
	hyperplasia:respiratory epithelium		(0)	(0)	(0)	(0)	(6)	(2)	(2)	(0)	(2)	(0)	(0)	(0)	(4)	(4)	(0)	(0)
larynx		<50>	0	0	0	0	0	0	0	0	2	0	0	0	0	0	0	0
	inflammation cell		(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(4)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
	inflammation		3	0	0	0	1	0	0	0	2	0	0	0	1	0	0	0
			(6)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(4)	(0)	(0)	(0)	(2)	(0)	(0)	(0)
lung		<50>	1	0	0	0	0	0	0	0	1	0	0	0	1	0	0	0
	congestion		(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(2)	(0)	(0)	(0)
	hemorrhage		0	0	0	0	1	1	0	0	2	0	0	0	3	1	0	0
			(0)	(0)	(0)	(0)	(2)	(2)	(0)	(0)	(4)	(0)	(0)	(0)	(6)	(2)	(0)	(0)
	edema		2	0	0	0	0	0	0	0	1	0	0	0	3	0	0	0
			(4)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(6)	(0)	(0)	(0)
	inflammatory infiltration		0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
			(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(2)	(0)	(0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name / No. of Animals on Study / Grade	Control 50 1+ (%)	Control 50 2+ (%)	Control 50 3+ (%)	Control 50 4+ (%)	3.2ppm 50 1+ (%)	3.2ppm 50 2+ (%)	3.2ppm 50 3+ (%)	3.2ppm 50 4+ (%)	8ppm 50 1+ (%)	8ppm 50 2+ (%)	8ppm 50 3+ (%)	8ppm 50 4+ (%)	20ppm 50 1+ (%)	20ppm 50 2+ (%)	20ppm 50 3+ (%)	20ppm 50 4+ (%)
{Respiratory system}																		
lung		<50>																
	lymphocytic infiltration		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)
	fibrosis:focal		1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	bronchiolar-alveolar cell hyperplasia		5 (10)	2 (4)	0 (0)	0 (0)	5 (10)	4 (8)	0 (0)	0 (0)	4 (8)	1 (2)	1 (2)	0 (0)	1 (2)	2 (4)	0 (0)	0 (0)
	accumulation of histiocyte		0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
{Hematopoietic system}																		
bone marrow		<50>																
	granulation		0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)
	increased hematopoiesis		7 (14)	3 (6)	3 (6)	0 (0)	10 (20)	7 (14)	3 (6)	0 (0)	9 (18)	14 (28)	8 (16)	0 ** (0)	7 (14)	9 (18)	6 (12)	0 (0)
lymph node		<50>																
	congestion		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name / No. of Animals on Study / Grade	Control 50 1+ (%)	Control 50 2+ (%)	Control 50 3+ (%)	Control 50 4+ (%)	3.2ppm 50 1+ (%)	3.2ppm 50 2+ (%)	3.2ppm 50 3+ (%)	3.2ppm 50 4+ (%)	8ppm 50 1+ (%)	8ppm 50 2+ (%)	8ppm 50 3+ (%)	8ppm 50 4+ (%)	20ppm 50 1+ (%)	20ppm 50 2+ (%)	20ppm 50 3+ (%)	20ppm 50 4+ (%)
{Hematopoietic system}																		
lymph node		<50>	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
	inflammatory infiltration		(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)
spleen		<50>	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
	congestion		(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)
	deposit of hemosiderin		1	0	0	0	0	0	0	0	0	0	0	0	5	0	0	0
			(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(10)	(0)	(0)	(0)
	fibrosis:focal		0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0
			(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
	extramedullary hematopoiesis		17	3	1	0	9	10	4	0 *	8	12	11	0 **	7	5	10	0 **
			(34)	(6)	(2)	(0)	(18)	(20)	(8)	(0)	(16)	(24)	(22)	(0)	(14)	(10)	(20)	(0)
{Circulatory system}																		
heart		<50>	0	0	0	0	0	0	0	0	1	0	0	0	2	0	0	0
	thrombus		(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(4)	(0)	(0)	(0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name / Grade	Control 1+ (%)	Control 2+ (%)	Control 3+ (%)	Control 4+ (%)	3.2ppm 1+ (%)	3.2ppm 2+ (%)	3.2ppm 3+ (%)	3.2ppm 4+ (%)	8ppm 1+ (%)	8ppm 2+ (%)	8ppm 3+ (%)	8ppm 4+ (%)	20ppm 1+ (%)	20ppm 2+ (%)	20ppm 3+ (%)	20ppm 4+ (%)
		No. of Animals on Study	50				50				50				50			
{Circulatory system}																		
heart			<50>				<50>				<50>				<50>			
	mineralization		1 (2)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	myocardial fibrosis		34 (68)	10 (20)	0 (0)	0 (0)	32 (64)	6 (12)	0 (0)	0 (0)	34 (68)	11 (22)	0 (0)	0 (0)	32 (64)	7 (14)	0 (0)	0 (0)
	subendocardial fibrosis		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
artery/aort			<50>				<50>				<50>				<50>			
	mineralization		1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
{Digestive system}																		
tongue			<50>				<50>				<50>				<50>			
	squamous cell hyperplasia		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	mineralization:artery		1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name / No. of Animals on Study / Grade	Control 50 1+ (%)	Control 50 2+ (%)	Control 50 3+ (%)	Control 50 4+ (%)	3.2ppm 50 1+ (%)	3.2ppm 50 2+ (%)	3.2ppm 50 3+ (%)	3.2ppm 50 4+ (%)	8ppm 50 1+ (%)	8ppm 50 2+ (%)	8ppm 50 3+ (%)	8ppm 50 4+ (%)	20ppm 50 1+ (%)	20ppm 50 2+ (%)	20ppm 50 3+ (%)	20ppm 50 4+ (%)
{Digestive system}																		
esophagus		<50>																
	inflammation		0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
			(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)
stomach		<50>																
	erosion:forestomach		0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
			(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)
	ulcer:forestomach		1	1	0	0	1	0	0	0	1	0	0	0	3	2	0	0
			(2)	(2)	(0)	(0)	(2)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(6)	(4)	(0)	(0)
	hyperplasia:forestomach		1	0	0	0	4	0	0	0	3	1	0	0	5	3	0	0 *
			(2)	(0)	(0)	(0)	(8)	(0)	(0)	(0)	(6)	(2)	(0)	(0)	(10)	(6)	(0)	(0)
	erosion:glandular stomach		0	0	0	0	3	0	0	0	0	0	0	0	1	1	0	0
			(0)	(0)	(0)	(0)	(6)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(2)	(2)	(0)	(0)
	ulcer:glandular stomach		1	1	0	0	1	0	0	0	0	0	0	0	1	1	0	0
			(2)	(2)	(0)	(0)	(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(2)	(2)	(0)	(0)
	hyperplasia:glandular stomach		1	1	0	0	3	0	0	0	2	0	0	0	1	0	0	0
			(2)	(2)	(0)	(0)	(6)	(0)	(0)	(0)	(4)	(0)	(0)	(0)	(2)	(0)	(0)	(0)
	mineralization:glandular stomach		0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			(0)	(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name / No. of Animals on Study / Grade	Control 50 1+ (%)	Control 50 2+ (%)	Control 50 3+ (%)	Control 50 4+ (%)	3.2ppm 50 1+ (%)	3.2ppm 50 2+ (%)	3.2ppm 50 3+ (%)	3.2ppm 50 4+ (%)	8ppm 50 1+ (%)	8ppm 50 2+ (%)	8ppm 50 3+ (%)	8ppm 50 4+ (%)	20ppm 50 1+ (%)	20ppm 50 2+ (%)	20ppm 50 3+ (%)	20ppm 50 4+ (%)
{Digestive system}																		
small intes		<50>																
	hyperplasia		0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
			(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(2)	(0)	(0)
liver		<50>																
	herniation		7	0	0	0	9	0	0	0	5	0	0	0	11	0	0	0
			(14)	(0)	(0)	(0)	(18)	(0)	(0)	(0)	(10)	(0)	(0)	(0)	(22)	(0)	(0)	(0)
	necrosis:central		0	0	0	0	0	1	0	0	1	0	0	0	2	0	0	0
			(0)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(2)	(0)	(0)	(0)	(4)	(0)	(0)	(0)
	granulation		8	0	0	0	6	0	0	0	4	1	0	0	1	0	0	0 *
			(16)	(0)	(0)	(0)	(12)	(0)	(0)	(0)	(8)	(2)	(0)	(0)	(2)	(0)	(0)	(0)
	inflammatory cell nest		7	0	0	0	5	0	0	0	1	0	0	0	1	0	0	0
			(14)	(0)	(0)	(0)	(10)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(2)	(0)	(0)	(0)
	extramedullary hematopoiesis		2	0	0	0	3	0	0	0	2	0	0	0	3	0	0	0
			(4)	(0)	(0)	(0)	(6)	(0)	(0)	(0)	(4)	(0)	(0)	(0)	(6)	(0)	(0)	(0)
	clear cell focus		1	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0
			(2)	(2)	(0)	(0)	(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
	acidophilic cell focus		24	3	1	0	28	5	2	0	32	3	0	0	9	0	0	0 **
			(48)	(6)	(2)	(0)	(56)	(10)	(4)	(0)	(64)	(6)	(0)	(0)	(18)	(0)	(0)	(0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name / No. of Animals on Study / Grade	Control 50 1+ (%)	Control 50 2+ (%)	Control 50 3+ (%)	Control 50 4+ (%)	3.2ppm 50 1+ (%)	3.2ppm 50 2+ (%)	3.2ppm 50 3+ (%)	3.2ppm 50 4+ (%)	8ppm 50 1+ (%)	8ppm 50 2+ (%)	8ppm 50 3+ (%)	8ppm 50 4+ (%)	20ppm 50 1+ (%)	20ppm 50 2+ (%)	20ppm 50 3+ (%)	20ppm 50 4+ (%)
{Digestive system}																		
liver		<50>																
	basophilic cell focus		11 (22)	0 (0)	0 (0)	0 (0)	17 (34)	1 (2)	0 (0)	0 (0)	16 (32)	1 (2)	0 (0)	0 (0)	7 (14)	0 (0)	0 (0)	0 (0)
	spongiosis hepatis		5 (10)	0 (0)	0 (0)	0 (0)	4 (8)	0 (0)	0 (0)	0 (0)	4 (8)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	bile duct hyperplasia		26 (52)	24 (48)	0 (0)	0 (0)	27 (54)	22 (44)	0 (0)	0 (0)	29 (58)	20 (40)	0 (0)	0 (0)	38 (76)	12 (24)	0 (0)	0 * (0)
	biliary cyst		1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
pancreas		<50>																
	atrophy		1 (2)	0 (0)	0 (0)	0 (0)	6 (12)	0 (0)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	islet cell hyperplasia		0 (0)	0 (0)	0 (0)	0 (0)	2 (4)	1 (2)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	1 (2)	2 (4)	0 (0)	0 (0)
{Urinary system}																		
kidney		<50>																
	cyst		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name / No. of Animals on Study / Grade	Control 50 1+ (%)	Control 50 2+ (%)	Control 50 3+ (%)	Control 50 4+ (%)	3.2ppm 50 1+ (%)	3.2ppm 50 2+ (%)	3.2ppm 50 3+ (%)	3.2ppm 50 4+ (%)	8ppm 50 1+ (%)	8ppm 50 2+ (%)	8ppm 50 3+ (%)	8ppm 50 4+ (%)	20ppm 50 1+ (%)	20ppm 50 2+ (%)	20ppm 50 3+ (%)	20ppm 50 4+ (%)
{Urinary system}																		
kidney		<50>	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0
	osseous metaplasia		(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
	chronic nephropathy		25 (50)	15 (30)	7 (14)	1 (2)	26 (52)	18 (36)	4 (8)	0 (0)	18 (36)	25 (50)	3 (6)	0 (0)	39 (78)	3 (6)	0 (0)	0 ** (0)
	mineralization:papilla		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)
	mineralization:pelvis		1 (2)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	urothelial hyperplasia:pelvis		0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	atypical tubule hyperplasia		0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	dilated pelvis		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
urin bladd		<50>	1	0	0	0	0	1	0	0	0	1	0	0	0	1	0	0
	dilatation		(2)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(2)	(0)	(0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name / Grade	Control 1+ (%)	Control 2+ (%)	Control 3+ (%)	Control 4+ (%)	3.2ppm 1+ (%)	3.2ppm 2+ (%)	3.2ppm 3+ (%)	3.2ppm 4+ (%)	8ppm 1+ (%)	8ppm 2+ (%)	8ppm 3+ (%)	8ppm 4+ (%)	20ppm 1+ (%)	20ppm 2+ (%)	20ppm 3+ (%)	20ppm 4+ (%)
{Urinary system}																		
urin bladd		No. of Animals on Study	50				50				50				50			
	papillary and/or nodular hyperplasia	<50>	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0
			(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(4)	(0)	(0)	(0)
{Endocrine system}																		
pituitary		<50>																
	angiectasis		0	0	1	0	2	1	0	0	0	0	0	0	2	0	0	0
			(0)	(0)	(2)	(0)	(4)	(2)	(0)	(0)	(0)	(0)	(0)	(0)	(4)	(0)	(0)	(0)
	cyst		3	0	0	0	2	0	0	0	3	0	0	0	2	0	0	0
			(6)	(0)	(0)	(0)	(4)	(0)	(0)	(0)	(6)	(0)	(0)	(0)	(4)	(0)	(0)	(0)
	hyperplasia		14	5	0	0	11	3	0	0	18	5	0	0	15	1	0	0
			(28)	(10)	(0)	(0)	(22)	(6)	(0)	(0)	(36)	(10)	(0)	(0)	(30)	(2)	(0)	(0)
	Rathke pouch		1	0	0	0	3	0	0	0	4	0	0	0	4	0	0	0
			(2)	(0)	(0)	(0)	(6)	(0)	(0)	(0)	(8)	(0)	(0)	(0)	(8)	(0)	(0)	(0)
thyroid		<50>																
	inflammatory infiltration		1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name / No. of Animals on Study / Grade	Control 50 1+ (%)	Control 50 2+ (%)	Control 50 3+ (%)	Control 50 4+ (%)	3.2ppm 50 1+ (%)	3.2ppm 50 2+ (%)	3.2ppm 50 3+ (%)	3.2ppm 50 4+ (%)	8ppm 50 1+ (%)	8ppm 50 2+ (%)	8ppm 50 3+ (%)	8ppm 50 4+ (%)	20ppm 50 1+ (%)	20ppm 50 2+ (%)	20ppm 50 3+ (%)	20ppm 50 4+ (%)
{Endocrine system}																		
thyroid		<50>																
	follicular hyperplasia		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)
	C-cell hyperplasia		12 (24)	2 (4)	1 (2)	0 (0)	5 (10)	3 (6)	4 (8)	0 (0)	8 (16)	1 (2)	1 (2)	0 (0)	4 (8)	1 (2)	1 (2)	0 (0)
adrenal		<50>																
	angiectasis		2 (4)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	peliosis-like lesion		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)
	fatty change		0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)
	extramedullary hematopoiesis		1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)
	hyperplasia:cortical cell		9 (18)	0 (0)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	0 (0)
	hyperplasia:medulla		4 (8)	2 (4)	0 (0)	0 (0)	4 (8)	1 (2)	0 (0)	0 (0)	4 (8)	4 (8)	0 (0)	0 (0)	2 (4)	1 (2)	1 (2)	0 (0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name / No. of Animals on Study / Grade	Control 50 1+ (%)	Control 50 2+ (%)	Control 50 3+ (%)	Control 50 4+ (%)	3.2ppm 50 1+ (%)	3.2ppm 50 2+ (%)	3.2ppm 50 3+ (%)	3.2ppm 50 4+ (%)	8ppm 50 1+ (%)	8ppm 50 2+ (%)	8ppm 50 3+ (%)	8ppm 50 4+ (%)	20ppm 50 1+ (%)	20ppm 50 2+ (%)	20ppm 50 3+ (%)	20ppm 50 4+ (%)
{Endocrine system}																		
adrenal		<50>																
	accesory cortical nodule		1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	0 (0)
	focal fatty change:cortex		3 (6)	0 (0)	0 (0)	0 (0)	6 (12)	1 (2)	0 (0)	0 (0)	7 (14)	1 (2)	0 (0)	0 (0)	7 (14)	0 (0)	0 (0)	0 (0)
{Reproductive system}																		
testis		<50>																
	mineralization		1 (2)	0 (0)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	0 (0)	3 (6)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)
	inflammation		1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	interstitial cell hyperplasia		4 (8)	0 (0)	0 (0)	0 (0)	2 (4)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	5 (10)	0 (0)	0 (0)	0 (0)
semin ves		<50>																
	inflammation		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name / No. of Animals on Study / Grade	Control 50 1+ (%)	Control 50 2+ (%)	Control 50 3+ (%)	Control 50 4+ (%)	3.2ppm 50 1+ (%)	3.2ppm 50 2+ (%)	3.2ppm 50 3+ (%)	3.2ppm 50 4+ (%)	8ppm 50 1+ (%)	8ppm 50 2+ (%)	8ppm 50 3+ (%)	8ppm 50 4+ (%)	20ppm 50 1+ (%)	20ppm 50 2+ (%)	20ppm 50 3+ (%)	20ppm 50 4+ (%)
{Reproductive system}																		
prostate		<50>	9	2	0	0	8	0	0	0	20	0	0	0 *	2	0	0	0 *
	inflammation		(18)	(4)	(0)	(0)	(16)	(0)	(0)	(0)	(40)	(0)	(0)	(0)	(4)	(0)	(0)	(0)
	hyperplasia		7	1	0	0	7	1	0	0	8	2	0	0	6	0	0	0
			(14)	(2)	(0)	(0)	(14)	(2)	(0)	(0)	(16)	(4)	(0)	(0)	(12)	(0)	(0)	(0)
mammary gl		<50>	2	1	0	0	0	0	0	0	0	1	0	0	0	0	0	0
	galactocele		(4)	(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(0)	(0)	(0)
prep/cli gl		<50>	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
	hyperplasia		(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(2)	(0)	(0)
{Nervous system}																		
brain		<50>	1	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0
	hemorrhage		(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(4)	(0)	(0)	(0)
	gliosis		0	0	0	0	0	0	0	0	0	0	0	0	3	0	0	0
			(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(6)	(0)	(0)	(0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name / No. of Animals on Study / Grade	Control 50 1+ (%)	Control 50 2+ (%)	Control 50 3+ (%)	Control 50 4+ (%)	3.2ppm 50 1+ (%)	3.2ppm 50 2+ (%)	3.2ppm 50 3+ (%)	3.2ppm 50 4+ (%)	8ppm 50 1+ (%)	8ppm 50 2+ (%)	8ppm 50 3+ (%)	8ppm 50 4+ (%)	20ppm 50 1+ (%)	20ppm 50 2+ (%)	20ppm 50 3+ (%)	20ppm 50 4+ (%)
{Special sense organs/appendage}																		
eye		<50>					<50>				<50>				<50>			
	cataract		6 (12)	2 (4)	0 (0)	0 (0)	2 (4)	4 (8)	0 (0)	0 (0)	3 (6)	5 (10)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 * (0)
	retinal atrophy		0 (0)	2 (4)	5 (10)	0 (0)	1 (2)	1 (2)	5 (10)	0 (0)	1 (2)	2 (4)	6 (12)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)
	keratitis		2 (4)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	3 (6)	0 (0)	0 (0)	0 (0)	13 (26)	7 (14)	1 (2)	0 ** (0)
	iritis		2 (4)	3 (6)	0 (0)	0 (0)	5 (10)	0 (0)	0 (0)	0 (0)	3 (6)	2 (4)	0 (0)	0 (0)	8 (16)	4 (8)	0 (0)	0 (0)
	degeneration:cornea		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)
	ulcer:cornea		0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	3 (6)	6 (12)	1 (2)	0 * (0)
Harder gl		<50>					<50>				<50>				<50>			
	lymphocytic infiltration		0 (0)	0 (0)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	hyperplasia		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name / No. of Animals on Study / Grade	Control 50 1+ (%)	Control 50 2+ (%)	Control 50 3+ (%)	Control 50 4+ (%)	3.2ppm 50 1+ (%)	3.2ppm 50 2+ (%)	3.2ppm 50 3+ (%)	3.2ppm 50 4+ (%)	8ppm 50 1+ (%)	8ppm 50 2+ (%)	8ppm 50 3+ (%)	8ppm 50 4+ (%)	20ppm 50 1+ (%)	20ppm 50 2+ (%)	20ppm 50 3+ (%)	20ppm 50 4+ (%)
{Musculoskeletal system}																		
bone			<50>				<50>				<50>				<50>			
	fracture		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	ostitis fibrosa		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

TABLE L2

HISTOPATHOLOGICAL FINDINGS :

NON-NEOPLASTIC LESIONS : FEMALE

Organ	Findings	Group Name / Grade	Control 1+ (%)	Control 2+ (%)	Control 3+ (%)	Control 4+ (%)	3.2ppm 1+ (%)	3.2ppm 2+ (%)	3.2ppm 3+ (%)	3.2ppm 4+ (%)	8ppm 1+ (%)	8ppm 2+ (%)	8ppm 3+ (%)	8ppm 4+ (%)	20ppm 1+ (%)	20ppm 2+ (%)	20ppm 3+ (%)	20ppm 4+ (%)
		No. of Animals on Study	50				50				50				50			
{Integumentary system/appandage}																		
skin/app		<50>					<50>				<50>				<50>			
	erosion	a	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0
		b	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
	inflammation	a	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0
		b	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
	scab	a	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
		b	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
{Respiratory system}																		
nasal cavit		<50>					<50>				<50>				<50>			
	thrombus	a	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0
		b	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
	mineralization	a	20	0	0	0	34	0	0	0 **	26	0	0	0	30	0	0	0
		b	(40)	(0)	(0)	(0)	(68)	(0)	(0)	(0)	(52)	(0)	(0)	(0)	(60)	(0)	(0)	(0)
	hyperplasia:gland	a	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0
		b	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(0)	(0)	(0)
	squamous cell hyperplasia with atypia	a	0	0	0	0	0	0	0	0	0	0	0	0	4	7	2	0 **
		b	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(8)	(14)	(4)	(0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name / No. of Animals on Study / Grade	Control 50 1+ (%)	Control 50 2+ (%)	Control 50 3+ (%)	Control 50 4+ (%)	3.2ppm 50 1+ (%)	3.2ppm 50 2+ (%)	3.2ppm 50 3+ (%)	3.2ppm 50 4+ (%)	8ppm 50 1+ (%)	8ppm 50 2+ (%)	8ppm 50 3+ (%)	8ppm 50 4+ (%)	20ppm 50 1+ (%)	20ppm 50 2+ (%)	20ppm 50 3+ (%)	20ppm 50 4+ (%)
{Respiratory system}																		
nasal cavit		<50>					<50>				<50>				<50>			
	eosinophilic change:olfactory epithelium		16 (32)	29 (58)	3 (6)	0 (0)	25 (50)	25 (50)	0 (0)	0 (0)	29 (58)	19 (38)	0 (0)	0 * (0)	37 (74)	7 (14)	0 (0)	0 ** (0)
	eosinophilic change:respiratory epithelium		33 (66)	0 (0)	0 (0)	0 (0)	35 (70)	0 (0)	0 (0)	0 (0)	22 (44)	0 (0)	0 (0)	0 * (0)	9 (18)	0 (0)	0 (0)	0 ** (0)
	inflammation:foreign body		0 (0)	0 (0)	0 (0)	0 (0)	3 (6)	0 (0)	0 (0)	0 (0)	3 (6)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	inflammation:respiratory epithelium		7 (14)	0 (0)	0 (0)	0 (0)	3 (6)	0 (0)	0 (0)	0 (0)	22 (44)	0 (0)	0 (0)	0 ** (0)	30 (60)	0 (0)	0 (0)	0 ** (0)
	respiratory metaplasia:olfactory epithelium		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	15 (30)	0 (0)	0 (0)	0 ** (0)
	respiratory metaplasia:gland		49 (98)	0 (0)	0 (0)	0 (0)	47 (94)	1 (2)	0 (0)	0 (0)	41 (82)	3 (6)	0 (0)	0 * (0)	39 (78)	6 (12)	0 (0)	0 ** (0)
	squamous cell metaplasia:respiratory epithelium		0 (0)	0 (0)	0 (0)	0 (0)	6 (12)	0 (0)	0 (0)	0 * (0)	21 (42)	7 (14)	0 (0)	0 ** (0)	13 (26)	5 (10)	0 (0)	0 ** (0)
	squamous cell metaplasia:olfactory epithelium		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name / No. of Animals on Study / Grade	Control 50 1+ (%)	Control 50 2+ (%)	Control 50 3+ (%)	Control 50 4+ (%)	3.2ppm 50 1+ (%)	3.2ppm 50 2+ (%)	3.2ppm 50 3+ (%)	3.2ppm 50 4+ (%)	8ppm 50 1+ (%)	8ppm 50 2+ (%)	8ppm 50 3+ (%)	8ppm 50 4+ (%)	20ppm 50 1+ (%)	20ppm 50 2+ (%)	20ppm 50 3+ (%)	20ppm 50 4+ (%)
{Respiratory system}																		
nasal cavit			<50>				<50>				<50>				<50>			
	squamous cell metaplasia with atypia:respiratory epithelium		0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	7 (14)	9 (18)	2 (4)	0 (0) **
	hyperplasia:nasal gland		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	hyperplasia:transitional epithelium		0 (0)	0 (0)	0 (0)	0 (0)	4 (8)	4 (8)	0 (0)	0 (0) *	23 (46)	15 (30)	0 (0)	0 (0) **	13 (26)	20 (40)	0 (0)	0 (0) **
	regeneration:respiratory epithelium		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)
	regeneration:olfactory epithelium		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	10 (20)	0 (0)	0 (0)	0 (0) **
	atrophy:olfactory epithelium		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	7 (14)	3 (6)	0 (0)	0 (0) **	21 (42)	24 (48)	0 (0)	0 (0) **
	necrosis:olfactory epithelium		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	5 (10)	0 (0)	0 (0)	0 (0)	4 (8)	0 (0)	0 (0)	0 (0)
	necrosis:respiratory epithelium		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name / Grade	Control 1+ (%)	Control 2+ (%)	Control 3+ (%)	Control 4+ (%)	3.2ppm 1+ (%)	3.2ppm 2+ (%)	3.2ppm 3+ (%)	3.2ppm 4+ (%)	8ppm 1+ (%)	8ppm 2+ (%)	8ppm 3+ (%)	8ppm 4+ (%)	20ppm 1+ (%)	20ppm 2+ (%)	20ppm 3+ (%)	20ppm 4+ (%)
		No. of Animals on Study	50				50				50				50			
{Respiratory system}																		
nasal cavit			<50>				<50>				<50>				<50>			
	hyperplasia:respiratory epithelium		0 (0)	0 (0)	0 (0)	0 (0)	3 (6)	1 (2)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	0 (0)	3 (6)	0 (0)	1 (2)	0 (0)
larynx			<50>				<50>				<50>				<50>			
	inflammation		1 (2)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
lung			<50>				<50>				<50>				<50>			
	congestion		0 (0)	0 (0)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	0 (0)
	hemorrhage		0 (0)	1 (2)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	edema		1 (2)	0 (0)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	3 (6)	0 (0)	0 (0)	0 (0)
	inflammatory infiltration		1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	accumulation of foamy cells		0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name	Control				3.2ppm				8ppm				20ppm			
		No. of Animals on Study	50				50				50				50			
		Grade	1+	2+	3+	4+	1+	2+	3+	4+	1+	2+	3+	4+	1+	2+	3+	4+
			(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)
{Respiratory system}																		
lung			<50>				<50>				<50>				<50>			
	bronchiolar-alveolar cell hyperplasia		0	0	0	0	0	0	0	0	1	0	0	0	2	0	0	0
			(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(4)	(0)	(0)	(0)
{Hematopoietic system}																		
bone marrow			<50>				<50>				<50>				<50>			
	congestion		0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
			(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)
	granulation		1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0
			(2)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
	increased hematopoiesis		5	1	0	0	3	5	2	0	5	5	2	0	1	9	2	0 **
			(10)	(2)	(0)	(0)	(6)	(10)	(4)	(0)	(10)	(10)	(4)	(0)	(2)	(18)	(4)	(0)
lymph node			<50>				<50>				<50>				<50>			
	deposit of hemosiderin		0	0	0	0	0	1	0	0	0	0	0	0	1	0	0	0
			(0)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)
spleen			<50>				<50>				<50>				<50>			
	congestion		0	0	0	0	0	0	0	0	1	0	0	0	1	0	0	0
			(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(2)	(0)	(0)	(0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name / No. of Animals on Study / Grade	Control 50 1+ (%)	Control 50 2+ (%)	Control 50 3+ (%)	Control 50 4+ (%)	3.2ppm 50 1+ (%)	3.2ppm 50 2+ (%)	3.2ppm 50 3+ (%)	3.2ppm 50 4+ (%)	8ppm 50 1+ (%)	8ppm 50 2+ (%)	8ppm 50 3+ (%)	8ppm 50 4+ (%)	20ppm 50 1+ (%)	20ppm 50 2+ (%)	20ppm 50 3+ (%)	20ppm 50 4+ (%)
{Hematopoietic system}																		
spleen		<50>	8	0	0	0	4	0	0	0	5	0	0	0	7	1	0	0
	deposit of hemosiderin		(16)	(0)	(0)	(0)	(8)	(0)	(0)	(0)	(10)	(0)	(0)	(0)	(14)	(2)	(0)	(0)
	extramedullary hematopoiesis		23	8	1	0	16	8	3	0	20	10	3	0	11	6	9	0 **
			(46)	(16)	(2)	(0)	(32)	(16)	(6)	(0)	(40)	(20)	(6)	(0)	(22)	(12)	(18)	(0)
{Circulatory system}																		
heart		<50>	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0
	thrombus		(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(4)	(0)	(0)	(0)
	mineralization		0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
			(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
	inflammatory infiltration		1	0	0	0	1	0	0	0	2	0	0	0	0	0	0	0
			(2)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(4)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
	myocardial fibrosis		33	3	0	0	29	2	0	0	25	3	0	0	28	4	0	0
			(66)	(6)	(0)	(0)	(58)	(4)	(0)	(0)	(50)	(6)	(0)	(0)	(56)	(8)	(0)	(0)
	subendocardial fibrosis		1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
			(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name	Control				3.2ppm				8ppm				20ppm			
		No. of Animals on Study	50				50				50				50			
		Grade	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)
{Circulatory system}																		
artery/aort			<50>				<50>				<50>				<50>			
	mineralization		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
{Digestive system}																		
oral cavity			<50>				<50>				<50>				<50>			
	inflammation		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
stomach			<50>				<50>				<50>				<50>			
	erosion:forestomach		0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	ulcer:forestomach		1 (2)	1 (2)	0 (0)	0 (0)	2 (4)	1 (2)	1 (2)	0 (0)	0 (0)	4 (8)	0 (0)	0 (0)	3 (6)	3 (6)	0 (0)	0 (0)
	hyperplasia:forestomach		1 (2)	0 (0)	0 (0)	0 (0)	4 (8)	0 (0)	0 (0)	0 (0)	1 (2)	2 (4)	1 (2)	0 (0)	10 (20)	2 (4)	0 (0)	0 ** (0)
	erosion:glandular stomach		1 (2)	0 (0)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	0 (0)	3 (6)	2 (4)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	0 (0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name / Grade	Control 1+ (%)	Control 2+ (%)	Control 3+ (%)	Control 4+ (%)	3.2ppm 1+ (%)	3.2ppm 2+ (%)	3.2ppm 3+ (%)	3.2ppm 4+ (%)	8ppm 1+ (%)	8ppm 2+ (%)	8ppm 3+ (%)	8ppm 4+ (%)	20ppm 1+ (%)	20ppm 2+ (%)	20ppm 3+ (%)	20ppm 4+ (%)
		No. of Animals on Study	50				50				50				50			
{Digestive system}																		
stomach			<50>				<50>				<50>				<50>			
	ulcer:glandular stomach		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	hyperplasia:glandular stomach		0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)
	mineralization:glandular stomach		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
liver			<50>				<50>				<50>				<50>			
	herniation		13 (26)	0 (0)	0 (0)	0 (0)	11 (22)	0 (0)	0 (0)	0 (0)	11 (22)	0 (0)	0 (0)	0 (0)	12 (24)	0 (0)	0 (0)	0 (0)
	peliosis-like lesion		1 (2)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	necrosis:focal		0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	inflammatory infiltration		1 (2)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	lymphocytic infiltration		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name / No. of Animals on Study / Grade	Control 50 1+ (%)	Control 50 2+ (%)	Control 50 3+ (%)	Control 50 4+ (%)	3.2ppm 50 1+ (%)	3.2ppm 50 2+ (%)	3.2ppm 50 3+ (%)	3.2ppm 50 4+ (%)	8ppm 50 1+ (%)	8ppm 50 2+ (%)	8ppm 50 3+ (%)	8ppm 50 4+ (%)	20ppm 50 1+ (%)	20ppm 50 2+ (%)	20ppm 50 3+ (%)	20ppm 50 4+ (%)
{Digestive system}																		
liver		<50>	17	1	0	0	7	1	0	0	10	1	0	0	4	1	0	0 **
	granulation		(34)	(2)	(0)	(0)	(14)	(2)	(0)	(0)	(20)	(2)	(0)	(0)	(8)	(2)	(0)	(0)
	inflammatory cell nest		6	0	0	0	6	0	0	0	6	1	0	0	5	1	0	0
			(12)	(0)	(0)	(0)	(12)	(0)	(0)	(0)	(12)	(2)	(0)	(0)	(10)	(2)	(0)	(0)
	extramedullary hematopoiesis		1	0	0	0	5	0	0	0	2	0	0	0	1	0	0	0
			(2)	(0)	(0)	(0)	(10)	(0)	(0)	(0)	(4)	(0)	(0)	(0)	(2)	(0)	(0)	(0)
	clear cell focus		0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0
			(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
	acidophilic cell focus		4	3	2	0	6	2	0	0	4	0	0	0	1	0	0	0
			(8)	(6)	(4)	(0)	(12)	(4)	(0)	(0)	(8)	(0)	(0)	(0)	(2)	(0)	(0)	(0)
	basophilic cell focus		36	2	0	0	41	1	0	0	40	0	0	0	40	1	0	0
			(72)	(4)	(0)	(0)	(82)	(2)	(0)	(0)	(80)	(0)	(0)	(0)	(80)	(2)	(0)	(0)
	bile duct hyperplasia		14	0	0	0	22	3	0	0 *	19	3	0	0	18	1	0	0
			(28)	(0)	(0)	(0)	(44)	(6)	(0)	(0)	(38)	(6)	(0)	(0)	(36)	(2)	(0)	(0)
	bile ductular proliferation		0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
			(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name / No. of Animals on Study / Grade	Control 50 1+ (%)	Control 50 2+ (%)	Control 50 3+ (%)	Control 50 4+ (%)	3.2ppm 50 1+ (%)	3.2ppm 50 2+ (%)	3.2ppm 50 3+ (%)	3.2ppm 50 4+ (%)	8ppm 50 1+ (%)	8ppm 50 2+ (%)	8ppm 50 3+ (%)	8ppm 50 4+ (%)	20ppm 50 1+ (%)	20ppm 50 2+ (%)	20ppm 50 3+ (%)	20ppm 50 4+ (%)
{Digestive system}																		
liver			<50>				<50>				<50>				<50>			
	cholangiofibrosis		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	biliary cyst		0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
pancreas			<50>				<50>				<50>				<50>			
	atrophy		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)
	inflammatory infiltration		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
{Urinary system}																		
kidney			<50>				<50>				<50>				<50>			
	aplasia		0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	angiectasis		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name / No. of Animals on Study / Grade	Control 50 1+ (%)	Control 50 2+ (%)	Control 50 3+ (%)	Control 50 4+ (%)	3.2ppm 50 1+ (%)	3.2ppm 50 2+ (%)	3.2ppm 50 3+ (%)	3.2ppm 50 4+ (%)	8ppm 50 1+ (%)	8ppm 50 2+ (%)	8ppm 50 3+ (%)	8ppm 50 4+ (%)	20ppm 50 1+ (%)	20ppm 50 2+ (%)	20ppm 50 3+ (%)	20ppm 50 4+ (%)
{Urinary system}																		
kidney		<50>	0	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0
	cyst		(0)	(2)	(0)	(0)	(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
	hyaline droplet		0	0	0	0	0	0	0	0	1	0	0	0	1	1	0	0
			(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(2)	(2)	(0)	(0)
	chronic nephropathy		25	5	2	0	23	4	1	0	30	1	1	0	19	1	0	0 *
			(50)	(10)	(4)	(0)	(46)	(8)	(2)	(0)	(60)	(2)	(2)	(0)	(38)	(2)	(0)	(0)
	hydronephrosis		0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
			(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(2)	(0)	(0)
	mineralization:cortico-medullary junction		0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
			(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
	mineralization:papilla		1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
	dilatation:tubular lumen		0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
			(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
	dilated pelvis		0	0	0	0	0	0	0	0	1	0	0	0	2	1	0	0
			(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(4)	(2)	(0)	(0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name / No. of Animals on Study / Grade	Control 50 1+ (%)	Control 50 2+ (%)	Control 50 3+ (%)	Control 50 4+ (%)	3.2ppm 50 1+ (%)	3.2ppm 50 2+ (%)	3.2ppm 50 3+ (%)	3.2ppm 50 4+ (%)	8ppm 50 1+ (%)	8ppm 50 2+ (%)	8ppm 50 3+ (%)	8ppm 50 4+ (%)	20ppm 50 1+ (%)	20ppm 50 2+ (%)	20ppm 50 3+ (%)	20ppm 50 4+ (%)
{Urinary system}																		
kidney		<50>																
	squamous cell metaplasia:pelvis		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
urin bladd		<50>																
	dilatation		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)
	simple hyperplasia:transitional epithelium		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	papillary and/or nodular hyperplasia		1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
{Endocrine system}																		
pituitary		<50>																
	angiectasis		2 (4)	1 (2)	0 (0)	0 (0)	3 (6)	2 (4)	0 (0)	0 (0)	3 (6)	1 (2)	0 (0)	0 (0)	3 (6)	2 (4)	0 (0)	0 (0)
	cyst		18 (36)	2 (4)	0 (0)	0 (0)	13 (26)	2 (4)	0 (0)	0 (0)	17 (34)	2 (4)	0 (0)	0 (0)	21 (42)	2 (4)	0 (0)	0 (0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name / No. of Animals on Study / Grade	Control 50 1+ (%)	Control 50 2+ (%)	Control 50 3+ (%)	Control 50 4+ (%)	3.2ppm 50 1+ (%)	3.2ppm 50 2+ (%)	3.2ppm 50 3+ (%)	3.2ppm 50 4+ (%)	8ppm 50 1+ (%)	8ppm 50 2+ (%)	8ppm 50 3+ (%)	8ppm 50 4+ (%)	20ppm 50 1+ (%)	20ppm 50 2+ (%)	20ppm 50 3+ (%)	20ppm 50 4+ (%)
{Endocrine system}																		
pituitary		<50>																
	hyperplasia		14 (28)	2 (4)	0 (0)	0 (0)	14 (28)	1 (2)	0 (0)	0 (0)	13 (26)	3 (6)	0 (0)	0 (0)	10 (20)	0 (0)	0 (0)	0 (0)
	Rathke pouch		2 (4)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)
thyroid		<50>																
	follicular hyperplasia		1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)
	C-cell hyperplasia		17 (34)	4 (8)	0 (0)	0 (0)	13 (26)	4 (8)	0 (0)	0 (0)	8 (16)	1 (2)	0 (0)	0 * (0)	9 (18)	2 (4)	0 (0)	0 (0)
adrenal		<50>																
	angiectasis		4 (8)	0 (0)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	3 (6)	1 (2)	0 (0)	0 (0)
	hemorrhage		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)
	peliosis-like lesion		3 (6)	0 (0)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	0 (0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name	Control				3.2ppm				8ppm				20ppm			
		No. of Animals on Study	50				50				50				50			
		Grade	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)
{Endocrine system}																		
adrenal			<50>				<50>				<50>				<50>			
	cyst		0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	extramedullary hematopoiesis		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)
	hyperplasia:cortical cell		9 (18)	0 (0)	1 (2)	0 (0)	6 (12)	1 (2)	0 (0)	0 (0)	5 (10)	0 (0)	0 (0)	0 (0)	12 (24)	0 (0)	0 (0)	0 (0)
	hyperplasia:medulla		1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	3 (6)	0 (0)	0 (0)	0 (0)	1 (2)	1 (2)	0 (0)	0 (0)
	focal fatty change:cortex		5 (10)	0 (0)	0 (0)	0 (0)	4 (8)	0 (0)	0 (0)	0 (0)	11 (22)	1 (2)	1 (2)	0 (0)	12 (24)	1 (2)	0 (0)	0 (0)
	necrosis:cortex		0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
{Reproductive system}																		
ovary			<50>				<50>				<50>				<50>			
	cyst		2 (4)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (4)	3 (6)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name	Control				3.2ppm				8ppm				20ppm			
		No. of Animals on Study	50				50				50				50			
		Grade	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)
{Reproductive system}																		
ovary			<50>				<50>				<50>				<50>			
	inflammatory infiltration		0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
			(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
	lymphocytic infiltration		0	0	0	0	0	0	0	0	1	0	0	0	1	0	0	0
			(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(2)	(0)	(0)	(0)
	hyperplasia		0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0
			(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
uterus			<50>				<50>				<50>				<50>			
	cystic endometrial hyperplasia		1	0	0	0	5	1	0	0	4	1	0	0	6	1	0	0
			(2)	(0)	(0)	(0)	(10)	(2)	(0)	(0)	(8)	(2)	(0)	(0)	(12)	(2)	(0)	(0)
mammary gl			<50>				<50>				<50>				<50>			
	hyperplasia		0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0
			(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
{Nervous system}																		
brain			<50>				<50>				<50>				<50>			
	necrosis:focal		0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
			(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name / Grade	Control 1+ (%)	Control 2+ (%)	Control 3+ (%)	Control 4+ (%)	3.2ppm 1+ (%)	3.2ppm 2+ (%)	3.2ppm 3+ (%)	3.2ppm 4+ (%)	8ppm 1+ (%)	8ppm 2+ (%)	8ppm 3+ (%)	8ppm 4+ (%)	20ppm 1+ (%)	20ppm 2+ (%)	20ppm 3+ (%)	20ppm 4+ (%)
{Nervous system}																		
brain		No. of Animals on Study	50				50				50				50			
	mineralization	<50>	0	0	0	0	0	0	0	0	1	0	0	0	1	0	0	0
			(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(2)	(0)	(0)	(0)
	degeneration:focal	<50>	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
			(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)
	gliosis	<50>	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0
			(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(4)	(0)	(0)	(0)
spinal cord		No. of Animals on Study	50				50				50				50			
	degeneration:focal	<50>	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0
			(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
{Special sense organs/appendage}																		
eye		No. of Animals on Study	50				50				50				50			
	cataract	<50>	3	3	0	0	0	2	0	0	0	2	0	0	1	1	0	0
			(6)	(6)	(0)	(0)	(0)	(4)	(0)	(0)	(0)	(4)	(0)	(0)	(2)	(2)	(0)	(0)
	retinal atrophy	<50>	0	0	5	0	0	0	2	0	0	0	2	0	0	0	1	0
			(0)	(0)	(10)	(0)	(0)	(0)	(4)	(0)	(0)	(0)	(4)	(0)	(0)	(0)	(2)	(0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name / No. of Animals on Study / Grade	Control 50 1+ (%)	Control 50 2+ (%)	Control 50 3+ (%)	Control 50 4+ (%)	3.2ppm 50 1+ (%)	3.2ppm 50 2+ (%)	3.2ppm 50 3+ (%)	3.2ppm 50 4+ (%)	8ppm 50 1+ (%)	8ppm 50 2+ (%)	8ppm 50 3+ (%)	8ppm 50 4+ (%)	20ppm 50 1+ (%)	20ppm 50 2+ (%)	20ppm 50 3+ (%)	20ppm 50 4+ (%)
{Special sense organs/appendage}																		
eye		<50>					<50>				<50>				<50>			
	keratitis		3 (6)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	3 (6)	0 (0)	0 (0)	0 (0)	5 (10)	4 (8)	0 (0)	0 (0)
	iritis		2 (4)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	2 (4)	1 (2)	0 (0)	0 (0)	5 (10)	1 (2)	0 (0)	0 (0)
	mineralization:cornea		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	0 (0)
	ulcer:cornea		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)
Harder gl		<50>					<50>				<50>				<50>			
	degeneration:focal		0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	lymphocytic infiltration		4 (8)	0 (0)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	0 (0)
{Musculoskeletal system}																		
bone		<50>					<50>				<50>				<50>			
	osteosclerosis		4 (8)	1 (2)	0 (0)	0 (0)	3 (6)	0 (0)	0 (0)	0 (0)	4 (8)	5 (10)	0 (0)	0 (0)	3 (6)	3 (6)	0 (0)	0 (0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

TABLE M1

NUMBER OF ANIMALS WITH TUMORS

AND NUMBER OF TUMORS-TIME RELATED : MALE

STUDY NO. : 0794
ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj]
REPORT TYPE : A1
SEX : MALE

NUMBER OF ANIMALS WITH TUMORS AND NUMBER OF TUMORS - TIME RELATED

Time-related Weeks	Items	Group Name	Control	3.2ppm	8ppm	20ppm
0 - 52	NO. OF EXAMINED ANIMALS		0	0	0	0
	NO. OF ANIMALS WITH TUMORS		0	0	0	0
	NO. OF ANIMALS WITH SINGLE TUMORS		0	0	0	0
	NO. OF ANIMALS WITH MULTIPLE TUMORS		0	0	0	0
	NO. OF BENIGN TUMORS		0	0	0	0
	NO. OF MALIGNANT TUMORS		0	0	0	0
	NO. OF TOTAL TUMORS		0	0	0	0
53 - 78	NO. OF EXAMINED ANIMALS		0	0	4	9
	NO. OF ANIMALS WITH TUMORS		0	0	3	9
	NO. OF ANIMALS WITH SINGLE TUMORS		0	0	0	6
	NO. OF ANIMALS WITH MULTIPLE TUMORS		0	0	3	3
	NO. OF BENIGN TUMORS		0	0	2	5
	NO. OF MALIGNANT TUMORS		0	0	4	9
	NO. OF TOTAL TUMORS		0	0	6	14
79 - 104	NO. OF EXAMINED ANIMALS		9	6	7	32
	NO. OF ANIMALS WITH TUMORS		9	6	7	32
	NO. OF ANIMALS WITH SINGLE TUMORS		4	0	0	3
	NO. OF ANIMALS WITH MULTIPLE TUMORS		5	6	7	29
	NO. OF BENIGN TUMORS		10	12	10	45
	NO. OF MALIGNANT TUMORS		9	4	7	42
	NO. OF TOTAL TUMORS		19	16	17	87
105 - 105	NO. OF EXAMINED ANIMALS		41	44	39	9
	NO. OF ANIMALS WITH TUMORS		40	44	39	9
	NO. OF ANIMALS WITH SINGLE TUMORS		17	12	7	0
	NO. OF ANIMALS WITH MULTIPLE TUMORS		23	32	32	9
	NO. OF BENIGN TUMORS		65	83	76	26
	NO. OF MALIGNANT TUMORS		6	18	28	14
	NO. OF TOTAL TUMORS		71	101	104	40

STUDY NO. : 0794
ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj]
REPORT TYPE : A1
SEX : MALE

NUMBER OF ANIMALS WITH TUMORS AND NUMBER OF TUMORS - TIME RELATED

Time-related Weeks	Items	Group Name	Control	3.2ppm	8ppm	20ppm
0 - 105	NO. OF EXAMINED ANIMALS		50	50	50	50
	NO. OF ANIMALS WITH TUMORS		49	50	49	50
	NO. OF ANIMALS WITH SINGLE TUMORS		21	12	7	9
	NO. OF ANIMALS WITH MULTIPLE TUMORS		28	38	42	41
	NO. OF BENIGN TUMORS		75	95	88	76
	NO. OF MALIGNANT TUMORS		15	22	39	65
	NO. OF TOTAL TUMORS		90	117	127	141

TABLE M2

NUMBER OF ANIMALS WITH TUMORS

AND NUMBER OF TUMORS-TIME RELATED : FEMALE

STUDY NO. : 0794
ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj]
REPORT TYPE : A1
SEX : FEMALE

NUMBER OF ANIMALS WITH TUMORS AND NUMBER OF TUMORS - TIME RELATED

Time-related Weeks	Items	Group Name	Control	3.2ppm	8ppm	20ppm
0 - 52	NO. OF EXAMINED ANIMALS		0	0	1	0
	NO. OF ANIMALS WITH TUMORS		0	0	1	0
	NO. OF ANIMALS WITH SINGLE TUMORS		0	0	1	0
	NO. OF ANIMALS WITH MULTIPLE TUMORS		0	0	0	0
	NO. OF BENIGN TUMORS		0	0	0	0
	NO. OF MALIGNANT TUMORS		0	0	1	0
	NO. OF TOTAL TUMORS		0	0	1	0
53 - 78	NO. OF EXAMINED ANIMALS		2	0	2	4
	NO. OF ANIMALS WITH TUMORS		2	0	2	4
	NO. OF ANIMALS WITH SINGLE TUMORS		2	0	2	3
	NO. OF ANIMALS WITH MULTIPLE TUMORS		0	0	0	1
	NO. OF BENIGN TUMORS		2	0	1	1
	NO. OF MALIGNANT TUMORS		0	0	1	4
	NO. OF TOTAL TUMORS		2	0	2	5
79 - 104	NO. OF EXAMINED ANIMALS		9	11	12	17
	NO. OF ANIMALS WITH TUMORS		8	11	11	17
	NO. OF ANIMALS WITH SINGLE TUMORS		5	4	4	6
	NO. OF ANIMALS WITH MULTIPLE TUMORS		3	7	7	11
	NO. OF BENIGN TUMORS		9	11	14	19
	NO. OF MALIGNANT TUMORS		4	8	7	16
	NO. OF TOTAL TUMORS		13	19	21	35
105 - 105	NO. OF EXAMINED ANIMALS		39	39	35	29
	NO. OF ANIMALS WITH TUMORS		22	30	28	26
	NO. OF ANIMALS WITH SINGLE TUMORS		15	10	12	9
	NO. OF ANIMALS WITH MULTIPLE TUMORS		7	20	16	17
	NO. OF BENIGN TUMORS		24	42	45	37
	NO. OF MALIGNANT TUMORS		5	11	5	13
	NO. OF TOTAL TUMORS		29	53	50	50

STUDY NO. : 0794
ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj]
REPORT TYPE : A1
SEX : FEMALE

NUMBER OF ANIMALS WITH TUMORS AND NUMBER OF TUMORS - TIME RELATED

Time-related Weeks	Items	Group Name	Control	3.2ppm	8ppm	20ppm
0 - 105	NO. OF EXAMINED ANIMALS		50	50	50	50
	NO. OF ANIMALS WITH TUMORS		32	41	42	47
	NO. OF ANIMALS WITH SINGLE TUMORS		22	14	19	18
	NO. OF ANIMALS WITH MULTIPLE TUMORS		10	27	23	29
	NO. OF BENIGN TUMORS		35	53	60	57
	NO. OF MALIGNANT TUMORS		9	19	14	33
	NO. OF TOTAL TUMORS		44	72	74	90

TABLE N1

HISTOPATHOLOGICAL FINDINGS :

NEOPLASTIC LESIONS : MALE

STUDY NO. : 0794
ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj]
REPORT TYPE : A1
SEX : MALE

HISTOPATHOLOGICAL FINDINGS : NEOPLASTIC LESIONS (SUMMARY)
ALL ANIMALS (0-105W)

Organ	Findings	Group Name	Control	3.2ppm	8ppm	20ppm
		No. of animals on Study	50	50	50	50
{Integumentary system/appandage}						
skin/app			<50>	<50>	<50>	<50>
	squamous cell papilloma		2 (4%)	1 (2%)	2 (4%)	1 (2%)
	trichoepithelioma		0 (0%)	0 (0%)	0 (0%)	2 (4%)
	basal cell epithelioma		0 (0%)	1 (2%)	1 (2%)	4 (8%)
	keratoacanthoma		0 (0%)	4 (8%)	3 (6%)	3 (6%)
	tricho lemoma		0 (0%)	1 (2%)	0 (0%)	0 (0%)
	squamous cell carcinoma		0 (0%)	2 (4%)	1 (2%)	2 (4%)
	trichoepithelioma:malignant		0 (0%)	1 (2%)	0 (0%)	0 (0%)
	basal cell carcinoma		0 (0%)	0 (0%)	1 (2%)	1 (2%)
subcutis			<50>	<50>	<50>	<50>
	fibroma		5 (10%)	4 (8%)	4 (8%)	13 (26%)
	lipoma		0 (0%)	1 (2%)	0 (0%)	0 (0%)
	schwannoma		1 (2%)	0 (0%)	0 (0%)	1 (2%)
	hemangioma		0 (0%)	0 (0%)	1 (2%)	0 (0%)
	fibrosarcoma		0 (0%)	2 (4%)	1 (2%)	0 (0%)

< a > a : Number of animals examined at the site
b (c) b : Number of animals with neoplasm c : b / a * 100

Organ	Findings	Group Name / No. of animals on Study	Control 50	3.2ppm 50	8ppm 50	20ppm 50
{Integumentary system/appandage}						
subcutis			<50>	<50>	<50>	<50>
	leiomyosarcoma		1 (2%)	0 (0%)	1 (2%)	0 (0%)
	histiocytic sarcoma		0 (0%)	0 (0%)	1 (2%)	0 (0%)
	sarcoma:NOS		0 (0%)	0 (0%)	1 (2%)	0 (0%)
{Respiratory system}						
nasal cavit			<50>	<50>	<50>	<50>
	squamous cell papilloma		0 (0%)	0 (0%)	0 (0%)	1 (2%)
	adenoma		0 (0%)	7 (14%)	9 (18%)	0 (0%)
	squamous cell carcinoma		0 (0%)	0 (0%)	0 (0%)	29 (58%)
	adenocarcinoma		0 (0%)	0 (0%)	0 (0%)	2 (4%)
	sarcoma:NOS		0 (0%)	0 (0%)	0 (0%)	1 (2%)
	adenosquamous carcinoma		0 (0%)	0 (0%)	1 (2%)	1 (2%)
	esthesioneuroepithelioma		0 (0%)	0 (0%)	0 (0%)	7 (14%)
lung			<50>	<50>	<50>	<50>
	bronchiolar-alveolar adenoma		2 (4%)	4 (8%)	2 (4%)	0 (0%)
	bronchiolar-alveolar carcinoma		0 (0%)	0 (0%)	2 (4%)	1 (2%)

< a > a : Number of animals examined at the site
b (c) b : Number of animals with neoplasm c : b / a * 100

Organ	Findings	Group Name / No. of animals on Study	Control 50	3.2ppm 50	8ppm 50	20ppm 50
{Hematopoietic system}						
bone marrow			<50>	<50>	<50>	<50>
	histiocytic sarcoma		0 (0%)	0 (0%)	1 (2%)	0 (0%)
spleen			<50>	<50>	<50>	<50>
	hemangioma		0 (0%)	0 (0%)	1 (2%)	0 (0%)
	mononuclear cell leukemia		4 (8%)	6 (12%)	3 (6%)	4 (8%)
{Digestive system}						
oral cavity			<50>	<50>	<50>	<50>
	squamous cell papilloma		0 (0%)	1 (2%)	0 (0%)	0 (0%)
tongue			<50>	<50>	<50>	<50>
	squamous cell carcinoma		0 (0%)	1 (2%)	0 (0%)	0 (0%)
stomach			<50>	<50>	<50>	<50>
	squamous cell papilloma		0 (0%)	1 (2%)	0 (0%)	1 (2%)
	neuroendocrine cell tumor:benign		0 (0%)	0 (0%)	1 (2%)	0 (0%)
	squamous cell carcinoma		0 (0%)	0 (0%)	1 (2%)	0 (0%)
liver			<50>	<50>	<50>	<50>
	hepatocellular adenoma		1 (2%)	1 (2%)	1 (2%)	2 (4%)
pancreas			<50>	<50>	<50>	<50>
	islet cell adenoma		2 (4%)	4 (8%)	2 (4%)	2 (4%)
	acinar cell adenoma		0 (0%)	1 (2%)	0 (0%)	0 (0%)
	islet cell adenocarcinoma		1 (2%)	1 (2%)	2 (4%)	2 (4%)

< a > a : Number of animals examined at the site
b (c) b : Number of animals with neoplasm c : b / a * 100

Organ	Findings	Group Name / No. of animals on Study	Control 50	3.2ppm 50	8ppm 50	20ppm 50
{Endocrine system}						
pituitary			<50>	<50>	<50>	<50>
	adenoma		13 (26%)	7 (14%)	5 (10%)	0 (0%)
thyroid			<50>	<50>	<50>	<50>
	C-cell adenoma		4 (8%)	5 (10%)	3 (6%)	4 (8%)
	follicular adenoma		0 (0%)	1 (2%)	0 (0%)	1 (2%)
	C-cell carcinoma		1 (2%)	1 (2%)	3 (6%)	1 (2%)
	follicular adenocarcinoma		0 (0%)	1 (2%)	0 (0%)	0 (0%)
parathyroid			<50>	<50>	<50>	<50>
	adenoma		0 (0%)	0 (0%)	0 (0%)	1 (2%)
adrenal			<50>	<50>	<50>	<50>
	pheochromocytoma		3 (6%)	1 (2%)	0 (0%)	2 (4%)
	cortical adenoma		0 (0%)	1 (2%)	0 (0%)	0 (0%)
	pheochromocytoma:malignant		1 (2%)	0 (0%)	2 (4%)	0 (0%)
{Reproductive system}						
testis			<50>	<50>	<50>	<50>
	interstitial cell tumor		40 (80%)	46 (92%)	47 (94%)	36 (72%)
prostate			<50>	<50>	<50>	<50>
	adenoma		0 (0%)	1 (2%)	1 (2%)	0 (0%)
mammary gl			<50>	<50>	<50>	<50>
	adenoma		0 (0%)	0 (0%)	1 (2%)	0 (0%)

< a > a : Number of animals examined at the site
b (c) b : Number of animals with neoplasm c : b / a * 100

Organ	Findings	Group Name / No. of animals on Study	Control 50	3.2ppm 50	8ppm 50	20ppm 50
{Reproductive system}						
mammary gl			<50>	<50>	<50>	<50>
	fibroadenoma		0 (0%)	0 (0%)	2 (4%)	1 (2%)
	adenocarcinoma		1 (2%)	0 (0%)	0 (0%)	0 (0%)
prep/cli gl			<50>	<50>	<50>	<50>
	adenoma		2 (4%)	1 (2%)	1 (2%)	1 (2%)
{Nervous system}						
brain			<50>	<50>	<50>	<50>
	leiomyosarcoma		0 (0%)	0 (0%)	1 (2%)	0 (0%)
	glioma		1 (2%)	0 (0%)	0 (0%)	0 (0%)
{Special sense organs/appendage}						
Harder gl			<50>	<50>	<50>	<50>
	adenoma		0 (0%)	1 (2%)	0 (0%)	0 (0%)
Zymbal gl			<50>	<50>	<50>	<50>
	Zymbal gland tumor:malignant		1 (2%)	0 (0%)	0 (0%)	0 (0%)
{Musculoskeletal system}						
muscle			<50>	<50>	<50>	<50>
	rhabdomyosarcoma		1 (2%)	0 (0%)	0 (0%)	0 (0%)
bone			<50>	<50>	<50>	<50>
	osteosarcoma		1 (2%)	0 (0%)	1 (2%)	0 (0%)
{Body cavities}						
peritoneum			<50>	<50>	<50>	<50>
	leiomyosarcoma		1 (2%)	0 (0%)	0 (0%)	0 (0%)

< a > a : Number of animals examined at the site
b (c) b : Number of animals with neoplasm c : b / a * 100

Organ	Findings	Group Name	Control	3.2ppm	8ppm	20ppm
		No. of animals on Study	50	50	50	50
{Body cavities}						
peritoneum			<50>	<50>	<50>	<50>
	mesothelioma		1 (2%)	7 (14%)	16 (32%)	14 (28%)
adipose			<50>	<50>	<50>	<50>
	lipoma		0 (0%)	0 (0%)	1 (2%)	0 (0%)

< a > a : Number of animals examined at the site
b (c) b : Number of animals with neoplasm c : b / a * 100

TABLE N2

HISTOPATHOLOGICAL FINDINGS :

NEOPLASTIC LESIONS : FEMALE

Organ	Findings	Group Name	Control	3.2ppm	8ppm	20ppm
		No. of animals on Study	50	50	50	50
{Integumentary system/appandage}						
skin/app			<50>	<50>	<50>	<50>
	squamous cell papilloma		0 (0%)	0 (0%)	1 (2%)	0 (0%)
	basal cell epithelioma		0 (0%)	0 (0%)	1 (2%)	0 (0%)
	squamous cell carcinoma		0 (0%)	0 (0%)	0 (0%)	1 (2%)
	basal cell carcinoma		1 (2%)	0 (0%)	0 (0%)	0 (0%)
subcutis			<50>	<50>	<50>	<50>
	fibroma		0 (0%)	2 (4%)	2 (4%)	3 (6%)
	lipoma		1 (2%)	0 (0%)	1 (2%)	0 (0%)
	schwannoma		0 (0%)	0 (0%)	1 (2%)	0 (0%)
	sarcoma:NOS		0 (0%)	0 (0%)	1 (2%)	0 (0%)
{Respiratory system}						
nasal cavit			<50>	<50>	<50>	<50>
	adenoma		0 (0%)	3 (6%)	3 (6%)	1 (2%)
	squamous cell carcinoma		0 (0%)	0 (0%)	0 (0%)	10 (20%)
	adenosquamous carcinoma		0 (0%)	0 (0%)	0 (0%)	1 (2%)
	esthesioneuroepithelioma		0 (0%)	0 (0%)	0 (0%)	2 (4%)

< a > a : Number of animals examined at the site
b (c) b : Number of animals with neoplasm c : b / a * 100

Organ	Findings	Group Name / No. of animals on Study	Control 50	3.2ppm 50	8ppm 50	20ppm 50
{Respiratory system}						
nasal cavit			<50>	<50>	<50>	<50>
	hemangiosarcoma		0 (0%)	0 (0%)	0 (0%)	1 (2%)
lung			<50>	<50>	<50>	<50>
	bronchiolar-alveolar adenoma		1 (2%)	1 (2%)	0 (0%)	1 (2%)
	bronchiolar-alveolar carcinoma		0 (0%)	1 (2%)	0 (0%)	0 (0%)
{Hematopoietic system}						
spleen			<50>	<50>	<50>	<50>
	mononuclear cell leukemia		5 (10%)	10 (20%)	8 (16%)	6 (12%)
{Digestive system}						
oral cavity			<50>	<50>	<50>	<50>
	squamous cell papilloma		1 (2%)	0 (0%)	0 (0%)	0 (0%)
tongue			<50>	<50>	<50>	<50>
	squamous cell papilloma		0 (0%)	1 (2%)	0 (0%)	1 (2%)
	squamous cell carcinoma		0 (0%)	0 (0%)	0 (0%)	1 (2%)
stomach			<50>	<50>	<50>	<50>
	squamous cell papilloma		0 (0%)	0 (0%)	1 (2%)	0 (0%)
	squamous cell carcinoma		0 (0%)	0 (0%)	0 (0%)	1 (2%)
liver			<50>	<50>	<50>	<50>
	hepatocellular adenoma		1 (2%)	0 (0%)	1 (2%)	0 (0%)
pancreas			<50>	<50>	<50>	<50>
	islet cell adenoma		1 (2%)	0 (0%)	1 (2%)	1 (2%)

< a > a : Number of animals examined at the site
b (c) b : Number of animals with neoplasm c : b / a * 100

Organ	Findings	Group Name / No. of animals on Study	Control 50	3.2ppm 50	8ppm 50	20ppm 50
{Digestive system}						
pancreas			<50>	<50>	<50>	<50>
	acinar cell adenoma		1 (2%)	0 (0%)	0 (0%)	0 (0%)
	islet cell adenocarcinoma		0 (0%)	1 (2%)	0 (0%)	0 (0%)
{Urinary system}						
urin bladd			<50>	<50>	<50>	<50>
	transitional cell papilloma		2 (4%)	0 (0%)	0 (0%)	0 (0%)
{Endocrine system}						
pituitary			<50>	<50>	<50>	<50>
	adenoma		11 (22%)	16 (32%)	13 (26%)	8 (16%)
	adenocarcinoma		1 (2%)	2 (4%)	0 (0%)	0 (0%)
thyroid			<50>	<50>	<50>	<50>
	C-cell adenoma		1 (2%)	1 (2%)	3 (6%)	4 (8%)
	follicular adenoma		1 (2%)	2 (4%)	3 (6%)	1 (2%)
	C-cell carcinoma		0 (0%)	0 (0%)	2 (4%)	0 (0%)
adrenal			<50>	<50>	<50>	<50>
	pheochromocytoma		1 (2%)	0 (0%)	2 (4%)	0 (0%)
	pheochromocytoma:malignant		1 (2%)	0 (0%)	0 (0%)	0 (0%)
{Reproductive system}						
ovary			<50>	<50>	<50>	<50>
	granular cell tumor		0 (0%)	0 (0%)	0 (0%)	1 (2%)

< a > a : Number of animals examined at the site
b (c) b : Number of animals with neoplasm c : b / a * 100

Organ	Findings	Group Name / No. of animals on Study	Control 50	3.2ppm 50	8ppm 50	20ppm 50
{Reproductive system}						
ovary			<50>	<50>	<50>	<50>
	granulosa-theca cell tumor		0 (0%)	0 (0%)	1 (2%)	0 (0%)
	Sertoli cell tumor:malignant		0 (0%)	0 (0%)	0 (0%)	1 (2%)
	granulosa cell tumor:malignant		0 (0%)	1 (2%)	0 (0%)	0 (0%)
uterus			<50>	<50>	<50>	<50>
	adenoma		0 (0%)	0 (0%)	0 (0%)	2 (4%)
	endometrial stromal polyp		6 (12%)	10 (20%)	7 (14%)	7 (14%)
	adenocarcinoma		0 (0%)	1 (2%)	0 (0%)	1 (2%)
	endometrial stromal sarcoma		1 (2%)	1 (2%)	1 (2%)	5 (10%)
vagina			<50>	<50>	<50>	<50>
	squamous cell papilloma		0 (0%)	0 (0%)	1 (2%)	0 (0%)
mammary gl			<50>	<50>	<50>	<50>
	adenoma		0 (0%)	0 (0%)	1 (2%)	0 (0%)
	fibroadenoma		7 (14%)	14 (28%)	14 (28%)	23 (46%)
	adenocarcinoma		0 (0%)	1 (2%)	1 (2%)	1 (2%)
prep/cli gl			<50>	<50>	<50>	<50>
	adenoma		0 (0%)	3 (6%)	3 (6%)	4 (8%)
{Special sense organs/appendage}						
Zymbal gl			<50>	<50>	<50>	<50>
	Zymbal gland tumor:malignant		0 (0%)	0 (0%)	0 (0%)	1 (2%)

< a > a : Number of animals examined at the site
b (c) b : Number of animals with neoplasm c : b / a * 100

Organ	Findings	Group Name / No. of animals on Study	Control 50	3.2ppm 50	8ppm 50	20ppm 50
{Musculoskeletal system}						
muscle			<50>	<50>	<50>	<50>
	leiomyosarcoma		0 (0%)	1 (2%)	0 (0%)	0 (0%)
{Body cavities}						
pleura			<50>	<50>	<50>	<50>
	histiocytic sarcoma		0 (0%)	0 (0%)	0 (0%)	1 (2%)
peritoneum			<50>	<50>	<50>	<50>
	sarcoma:NOS		0 (0%)	0 (0%)	1 (2%)	0 (0%)

< a > a : Number of animals examined at the site
b (c) b : Number of animals with neoplasm c : b / a * 100

TABLE O1

NEOPLASTIC LESIONS-INCIDENCE

AND STATISTICAL ANALYSIS : MALE

Group Name	Control	3.2ppm	8ppm	20ppm
SITE : skin/appendage				
TUMOR : basal cell epithelioma				
Tumor rate				
Overall rates(a)	0/50(0.0)	1/50(2.0)	1/50(2.0)	4/50(8.0)
Adjusted rates(b)	0.0	2.27	2.56	23.08
Terminal rates(c)	0/41(0.0)	1/44(2.3)	1/39(2.6)	1/ 9(11.1)
Statistical analysis				
Peto test				
Standard method(d)	P = ------			
Prevalence method(d)	P = 0.0003**			
Combined analysis(d)	P = ------			
Cochran-Armitage test(e)	P = 0.0154*			
Fisher Exact test(e)		P = 0.5000	P = 0.5000	P = 0.0587
SITE : skin/appendage				
TUMOR : keratoacanthoma				
Tumor rate				
Overall rates(a)	0/50(0.0)	4/50(8.0)	3/50(6.0)	3/50(6.0)
Adjusted rates(b)	0.0	8.00	7.69	23.08
Terminal rates(c)	0/41(0.0)	2/44(4.5)	3/39(7.7)	1/ 9(11.1)
Statistical analysis				
Peto test				
Standard method(d)	P = ------			
Prevalence method(d)	P = 0.0250*			
Combined analysis(d)	P = ------			
Cochran-Armitage test(e)	P = 0.4221			
Fisher Exact test(e)		P = 0.0587	P = 0.1212	P = 0.1212
SITE : skin/appendage				
TUMOR : squamous cell papilloma,keratoacanthoma				
Tumor rate				
Overall rates(a)	2/50(4.0)	5/50(10.0)	4/50(8.0)	4/50(8.0)
Adjusted rates(b)	4.44	10.00	10.26	23.08
Terminal rates(c)	1/41(2.4)	2/44(4.5)	4/39(10.3)	1/ 9(11.1)
Statistical analysis				
Peto test				
Standard method(d)	P = ------			
Prevalence method(d)	P = 0.0720			
Combined analysis(d)	P = ------			
Cochran-Armitage test(e)	P = 0.6975			
Fisher Exact test(e)		P = 0.2180	P = 0.3389	P = 0.3389

Group Name	Control	3.2ppm	8ppm	20ppm
	SITE : skin/appendage			
	TUMOR : basal cell epithelioma, basal cell carcinoma			
Tumor rate				
Overall rates(a)	0/50(0.0)	1/50(2.0)	2/50(4.0)	5/50(10.0)
Adjusted rates(b)	0.0	2.27	2.56	23.08
Terminal rates(c)	0/41(0.0)	1/44(2.3)	1/39(2.6)	1/ 9(11.1)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.2314			
Prevalence method(d)	P = 0.0001**			
Combined analysis(d)	P = 0.0001**			
Cochran-Armitage test(e)	P = 0.0070**			
Fisher Exact test(e)		P = 0.5000	P = 0.2475	P = 0.0281*
	SITE : skin/appendage			
	TUMOR : squamous cell papilloma, keratoacanthoma, squamous cell carcinoma			
Tumor rate				
Overall rates(a)	2/50(4.0)	7/50(14.0)	5/50(10.0)	6/50(12.0)
Adjusted rates(b)	4.44	12.24	12.82	30.77
Terminal rates(c)	1/41(2.4)	3/44(6.8)	5/39(12.8)	2/ 9(22.2)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.4952			
Prevalence method(d)	P = 0.0132*			
Combined analysis(d)	P = 0.0180*			
Cochran-Armitage test(e)	P = 0.4128			
Fisher Exact test(e)		P = 0.0798	P = 0.2180	P = 0.1343
	SITE : subcutis			
	TUMOR : fibroma			
Tumor rate				
Overall rates(a)	5/50(10.0)	4/50(8.0)	4/50(8.0)	13/50(26.0)
Adjusted rates(b)	10.64	9.09	10.26	60.00
Terminal rates(c)	3/41(7.3)	4/44(9.1)	4/39(10.3)	5/ 9(55.6)
Statistical analysis				
Peto test				
Standard method(d)	P = ------			
Prevalence method(d)	P < 0.0001**			
Combined analysis(d)	P = ------			
Cochran-Armitage test(e)	P = 0.0048**			
Fisher Exact test(e)		P = 0.5000	P = 0.5000	P = 0.0332*

Group Name	Control	3.2ppm	8ppm	20ppm
SITE : subcutis				
TUMOR : fibroma,fibrosarcoma				
Tumor rate				
Overall rates(a)	5/50(10.0)	6/50(12.0)	5/50(10.0)	13/50(26.0)
Adjusted rates(b)	10.64	13.64	12.82	60.00
Terminal rates(c)	3/41(7.3)	6/44(13.6)	5/39(12.8)	5/ 9(55.6)
Statistical analysis				
Peto test				
Standard method(d)	P = ------			
Prevalence method(d)	P = 0.0002**			
Combined analysis(d)	P = -------			
Cochran-Armitage test(e)	P = 0.0140*			
Fisher Exact test(e)		P = 0.5000	P = 0.6297	P = 0.0332*
SITE : nasal cavity				
TUMOR : adenoma				
Tumor rate				
Overall rates(a)	0/50(0.0)	7/50(14.0)	9/50(18.0)	0/50(0.0)
Adjusted rates(b)	0.0	15.91	20.51	0.0
Terminal rates(c)	0/41(0.0)	7/44(15.9)	8/39(20.5)	0/ 9(0.0)
Statistical analysis				
Peto test				
Standard method(d)	P = ------			
Prevalence method(d)	P = 0.2473			
Combined analysis(d)	P = -------			
Cochran-Armitage test(e)	P = 0.2970			
Fisher Exact test(e)		P = 0.0062**	P = 0.0013**	P = N.C.
SITE : nasal cavity				
TUMOR : squamous cell carcinoma				
Tumor rate				
Overall rates(a)	0/50(0.0)	0/50(0.0)	0/50(0.0)	29/50(58.0)
Adjusted rates(b)	0.0	0.0	0.0	40.00
Terminal rates(c)	0/41(0.0)	0/44(0.0)	0/39(0.0)	3/ 9(33.3)
Statistical analysis				
Peto test				
Standard method(d)	P < 0.0001**?			
Prevalence method(d)	P < 0.0001**?			
Combined analysis(d)	P < 0.0001**?			
Cochran-Armitage test(e)	P < 0.0001**			
Fisher Exact test(e)		P = N.C.	P = N.C.	P < 0.0001**

Group Name	Control	3.2ppm	8ppm	20ppm
	SITE : nasal cavity			
	TUMOR : esthesioneuroepithelioma			
Tumor rate				
Overall rates(a)	0/50(0.0)	0/50(0.0)	0/50(0.0)	7/50(14.0)
Adjusted rates(b)	0.0	0.0	0.0	6.67
Terminal rates(c)	0/41(0.0)	0/44(0.0)	0/39(0.0)	0/ 9(0.0)
Statistical analysis				
Peto test				
Standard method(d)	P < 0.0001**?			
Prevalence method(d)	P = 0.0328* ?			
Combined analysis(d)	P < 0.0001**?			
Cochran-Armitage test(e)	P < 0.0001**			
Fisher Exact test(e)		P = N.C.	P = N.C.	P = 0.0062**
	SITE : nasal cavity			
	TUMOR : squamous cell papilloma, squamous cell carcinoma			
Tumor rate				
Overall rates(a)	0/50(0.0)	0/50(0.0)	0/50(0.0)	30/50(60.0)
Adjusted rates(b)	0.0	0.0	0.0	50.00
Terminal rates(c)	0/41(0.0)	0/44(0.0)	0/39(0.0)	4/ 9(44.4)
Statistical analysis				
Peto test				
Standard method(d)	P < 0.0001**?			
Prevalence method(d)	P < 0.0001**?			
Combined analysis(d)	P < 0.0001**?			
Cochran-Armitage test(e)	P < 0.0001**			
Fisher Exact test(e)		P = N.C.	P = N.C.	P < 0.0001**
	SITE : nasal cavity			
	TUMOR : adenoma, adenocarcinoma			
Tumor rate				
Overall rates(a)	0/50(0.0)	7/50(14.0)	9/50(18.0)	2/50(4.0)
Adjusted rates(b)	0.0	15.91	20.51	11.11
Terminal rates(c)	0/41(0.0)	7/44(15.9)	8/39(20.5)	1/ 9(11.1)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.0508 ?			
Prevalence method(d)	P = 0.0916			
Combined analysis(d)	P = 0.0320*			
Cochran-Armitage test(e)	P = 0.8453			
Fisher Exact test(e)		P = 0.0062**	P = 0.0013**	P = 0.2475

Group Name	Control	3.2ppm	8ppm	20ppm
	SITE : nasal cavity			
	TUMOR : squamous cell carcinoma, adenocarcinoma, adenosquamous carcinoma, esthesioneuroepithelioma			
Tumor rate				
Overall rates(a)	0/50(0.0)	0/50(0.0)	1/50(2.0)	38/50(76.0)
Adjusted rates(b)	0.0	0.0	2.56	63.64
Terminal rates(c)	0/41(0.0)	0/44(0.0)	1/39(2.6)	5/ 9(55.6)
Statistical analysis				
Peto test				
Standard method(d)	P < 0.0001**?			
Prevalence method(d)	P < 0.0001**?			
Combined analysis(d)	P < 0.0001**?			
Cochran-Armitage test(e)	P < 0.0001**			
Fisher Exact test(e)		P = N.C.	P = 0.5000	P < 0.0001**
	SITE : nasal cavity			
	TUMOR : squamous cell papilloma, adenoma, squamous cell carcinoma, adenocarcinoma, adenosquamous carcinoma			
Tumor rate				
Overall rates(a)	0/50(0.0)	7/50(14.0)	10/50(20.0)	33/50(66.0)
Adjusted rates(b)	0.0	15.91	23.08	70.00
Terminal rates(c)	0/41(0.0)	7/44(15.9)	9/39(23.1)	6/ 9(66.7)
Statistical analysis				
Peto test				
Standard method(d)	P < 0.0001**?			
Prevalence method(d)	P < 0.0001**			
Combined analysis(d)	P < 0.0001**?			
Cochran-Armitage test(e)	P < 0.0001**			
Fisher Exact test(e)		P = 0.0062**	P = 0.0006**	P < 0.0001**
	SITE : lung			
	TUMOR : bronchiolar-alveolar adenoma			
Tumor rate				
Overall rates(a)	2/50(4.0)	4/50(8.0)	2/50(4.0)	0/50(0.0)
Adjusted rates(b)	4.88	9.09	4.55	0.0
Terminal rates(c)	2/41(4.9)	4/44(9.1)	1/39(2.6)	0/ 9(0.0)
Statistical analysis				
Peto test				
Standard method(d)	P = ------			
Prevalence method(d)	P = 0.7960			
Combined analysis(d)	P = ------			
Cochran-Armitage test(e)	P = 0.1105			
Fisher Exact test(e)		P = 0.3389	P = 0.6913	P = 0.2475

Group Name	Control	3.2ppm	8ppm	20ppm
	SITE : lung			
	TUMOR : bronchiolar-alveolar adenoma, bronchiolar-alveolar carcinoma			
Tumor rate				
Overall rates(a)	2/50(4.0)	4/50(8.0)	4/50(8.0)	1/50(2.0)
Adjusted rates(b)	4.88	9.09	8.16	11.11
Terminal rates(c)	2/41(4.9)	4/44(9.1)	2/39(5.1)	1/ 9(11.1)
Statistical analysis				
Peto test				
Standard method(d)	P = ------			
Prevalence method(d)	P = 0.5456			
Combined analysis(d)	P = ------			
Cochran-Armitage test(e)	P = 0.3913			
Fisher Exact test(e)		P = 0.3389	P = 0.3389	P = 0.5000
	SITE : spleen			
	TUMOR : mononuclear cell leukemia			
Tumor rate				
Overall rates(a)	4/50(8.0)	6/50(12.0)	3/50(6.0)	4/50(8.0)
Adjusted rates(b)	2.44	6.82	5.13	0.0
Terminal rates(c)	1/41(2.4)	3/44(6.8)	2/39(5.1)	0/ 9(0.0)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.0456*			
Prevalence method(d)	P = 0.5503			
Combined analysis(d)	P = 0.0865			
Cochran-Armitage test(e)	P = 0.7537			
Fisher Exact test(e)		P = 0.3703	P = 0.5000	P = 0.6425
	SITE : pancreas			
	TUMOR : islet cell adenoma			
Tumor rate				
Overall rates(a)	2/50(4.0)	4/50(8.0)	2/50(4.0)	2/50(4.0)
Adjusted rates(b)	4.88	9.09	5.13	11.11
Terminal rates(c)	2/41(4.9)	4/44(9.1)	2/39(5.1)	1/ 9(11.1)
Statistical analysis				
Peto test				
Standard method(d)	P = ------			
Prevalence method(d)	P = 0.1905			
Combined analysis(d)	P = ------			
Cochran-Armitage test(e)	P = 0.6944			
Fisher Exact test(e)		P = 0.3389	P = 0.6913	P = 0.6913

Group Name	Control	3.2ppm	8ppm	20ppm
SITE : pancreas				
TUMOR : islet cell adenoma, islet cell adenocarcinoma				
Tumor rate				
Overall rates(a)	3/50(6.0)	5/50(10.0)	4/50(8.0)	4/50(8.0)
Adjusted rates(b)	7.32	11.36	10.26	22.22
Terminal rates(c)	3/41(7.3)	5/44(11.4)	4/39(10.3)	2/ 9(22.2)
Statistical analysis				
Peto test				
Standard method(d)	P = ------			
Prevalence method(d)	P = 0.0406*			
Combined analysis(d)	P = ------			
Cochran-Armitage test(e)	P = 0.9126			
Fisher Exact test(e)		P = 0.3575	P = 0.5000	P = 0.5000
SITE : pituitary gland				
TUMOR : adenoma				
Tumor rate				
Overall rates(a)	13/50(26.0)	7/50(14.0)	5/50(10.0)	0/50(0.0)
Adjusted rates(b)	25.00	11.36	10.26	0.0
Terminal rates(c)	10/41(24.4)	5/44(11.4)	4/39(10.3)	0/ 9(0.0)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.6722			
Prevalence method(d)	P = 0.9991			
Combined analysis(d)	P = 0.9990			
Cochran-Armitage test(e)	P = 0.0002**			
Fisher Exact test(e)		P = 0.1054	P = 0.0332*	P < 0.0001**
SITE : thyroid				
TUMOR : C-cell adenoma				
Tumor rate				
Overall rates(a)	4/50(8.0)	5/50(10.0)	3/50(6.0)	4/50(8.0)
Adjusted rates(b)	9.76	11.36	6.98	33.33
Terminal rates(c)	4/41(9.8)	5/44(11.4)	2/39(5.1)	3/ 9(33.3)
Statistical analysis				
Peto test				
Standard method(d)	P = ------			
Prevalence method(d)	P = 0.0783			
Combined analysis(d)	P = ------			
Cochran-Armitage test(e)	P = 0.8692			
Fisher Exact test(e)		P = 0.5000	P = 0.5000	P = 0.6425

Group Name	Control	3.2ppm	8ppm	20ppm
SITE : thyroid				
TUMOR : C-cell carcinoma				
Tumor rate				
Overall rates(a)	1/50(2.0)	1/50(2.0)	3/50(6.0)	1/50(2.0)
Adjusted rates(b)	2.44	2.27	7.69	11.11
Terminal rates(c)	1/41(2.4)	1/44(2.3)	3/39(7.7)	1/ 9(11.1)
Statistical analysis				
Peto test				
Standard method(d)	P = ------			
Prevalence method(d)	P = 0.0809			
Combined analysis(d)	P = ------			
Cochran-Armitage test(e)	P = 0.9826			
Fisher Exact test(e)		P = 0.7525	P = 0.3087	P = 0.7525
SITE : thyroid				
TUMOR : C-cell adenoma, C-cell carcinoma				
Tumor rate				
Overall rates(a)	5/50(10.0)	6/50(12.0)	6/50(12.0)	5/50(10.0)
Adjusted rates(b)	12.20	13.64	13.95	44.44
Terminal rates(c)	5/41(12.2)	6/44(13.6)	5/39(12.8)	4/ 9(44.4)
Statistical analysis				
Peto test				
Standard method(d)	P = ------			
Prevalence method(d)	P = 0.0234*			
Combined analysis(d)	P = ------			
Cochran-Armitage test(e)	P = 0.8959			
Fisher Exact test(e)		P = 0.5000	P = 0.5000	P = 0.6297
SITE : adrenal gland				
TUMOR : pheochromocytoma				
Tumor rate				
Overall rates(a)	3/50(6.0)	1/50(2.0)	0/50(0.0)	2/50(4.0)
Adjusted rates(b)	7.32	2.13	0.0	11.11
Terminal rates(c)	3/41(7.3)	0/44(0.0)	0/39(0.0)	1/ 9(11.1)
Statistical analysis				
Peto test				
Standard method(d)	P = ------			
Prevalence method(d)	P = 0.4240			
Combined analysis(d)	P = ------			
Cochran-Armitage test(e)	P = 0.8443			
Fisher Exact test(e)		P = 0.3087	P = 0.1212	P = 0.5000

Group Name	Control	3.2ppm	8ppm	20ppm
	SITE : adrenal gland			
	TUMOR : pheochromocytoma, pheochromocytoma:malignant			
Tumor rate				
Overall rates(a)	4/50(8.0)	1/50(2.0)	2/50(4.0)	2/50(4.0)
Adjusted rates(b)	9.76	2.13	4.44	11.11
Terminal rates(c)	4/41(9.8)	0/44(0.0)	1/39(2.6)	1/ 9(11.1)
Statistical analysis				
Peto test				
Standard method(d)	P = ------			
Prevalence method(d)	P = 0.5013			
Combined analysis(d)	P = ------			
Cochran-Armitage test(e)	P = 0.6214			
Fisher Exact test(e)		P = 0.1811	P = 0.3389	P = 0.3389
	SITE : testis			
	TUMOR : interstitial cell tumor			
Tumor rate				
Overall rates(a)	40/50(80.0)	46/50(92.0)	47/50(94.0)	36/50(72.0)
Adjusted rates(b)	88.10	92.00	100.00	100.00
Terminal rates(c)	36/41(87.8)	40/44(90.9)	39/39(100.0)	9/ 9(100.0)
Statistical analysis				
Peto test				
Standard method(d)	P = ------			
Prevalence method(d)	P = 0.0031**			
Combined analysis(d)	P = ------			
Cochran-Armitage test(e)	P = 0.0538			
Fisher Exact test(e)		P = 0.0739	P = 0.0357*	P = 0.2415
	SITE : mammary gland			
	TUMOR : adenoma, fibroadenoma			
Tumor rate				
Overall rates(a)	0/50(0.0)	0/50(0.0)	3/50(6.0)	1/50(2.0)
Adjusted rates(b)	0.0	0.0	7.69	11.11
Terminal rates(c)	0/41(0.0)	0/44(0.0)	3/39(7.7)	1/ 9(11.1)
Statistical analysis				
Peto test				
Standard method(d)	P = ------			
Prevalence method(d)	P = 0.0200*			
Combined analysis(d)	P = ------			
Cochran-Armitage test(e)	P = 0.3948			
Fisher Exact test(e)		P = N.C.	P = 0.1212	P = 0.5000

Group Name	Control	3.2ppm	8ppm	20ppm
	SITE : mammary gland			
	TUMOR : adenoma, fibroadenoma, adenocarcinoma			
Tumor rate				
Overall rates(a)	1/50(2.0)	0/50(0.0)	3/50(6.0)	1/50(2.0)
Adjusted rates(b)	2.44	0.0	7.69	11.11
Terminal rates(c)	1/41(2.4)	0/44(0.0)	3/39(7.7)	1/ 9(11.1)
Statistical analysis				
Peto test				
Standard method(d)	P = ------			
Prevalence method(d)	P = 0.0551			
Combined analysis(d)	P = ------			
Cochran-Armitage test(e)	P = 0.7656			
Fisher Exact test(e)		P = 0.5000	P = 0.3087	P = 0.7525
	SITE : peritoneum			
	TUMOR : mesothelioma			
Tumor rate				
Overall rates(a)	1/50(2.0)	7/50(14.0)	16/50(32.0)	14/50(28.0)
Adjusted rates(b)	0.0	15.91	33.33	55.56
Terminal rates(c)	0/41(0.0)	7/44(15.9)	13/39(33.3)	5/ 9(55.6)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.0005**			
Prevalence method(d)	P < 0.0001**			
Combined analysis(d)	P < 0.0001**			
Cochran-Armitage test(e)	P = 0.0015**			
Fisher Exact test(e)		P = 0.0297*	P < 0.0001**	P = 0.0002**

(HPT360A) BAIS5

(a) : Number of tumor-bearing animals/number of animals examined at the site.
(b) : Kaplan-Meier estimated tumor incidence at the end of the study after adjusting for intercurrent mortality.
(c) : Observed tumor incidence at terminal kill.
(d) : Beneath the control incidence are the P-values associated with the trend test.
Standard method : Death analysis
Prevalence method : Incidental tumor test
Combined analysis : Death analysis + Incidental tumor test
(e) : The Cochran-Armitage and Fisher exact test compare directly the overall incidence rates.
? : The conditional probabilities of the largest and smallest possible out comes can not estimated or this P-value is beyond the estimated P-value.
------ : There is no data which should be statistical analysis.
Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01
N.C. :Statistical value cannot be calculated and was not significant.

TABLE O2

NEOPLASTIC LESIONS-INCIDENCE

AND STATISTICAL ANALYSIS : FEMALE

Group Name	Control	3.2ppm	8ppm	20ppm
	SITE : subcutis			
	TUMOR : fibroma			
Tumor rate				
Overall rates(a)	0/50(0.0)	2/50(4.0)	2/50(4.0)	3/50(6.0)
Adjusted rates(b)	0.0	0.0	5.71	7.69
Terminal rates(c)	0/39(0.0)	0/39(0.0)	2/35(5.7)	2/29(6.9)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.7271			
Prevalence method(d)	P = 0.0126*			
Combined analysis(d)	P = 0.0608			
Cochran-Armitage test(e)	P = 0.1592			
Fisher Exact test(e)		P = 0.2475	P = 0.2475	P = 0.1212
	SITE : nasal cavity			
	TUMOR : adenoma			
Tumor rate				
Overall rates(a)	0/50(0.0)	3/50(6.0)	3/50(6.0)	1/50(2.0)
Adjusted rates(b)	0.0	7.69	5.71	3.45
Terminal rates(c)	0/39(0.0)	3/39(7.7)	2/35(5.7)	1/29(3.4)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.3519			
Prevalence method(d)	P = 0.3883			
Combined analysis(d)	P = 0.3809			
Cochran-Armitage test(e)	P = 0.9596			
Fisher Exact test(e)		P = 0.1212	P = 0.1212	P = 0.5000
	SITE : nasal cavity			
	TUMOR : squamous cell carcinoma			
Tumor rate				
Overall rates(a)	0/50(0.0)	0/50(0.0)	0/50(0.0)	10/50(20.0)
Adjusted rates(b)	0.0	0.0	0.0	16.67
Terminal rates(c)	0/39(0.0)	0/39(0.0)	0/35(0.0)	4/29(13.8)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.0001**?			
Prevalence method(d)	P < 0.0001**?			
Combined analysis(d)	P < 0.0001**?			
Cochran-Armitage test(e)	P < 0.0001**			
Fisher Exact test(e)		P = N.C.	P = N.C.	P = 0.0006**

Group Name	Control	3.2ppm	8ppm	20ppm
	SITE : nasal cavity			
	TUMOR : adenoma, squamous cell carcinoma, adenosquamous carcinoma			
Tumor rate				
Overall rates(a)	0/50(0.0)	3/50(6.0)	3/50(6.0)	12/50(24.0)
Adjusted rates(b)	0.0	7.69	5.71	20.00
Terminal rates(c)	0/39(0.0)	3/39(7.7)	2/35(5.7)	5/29(17.2)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.0001**			
Prevalence method(d)	P = 0.0028**			
Combined analysis(d)	P < 0.0001**			
Cochran-Armitage test(e)	P < 0.0001**			
Fisher Exact test(e)		P = 0.1212	P = 0.1212	P = 0.0001**
	SITE : nasal cavity			
	TUMOR : squamous cell carcinoma, adenosquamous carcinoma, esthesioneuroepithelioma, hemangiosarcoma			
Tumor rate				
Overall rates(a)	0/50(0.0)	0/50(0.0)	0/50(0.0)	14/50(28.0)
Adjusted rates(b)	0.0	0.0	0.0	25.81
Terminal rates(c)	0/39(0.0)	0/39(0.0)	0/35(0.0)	6/29(20.7)
Statistical analysis				
Peto test				
Standard method(d)	P < 0.0001**?			
Prevalence method(d)	P < 0.0001**?			
Combined analysis(d)	P < 0.0001**?			
Cochran-Armitage test(e)	P < 0.0001**			
Fisher Exact test(e)		P = N.C.	P = N.C.	P < 0.0001**
	SITE : spleen			
	TUMOR : mononuclear cell leukemia			
Tumor rate				
Overall rates(a)	5/50(10.0)	10/50(20.0)	8/50(16.0)	6/50(12.0)
Adjusted rates(b)	5.13	15.38	5.71	3.45
Terminal rates(c)	2/39(5.1)	6/39(15.4)	2/35(5.7)	1/29(3.4)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.1795			
Prevalence method(d)	P = 0.8143			
Combined analysis(d)	P = 0.4110			
Cochran-Armitage test(e)	P = 0.7875			
Fisher Exact test(e)		P = 0.1312	P = 0.2768	P = 0.5000

Group Name	Control	3.2ppm	8ppm	20ppm
	SITE : pituitary gland			
	TUMOR : adenoma			
Tumor rate				
Overall rates(a)	11/50(22.0)	16/50(32.0)	13/50(26.0)	8/50(16.0)
Adjusted rates(b)	16.67	35.00	26.32	15.91
Terminal rates(c)	6/39(15.4)	13/39(33.3)	8/35(22.9)	3/29(10.3)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.8246			
Prevalence method(d)	P = 0.6858			
Combined analysis(d)	P = 0.8159			
Cochran-Armitage test(e)	P = 0.1970			
Fisher Exact test(e)		P = 0.1839	P = 0.4076	P = 0.3055
	SITE : pituitary gland			
	TUMOR : adenoma, adenocarcinoma			
Tumor rate				
Overall rates(a)	12/50(24.0)	18/50(36.0)	13/50(26.0)	8/50(16.0)
Adjusted rates(b)	17.07	35.00	26.32	15.91
Terminal rates(c)	6/39(15.4)	13/39(33.3)	8/35(22.9)	3/29(10.3)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.9242			
Prevalence method(d)	P = 0.7149			
Combined analysis(d)	P = 0.8951			
Cochran-Armitage test(e)	P = 0.1037			
Fisher Exact test(e)		P = 0.1376	P = 0.5000	P = 0.2270
	SITE : thyroid			
	TUMOR : C-cell adenoma			
Tumor rate				
Overall rates(a)	1/50(2.0)	1/50(2.0)	3/50(6.0)	4/50(8.0)
Adjusted rates(b)	2.44	2.56	8.57	11.43
Terminal rates(c)	0/39(0.0)	1/39(2.6)	3/35(8.6)	3/29(10.3)
Statistical analysis				
Peto test				
Standard method(d)	P = ------			
Prevalence method(d)	P = 0.0327*			
Combined analysis(d)	P = ------			
Cochran-Armitage test(e)	P = 0.0967			
Fisher Exact test(e)		P = 0.7525	P = 0.3087	P = 0.1811

Group Name	Control	3.2ppm	8ppm	20ppm
	SITE : thyroid			
	TUMOR : follicular adenoma			
Tumor rate				
Overall rates(a)	1/50(2.0)	2/50(4.0)	3/50(6.0)	1/50(2.0)
Adjusted rates(b)	2.56	4.88	6.98	3.45
Terminal rates(c)	1/39(2.6)	1/39(2.6)	2/35(5.7)	1/29(3.4)
Statistical analysis				
Peto test				
Standard method(d)	P = ------			
Prevalence method(d)	P = 0.4757			
Combined analysis(d)	P = ------			
Cochran-Armitage test(e)	P = 0.8316			
Fisher Exact test(e)		P = 0.5000	P = 0.3087	P = 0.7525
	SITE : thyroid			
	TUMOR : C-cell adenoma, C-cell carcinoma			
Tumor rate				
Overall rates(a)	1/50(2.0)	1/50(2.0)	5/50(10.0)	4/50(8.0)
Adjusted rates(b)	2.44	2.56	14.29	11.43
Terminal rates(c)	0/39(0.0)	1/39(2.6)	5/35(14.3)	3/29(10.3)
Statistical analysis				
Peto test				
Standard method(d)	P = ------			
Prevalence method(d)	P = 0.0396*			
Combined analysis(d)	P = ------			
Cochran-Armitage test(e)	P = 0.1268			
Fisher Exact test(e)		P = 0.7525	P = 0.1022	P = 0.1811
	SITE : uterus			
	TUMOR : endometrial stromal polyp			
Tumor rate				
Overall rates(a)	6/50(12.0)	10/50(20.0)	7/50(14.0)	7/50(14.0)
Adjusted rates(b)	9.52	21.28	20.00	17.24
Terminal rates(c)	3/39(7.7)	8/39(20.5)	7/35(20.0)	5/29(17.2)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.9637			
Prevalence method(d)	P = 0.2895			
Combined analysis(d)	P = 0.4454			
Cochran-Armitage test(e)	P = 0.8757			
Fisher Exact test(e)		P = 0.2070	P = 0.5000	P = 0.5000

Group Name	Control	3.2ppm	8ppm	20ppm
	SITE : uterus			
	TUMOR : endometrial stromal sarcoma			
Tumor rate				
Overall rates(a)	1/50(2.0)	1/50(2.0)	1/50(2.0)	5/50(10.0)
Adjusted rates(b)	2.56	0.0	0.0	6.90
Terminal rates(c)	1/39(2.6)	0/39(0.0)	0/35(0.0)	2/29(6.9)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.0286*			
Prevalence method(d)	P = 0.0809			
Combined analysis(d)	P = 0.0083**			
Cochran-Armitage test(e)	P = 0.0205*			
Fisher Exact test(e)		P = 0.7525	P = 0.7525	P = 0.1022
	SITE : mammary gland			
	TUMOR : fibroadenoma			
Tumor rate				
Overall rates(a)	7/50(14.0)	14/50(28.0)	14/50(28.0)	23/50(46.0)
Adjusted rates(b)	16.28	31.71	36.11	57.89
Terminal rates(c)	6/39(15.4)	12/39(30.8)	12/35(34.3)	16/29(55.2)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.1182			
Prevalence method(d)	P < 0.0001**			
Combined analysis(d)	P < 0.0001**			
Cochran-Armitage test(e)	P = 0.0007**			
Fisher Exact test(e)		P = 0.0698	P = 0.0698	P = 0.0004**
	SITE : mammary gland			
	TUMOR : adenoma, fibroadenoma, adenocarcinoma			
Tumor rate				
Overall rates(a)	7/50(14.0)	15/50(30.0)	15/50(30.0)	23/50(46.0)
Adjusted rates(b)	16.28	31.71	38.46	57.89
Terminal rates(c)	6/39(15.4)	12/39(30.8)	12/35(34.3)	16/29(55.2)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.1182			
Prevalence method(d)	P = 0.0001**			
Combined analysis(d)	P < 0.0001**			
Cochran-Armitage test(e)	P = 0.0012**			
Fisher Exact test(e)		P = 0.0448*	P = 0.0448*	P = 0.0004**

Group Name	Control	3.2ppm	8ppm	20ppm
SITE : preputial/clitoral gland				
TUMOR : adenoma				
Tumor rate				
Overall rates(a)	0/50(0.0)	3/50(6.0)	3/50(6.0)	4/50(8.0)
Adjusted rates(b)	0.0	7.69	5.71	4.35
Terminal rates(c)	0/39(0.0)	3/39(7.7)	2/35(5.7)	1/29(3.4)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.0346*			
Prevalence method(d)	P = 0.2199			
Combined analysis(d)	P = 0.0467*			
Cochran-Armitage test(e)	P = 0.1284			
Fisher Exact test(e)		P = 0.1212	P = 0.1212	P = 0.0587

(a): Number of tumor-bearing animals/number of animals examined at the site.
(b): Kaplan-Meier estimated tumor incidence at the end of the study after adjusting for intercurrent mortality.
(c): Observed tumor incidence at terminal kill.
(d): Beneath the control incidence are the P-values associated with the trend test.
Standard method : Death analysis
Prevalence method : Incidental tumor test
Combined analysis : Death analysis + Incidental tumor test
(e): The Cochran-Armitage and Fisher exact test compare directly the overall incidence rates.
? : The conditional probabilities of the largest and smallest possible out comes can not estimated or this P-value is beyond the estimated P-value.
------ : There is no data which should be statistical analysis.
Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01
N.C. :Statistical value cannot be calculated and was not significant.

TABLE P1

HISTOPATHOLOGICAL FINDINGS :

METASTASIS OF TUMOR :

MALE

Organ	Findings	Group Name / No. of Animals on Study	Control	3.2ppm	8ppm	20ppm
			50	50	50	50
{Respiratory system}						
nasal cavit			<50>	<50>	<50>	<50>
	leukemic cell infiltration		2	0	0	0
nasopharynx			<50>	<50>	<50>	<50>
	metastasis:nasal tumor		0	0	0	4
lung			<50>	<50>	<50>	<50>
	leukemic cell infiltration		2	5	2	3
	metastasis:adrenal tumor		0	0	1	0
	metastasis:subcutis tumor		0	0	1	0
	metastasis:bone tumor		0	0	1	0
	metastasis:Zymbal gland tumor		1	0	0	0
	metastasis:skin/appendage tumor		0	0	1	0
{Hematopoietic system}						
bone marrow			<50>	<50>	<50>	<50>
	leukemic cell infiltration		4	3	2	4
lymph node			<50>	<50>	<50>	<50>
	leukemic cell infiltration		2	3	2	1
	metastasis:bone tumor		0	0	1	0
	metastasis:skin/appendage tumor		0	0	1	0
thymus			<50>	<50>	<50>	<50>
	leukemic cell infiltration		0	0	1	0
spleen			<50>	<50>	<50>	<50>
	metastasis:skin/appendage tumor		0	0	1	0

< a > a : Number of animals examined at the site
b b : Number of animals with lesion

Organ	Findings	Group Name / No. of Animals on Study	Control	3.2ppm	8ppm	20ppm
			50	50	50	50
{Circulatory system}						
heart			<50>	<50>	<50>	<50>
	leukemic cell infiltration		1	2	0	1
	metastasis:subcutis tumor		0	0	1	0
{Digestive system}						
salivary gl			<50>	<50>	<50>	<50>
	leukemic cell infiltration		1	0	0	0
stomach			<50>	<50>	<50>	<50>
	leukemic cell infiltration		0	1	0	0
liver			<50>	<50>	<50>	<50>
	leukemic cell infiltration		4	5	2	4
	metastasis:bone tumor		0	0	1	0
pancreas			<50>	<50>	<50>	<50>
	leukemic cell infiltration		1	1	0	0
	metastasis:subcutis tumor		0	0	0	1
	metastasis:bone tumor		0	0	1	0
{Urinary system}						
kidney			<50>	<50>	<50>	<50>
	leukemic cell infiltration		0	2	0	0
{Endocrine system}						
pituitary			<50>	<50>	<50>	<50>
	leukemic cell infiltration		1	1	0	1

< a > a : Number of animals examined at the site
b b : Number of animals with lesion

Organ	Findings	Group Name / No. of Animals on Study	Control	3.2ppm	8ppm	20ppm
			50	50	50	50
{Endocrine system}						
thyroid			<50>	<50>	<50>	<50>
	leukemic cell infiltration		0	0	1	0
adrenal			<50>	<50>	<50>	<50>
	leukemic cell infiltration		1	3	2	2
{Nervous system}						
brain			<50>	<50>	<50>	<50>
	leukemic cell infiltration		1	3	1	1
	metastasis:nasal tumor		0	0	0	5
spinal cord			<50>	<50>	<50>	<50>
	leukemic cell infiltration		0	1	0	2
{Musculoskeletal system}						
muscle			<50>	<50>	<50>	<50>
	metastasis:peritoneum tumor		0	0	0	1
	metastasis:subcutis tumor		0	0	1	0
{Body cavities}						
pleura			<50>	<50>	<50>	<50>
	metastasis:peritoneum tumor		0	1	0	0
	metastasis:lung tumor		0	0	0	1
peritoneum			<50>	<50>	<50>	<50>
	metastasis:bone tumor		0	0	1	0

< a > a : Number of animals examined at the site
b b : Number of animals with lesion

TABLE P2

HISTOPATHOLOGICAL FINDINGS :

METASTASIS OF TUMOR :

FEMALE

Organ	Findings	Group Name / No. of Animals on Study	Control	3.2ppm	8ppm	20ppm
			50	50	50	50
{Integumentary system/appandage}						
subcutis			<50>	<50>	<50>	<50>
	leukemic cell infiltration		0	0	1	0
{Respiratory system}						
nasal cavit			<50>	<50>	<50>	<50>
	leukemic cell infiltration		3	0	0	0
nasopharynx			<50>	<50>	<50>	<50>
	leukemic cell infiltration		1	0	0	0
	metastasis:nasal tumor		0	0	0	1
larynx			<50>	<50>	<50>	<50>
	leukemic cell infiltration		0	0	1	0
lung			<50>	<50>	<50>	<50>
	leukemic cell infiltration		3	7	8	5
	metastasis:adrenal tumor		1	0	0	0
	metastasis:pleura tumor		0	0	0	1
{Hematopoietic system}						
bone marrow			<50>	<50>	<50>	<50>
	leukemic cell infiltration		3	4	4	5
	metastasis:pleura tumor		0	0	0	1
lymph node			<50>	<50>	<50>	<50>
	leukemic cell infiltration		1	1	2	2
thymus			<50>	<50>	<50>	<50>
	metastasis:pleura tumor		0	0	0	1

< a > a : Number of animals examined at the site
b b : Number of animals with lesion

Organ	Findings	Group Name / No. of Animals on Study	Control	3.2ppm	8ppm	20ppm
			50	50	50	50
{Circulatory system}						
heart			<50>	<50>	<50>	<50>
	leukemic cell infiltration		1	2	2	2
{Digestive system}						
large intes			<50>	<50>	<50>	<50>
	leukemic cell infiltration		0	0	1	0
	metastasis:uterus tumor		0	0	0	1
liver			<50>	<50>	<50>	<50>
	leukemic cell infiltration		5	9	7	5
	metastasis:pleura tumor		0	0	0	1
pancreas			<50>	<50>	<50>	<50>
	leukemic cell infiltration		0	0	2	0
{Urinary system}						
kidney			<50>	<50>	<50>	<50>
	leukemic cell infiltration		2	0	1	3
urin bladd			<50>	<50>	<50>	<50>
	leukemic cell infiltration		0	0	1	0
	metastasis:uterus tumor		0	0	0	1
{Endocrine system}						
pituitary			<50>	<50>	<50>	<50>
	leukemic cell infiltration		0	1	1	0

< a > a : Number of animals examined at the site
b b : Number of animals with lesion

Organ	Findings	Group Name / No. of Animals on Study	Control	3.2ppm	8ppm	20ppm
			50	50	50	50
{Endocrine system}						
thyroid			<50>	<50>	<50>	<50>
	leukemic cell infiltration		0	0	1	0
adrenal			<50>	<50>	<50>	<50>
	leukemic cell infiltration		3	4	5	5
{Reproductive system}						
ovary			<50>	<50>	<50>	<50>
	leukemic cell infiltration		4	2	5	3
	metastasis:pleura tumor		0	0	0	1
uterus			<50>	<50>	<50>	<50>
	leukemic cell infiltration		1	0	2	0
vagina			<50>	<50>	<50>	<50>
	leukemic cell infiltration		1	0	1	0
	metastasis:uterus tumor		0	1	1	2
{Nervous system}						
brain			<50>	<50>	<50>	<50>
	leukemic cell infiltration		1	0	1	2
	metastasis:pituitary tumor		2	2	0	0
	metastasis:nasal tumor		0	0	0	1
spinal cord			<50>	<50>	<50>	<50>
	leukemic cell infiltration		1	0	0	1
{Special sense organs/appendage}						
Harder gl			<50>	<50>	<50>	<50>
	leukemic cell infiltration		0	0	1	0

< a > a : Number of animals examined at the site
b b : Number of animals with lesion

Organ	Findings	Group Name / No. of Animals on Study	Control	3.2ppm	8ppm	20ppm
		No. of Animals on Study	50	50	50	50
{Musculoskeletal system}						
muscle			<50>	<50>	<50>	<50>
	leukemic cell infiltration		0	0	1	0

< a > a : Number of animals examined at the site
b b : Number of animals with lesion

TABLE Q1

HISTORICAL CONTROL DATA OF SELECTED NEOPLASTIC LESIONS IN JAPAN BIOASSAY RESEARCH CENTER : F344/DuCrlCrlj MALE RATS

TABLE Q1 HISTORICAL CONTROL DATA OF SELECTED NEOPLASTIC LESIONS IN JAPAN BIOASSAY RESEARCH CENTER : F344/DuCrlCrlj MALE

Organs Tumors	No. of animals examined	No. of animals bearing tumor	Incidence (%)	Min. - Max. (%)
Skin	3048			
Basal cell epithelioma [1]		2	0.1	0 - 2
Basal cell carcinoma [2]		2	0.1	0 - 2
1) + 2)		4	0.1	0 - 2
Keratoacanthoma		100	3.3	0 - 14
Subcutis	3048			
Fibroma		258	8.5	2 - 20
Nasal cavity	3048			
Adenoma		3	0.1	0 - 2
Adenocarcinoma		0	0.0	0 - 0
Adenosquamous carcinoma		0	0.0	0 - 0
Squamous cell papilloma		0	0.0	0 - 0
Squamous cell carcinoma		0	0.0	0 - 0
Esthesioneuroepithelioma		0	0.0	0 - 0
Spleen	3048			
Mononuclear cell leukemia		345	11.3	2 - 22
Pancreas	3047			
Islet cell adenoma [1]		217	7.1	0 - 14
Islet cell adenocarcinoma [2]		17	0.6	0 - 4
1) + 2)		234	7.7	0 - 14
Thyroid	3041			
C-cell adenoma [1]		461	15.2	2 - 36
C-cell carcinoma [2]		72	2.4	0 - 12
1) + 2)		532	17.5	4 - 38
Mammary	3048			
Adenoma [1]		16	0.5	0 - 4
Fibroadenoma [2]		55	1.8	0 - 6
1) + 2)		71	2.3	0 - 8
Testis	3047			
Interstitial cell tumor		2508	82.3	56 - 98
Peritoneum	3046			
Mesothelioma		76	2.5	0 - 8

61 carcinogenicity studies examined in Japan Bioassay Research Center were used.

Study No. : 0043, 0059, 0061, 0063, 0065, 0067, 0095, 0104, 0115, 0130, 0141, 0158, 0162, 0189, 0205, 0210, 0224, 0242, 0246, 0267, 0269, 0278, 0284, 0288, 0294, 0296, 0318, 0328, 0342, 0347, 0365, 0371, 0396, 0399, 0401, 0407, 0417, 0421, 0437, 0448, 0457, 0461, 0497, 0535, 0560, 0579, 0581, 0610, 0612, 0641, 0667, 0675, 0684, 0686, 0691, 0704, 0711, 0731, 0739, 0753, 0774

TABLE Q2

HISTORICAL CONTROL DATA OF SELECTED NEOPLASTIC LESIONS IN JAPAN BIOASSAY RESEARCH CENTER : F344/DuCrlCrlj FEMALE RATS

TABLE Q2 HISTORICAL CONTROL DATA OF SELECTED NEOPLASTIC LESIONS IN JAPAN BIOASSAY RESEARCH CENTER : F344/DuCrlCrlj FEMALE

Organs Tumors	No. of animals examined	No. of animals bearing tumor	Incidence (%)	Min. - Max. (%)
Subcutis	2847			
Fibroma		31	1.1	0 - 8
Nasal cavity	2847			
Adenoma		2	0.1	0 - 2
Adenosquamous carcinoma		0	0.0	0 - 0
Squamous cell carcinoma		0	0.0	0 - 0
Esthesioneuroepithelioma		0	0.0	0 - 0
Hemangiosarcoma		0	0.0	0 - 0
Thyroid	2838			
C-cell adenoma		296	10.4	0 - 20
Uterus	2846			
Endometrial stromal sarcoma		54	1.9	0 - 8
Mammary gland	2847			
Adenoma [1)]		60	2.1	0 - 18
Fibroadenoma [2)]		329	11.6	0 - 28
Adenocarcinoma [3)]		35	1.2	0 - 6
1) + 2) + 3)		416	14.6	4 - 30
Clitoral gland	2847			
Adenoma		85	3.0	0 - 10

57 carcinogenicity studies examined in Japan Bioassay Research Center were used.

Study No. : 0043, 0059, 0061, 0063, 0065, 0067, 0095, 0104, 0115, 0130, 0141, 0158, 0162, 0189, 0205, 0210, 0224, 0242, 0246, 0267, 0269, 0278, 0284, 0296, 0303, 0318, 0328, 0342, 0347, 0365, 0371, 0399, 0401, 0417, 0421, 0437, 0448, 0457, 0461, 0497, 0535, 0560, 0579, 0610, 0612, 0641, 0667, 0675, 0684, 0686, 0691, 0704, 0711, 0731, 0739, 0753, 0774

TABLE R1

CAUSE OF DEATH : MALE

STUDY NO. : 0794
ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj]
SEX : MALE

COUSE OF DEATH (SUMMARY)
(0-105W)

Group Name	Control	3.2ppm	8ppm	20ppm
Number of Dead and Moribund Animal	9	6	11	41
no microscop confirm	0	0	1	0
chronic nephropathy	1	0	0	0
nasal lesion	0	0	0	1
tumor d:leukemia	3	3	1	4
tumor d:skin/app	0	1	1	0
tumor d:subcutis	1	0	2	0
tumor d:nasal cavit	0	0	0	31
tumor d:pituitary	1	2	1	0
tumor d:brain	1	0	1	0
tumor d:bone	0	0	1	0
tumor d:peritoneum	2	0	3	5

TABLE R2

CAUSE OF DEATH : FEMALE

STUDY NO. : 0794
ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj]
SEX : FEMALE

COUSE OF DEATH (SUMMARY)
(0-105W)

Group Name	Control	3.2ppm	8ppm	20ppm
Number of Dead and Moribund Animal	11	11	15	21
deglutition disorder	1	0	1	0
tumor d:leukemia	3	4	6	5
tumor d:subcutis	0	2	1	0
tumor d:nasal cavit	0	0	1	6
tumor d:tongue	0	0	0	1
tumor d:pituitary	5	4	3	1
tumor d:ovary	0	0	0	1
tumor d:uterus	2	1	1	3
tumor d:mammary gl	0	0	0	1
tumor d:prep/cli gl	0	0	1	2
tumor d:Zymbal gl	0	0	0	1
tumor d:peritoneum	0	0	1	0